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Abstract
Metalloglycomics: Investigating the Interactions of Metal Complexes with Heparan Mimetics

By Wyatt E. Johnson
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Chemical Biology at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Major Director: Nicholas P. Farrell, Professor, Department of Chemistry
Proteoglycans containing Heparan Sulfate (HS), a sulfated glycosaminoglycan (GAG), play a
major role in the cell signaling process, interacting with many different proteins. HS is over
expressed on the surface of many cancer cells. Enzymatic cleavage of HS-GAGs by heparanase
causes release of angiogenic growth factors leading to tumor cell migration. Heparanase is also
over-expressed in tumors with significant correlation between metastatic potential and heparanase
activity. Proteoglycans and their associated enzymes are thus significant drug targets of high
biological relevance.
A functional consequence of strong PPC-HS binding has been shown in proof-of-concept studies
confirming inhibition of the model pentasaccharide, Fondaparinux, by bacterial Heparinase. Such
metalloshielding by PPCs may also protect HS from enzymatic cleavage by the mammalian
heparanase; preventing growth factors from binding to HS and/or preventing release of bound
growth factors and thus inhibiting the metastatic response in the cancer cells. HS-GAGs are also
receptors for cellular accumulation of cationic Polynuclear Platinum Complexes (PPCs) through
high-affinity binding to the highly anionic HS. PPCs competitively inhibit uptake of TAMRA-R9,
a fluorescent nona-arginine derivative, in CHO cells.
The previously reported series of Pt(II) complexes were investigated as DNA binders, initiating
the apoptotic cascade. The result of PPC-DNA binding produces long range inter and intra-strand

xi

cross-links, that produce structural and conformational changes. Hydrogen bonding between
phosphate oxygens and square planar Pt(II) nitrogen results in bidentate complexes by either
backbone tracking or groove spanning of DNA. This complex forms a clamp like structure, called
a phosphate clamp, similar to that of the arginine fork. Understanding this clamp allows us to
investigate the structurally similar sulfate binding between metal complexes and target HSPG.
HSPGs may allow significant research into both a novel cellular internalization of principal metals
and “metalloshielding” of heparin by these compounds.
Previous studies have shown that a wide range of metal ions have high affinity to heparin. The
trend of metal/heparin affinity is believed to be dependent on parameters consisting of the metal’s
overall size, spatial orientation of the ligands attached to each metal, the net charge and oxidation
state of these metals, and number of binding sites. Studies have shown relative affinities of sulfate
and carboxylate groups for the metal ions. These metal cations play an important role in the
affinity, specificity, and stability of many protein/heparin interactions. The study of simple
coordination compounds, like Pt, Mn, V, Ru and Co, will allow preliminary results which will
extend into the PPCs mode of binding.
This thesis focuses on the concept of metalloglycomics and reviews the interactions of various
metal complexes with heparin. The covalent and non-covalent interactions of metal complexes
with heparin resulting in strong bonding are explained through spectroscopy and calorimetry. The
cleavage inhibition of heparanase by metal complexes is also described. Sulfate cluster anchoring
shields the sulfates from loss as seen in mass spectrometry. The study of metalloglycomics offers
potential understanding into the relevance of metal-heparin interactions and possibilities into the
development of new compounds as therapeutic agents.

xii

Chapter 1: Introduction

1.1 Platinum Complexes

Cisplatin (cis-diamminedichloroplatinum(II)) was first synthesized in 1845, however, it was not
until 1965 by Rosenberg that platinum complexes were shown to inhibit cell division and even
later in 1969 that they were shown to possess anticancer properties.(1,2) Since 1978, cisplatin has
been in clinical use for treatment in breast, ovarian, bladder, head and neck carcinomas.(3)
Cisplatin is most well-known as part of the combination therapy that is used in the treatment of
testicular cancer, with a cure rate over 90%.(3) While twenty-eight direct structural analogues of
cisplatin have entered clinical trials, only cisplatin, carboplatin and oxaliplatin have been approved
for use in the United States, Figure 1.1.(4) The remaining platinum complexes have failed to show
improvement over the efficacy of cisplatin.(3)
Structurally, cisplatin consists of two inert ammine ligands and two labile chloride ligands.
Platinum (II) exhibits a square planar geometry with a high affinity for nitrogen and sulfur
molecules found commonly in proteins and DNA nucleobases. The accepted mechanism of
cisplatin cytotoxicity is through DNA binding.(3) Extracellularly, replacement of the labile
chlorides is limited due to the high chloride concentration, ~100 mM. Once cisplatin enters the
cell, either through passive diffusion or active transport, the labile chlorides are replaced forming
an aquated active platinum species.(6-9) Cisplatin, following aquation, acts as a soft Lewis acid
and forms stable complexes with S or N donors found in proteins. Cisplatin forms bifunctional
intra- or inter-strand cross-links with the N7 on guanine and to a lesser extent adenine bases.(1014) The 1,2 intrastrand cross-link bends the DNA helix by 32-34o towards the cisplatin bound in
the major grove, Figure 1.2.(15) These structural distortions can hinder the replication and
transcription processes and lead to the initiation of the apoptotic cascade.(16)
While cisplatin and its analogs have been very successful anticancer drugs, their use is limited by
developed or intrinsic resistance.(17, 18) Resistances may arise from multiple sources including a
1

Figure 1.1 Structures of FDA approved platinum-based anticancer
drugs.

Figure 1.2 Pathways for GG intrastrand crosslinking of DNA by cisplatin. The insert shows the structure of
guanine and the position of N7, the major Pt binding site. From Ref. 5
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decrease in cellular accumulation due to increased efflux, increase in deactivation of cisplatin by
sulfur-containing molecules, Figure 1.3, and increased recognition and repair of cisplatin-DNA
adducts, Figure 1.4.(19, 20) Reaction with human serum albumin (HSA), a single chain protein
containing 17 disulfide bridges and one free thiol at Cys-34, is thought to be the main route for
inactivation in human blood plasma. Another known biomolecule responsible for cisplatin
inactivation is glutathione (GSH), an abundant thiol-containing tripeptide, which is present in a
concentration of 1~10 mM intracellularly. Due to the centrality of DNA in both the development
of the mechanism of action and resistance, new platinum compounds should produce different
interactions than cisplatin leading to a greater antitumor efficacy.
The cis configuration of Pt(II) compounds was extensively studied since the trans configuration
was shown to be clinically inactive. Structure-activity studies showed that a cis configuration was
necessary for the Pt(II) complex to exhibit anticancer properties. The trans configuration of Pt(II)
complexes is inactive due to the fast deactivation of the compound and their inability to induce
DNA structural distortions. However, replacement of the ammine ligands with sterically hindered
planar ammine ligands produces an equivalent cytotoxicity as cisplatin.(21) The steric effects of
these ligands resulted in the formation of structurally unique cross-links, Figure 1.5, exhibiting
cytotoxic activity toward cisplatin-resistant cell lines.(22-26) While certain trans Pt(II) complexes
exhibit similar cytotoxicity to cisplatin, the reactivity potential of trans complexes with
inactivating sulfur-containing nucleophiles increases due to the trans-influencing chlorides.(27) In
an effort to optimize the pharmacological properties of trans compounds, another innovative
approach was used, synthesizing cationic polynuclear platinum complexes (PPCs). A
representative trinuclear complex, BBR364, was the first polynuclear platinum compound to enter
clinical trials as an anticancer agent, Figure 1.6. BBR3464 binds to DNA through long range interand intra-strand cross-links, Figure 1.7.(30, 31) These lesions do not significantly bend the DNA
and are therefore not recognized by high mobility group (HMG) and are a poor substrate for
nucleotide excision repair (NER).(31) Upon binding to DNA, PPCs are capable of producing a B
to A or Z transition.(4) Although BBR3464 resulted in a non-cross resistant cytotoxicity with
3

Figure 1.3 Structure of sulfur containing nucleophiles: Cysteine, methionine, and
glutathione.

Figure 1.4 Resistance pathways for cisplatin and its analogs after DNA binding. From Ref. 8

4

cisplatin by inducing a distinct mode of DNA binding, degradation into inactive metabolites by
sulfur-containing nucleophiles was no exception for BBR3464 as with other covalently binding
platinum compounds.(4) Replacement of the reactive chlorides by ammines or dangling ammines,
Figure 1.8, negated the pharmacokinetic difficulties of inactivation by sulfur-containing
nucleophiles.(32, 33) Replacement of Pt-Cl by substitution-inert ligands becomes unreactive
toward sulfur nucleophiles, thus enhancing metabolic stability, and also allows study of noncovalent contributions. Non-covalent interactions showed a new mode of ligand-DNA recognition
distinct from the conventional modes of intercalation and groove binding. Hydrogen bonding with
phosphate oxygens results in either backbone tracking or groove spanning through formation of
phosphate clamps where the PtN4 coordination sphere forms bidentate N-O-N complexes with
phosphate oxygen atoms condensing DNA.
One of the major requirements for the effectiveness of an anticancer therapeutic is the successful
cellular uptake of the compound. A series of structure-activity relationship rules that define the
favorable characteristics that a successful therapeutic agent should possess was broadly defined
as: possess a zero net charge, contain two leaving groups or one bidentate leaving group, have
chloride leaving groups or similar ligands, leaving groups oriented in the cis-configuration, no
hydroxy or hydroxo ligands as it increases toxicity, and have inert non-leaving groups such as
amines.(34-36) However, the previous assumption that platinum complexes need to be neutral to
enter cells was contradicted by the higher cellular accumulation of the highly cationic PPCs over
cisplatin.(37) Polynuclear platinum compounds have a remarkable cellular uptake that appears to
be based on the charge of the compounds. Recently, the endocytic pathway has been utilized as a
means to deliver the bioactive structure into the cell.(8) Cell penetrating peptides (CPPs), which
consist of polycationic arginine rich oligopeptides, are capable of migrating across the membrane
in a short time with the ability to assist other biomolecular compounds that may not readily migrate
across the membrane.(34-36) For polyarginine CPPs, the effective arginine residues for cellular
translocation ranged from 6 to 20 residues, with a maximal uptake of approximately 15
residues.(12) A length over 20 arginines increases the association to a level that is too high for the
5

Figure 1.5 Unique cross-links formed by transplatin derivatives. From Ref. 29

Figure 1.6 Structures of transplatin and BBR3464.
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effective release of the structure from the membrane. The cell surface contains an array of possible
anionic binding sites, like phospholipids and polysaccharide constituents. While it has been well
established that charged compounds do not readily cross the membrane without some sort of
energetic assistance, which may come in the form of pumps or channels. Arginine rich peptides
have been heavily studied because of their ability to translocate across the plasma membrane of
living cells.(14)
The mechanism of PPCs cellular internalization and reactivity with DNA prompted studies into
PPCs interactions with extracellular heparan sulfate proteoglycans (HSPG) as the mechanism of
internalization and expand its studies into other transition metals to lower the cytotoxic profile.

1.2 Other Metal Complexes

In the early development of platinum complex analogs, other transition metals with similar
reactivities as cisplatin were examined. A wide variety of ruthenium-based complexes exhibited
anti-cancer properties.(38-43) NAMI-A, Figure 1.9, exerts antimetastatic effects which may occur
through multiple mechanisms.(41-53) Superoxide dismutase (SOD) with an attached manganese
performs the role of superoxide detoxification in the mitochondria. M40403, Figure 1.9, a SOD
mimic, has been used as a cancer co-therapy with interleukin-2 (IL-2), an immune-stimulating
cytokine drug. IL-2 shows enhanced efficacy when used in combination with M40403.(56-65)
Metals like vanadium, while not specifically used in cancer treatments, have sparked increasing
interest over their role in biological systems. The discovery of insulin-like properties of the
vanadate ions stimulated research into the use of vanadium complexes as insulin mimics.(66-79)
Many more examples of metal-containing drugs have been reported. Complexes containing gold,
technetium, rhenium, gadolinium, lithium, bismuth, iron, calcium, lanthanum, gallium, tin,
arsenic, rhodium, copper, zinc, aluminum, and lutetium have all been used in medicine.(80) More
recently, cobalt complexes have been found to possess antiviral activity.

7

Figure 1.7 Structures from molecular modeling of the major DNA adducts of BBR3464. From Ref. 29

Figure 1.8 Structures of platinum complexes.
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The cobalt (III) ion in vitamin B12 is one of a few organometallic complexes found naturally in the
human body. Due to cobalt’s role in biological processes, mechanisms have been developed to
overcome cobalt overload, thus cobalt is less toxic to humans than non-essential metals like
platinum. Cobalt (III), while normally unstable in water, can be stabilized against reduction by
chelating ligands. One of the most promising applications of cobalt (III) complexes is the CTC
series, Figure 1.10, that was shown to inhibit replication of Herpes Simplex Virus Type 1 (HSV1).(81-87) Hexamminecoablt(III) chloride (Cohex), Figure 1.10, is an example of a classical
Werner complex that is kinetically stable in aqueous solutions. While Cohex possesses the ability
to hydrogen bond with the phosphate backbone of DNA, the mechanism of action is still not fully
understood. Cohex also exhibits significant antiviral activity and acts at the point of viral entry. It
is conjectured that the high positive charge density of Cohex allows it to disrupt the interaction of
Sindbis virus glycoproteins with highly negatively charged, polysulfonated heparan sulfate
receptors, Figure 1.11.(88, 89)
The acquired and intrinsic resistances to traditional platinum-based anticancer drugs have
compelled research into the investigation of the properties of other transition metal-based
compounds.(90-96) The less cytotoxic anticancer potential of cobalt complexes has been
extensively studied over the last three decades with much time being devoted to the understanding
of their mechanisms of action.(97, 98) This stimulated research into investigating cobaltcontaining compounds as less toxic alternatives to platinum-based anticancer drugs. In 1952, the
first biological studies were conducted with cobalt(III) complexes, verifying the low systemic
toxicity, while some complexes (99) also exhibiting antibacterial properties, Figure 1.12.(100)
Cohex has been found to have low to moderate toxicity, much less than cisplatin. The cytotoxicity
of Cohex was measured against BHK cells and compared to that of cisplatin, Figure 1.13.(101)
The Cohex cytotoxic effects are observed around 1 mM or higher, whereas cisplatin was cytotoxic
at even the lowest concentration of 80 µM.
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Figure 1.9 Structure of NAMI-A (left) and M40403 (right).

Figure 1.10 Structure of CTC (left) and Cohex (right).
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The most significant medical advancement in terms of cobalt compounds thus far, is the clinical
development of Doxovir (CTC-96) for Herpes Simplex Virus 1, Figure 1.12.(102) The mechanism
of action of Doxovir is still unknown, however it is speculated that Doxovir covalently binds to
histidine residues in the active site of a viral enzyme which is crucial for Herpes replication, Figure
1.14.(103) The hexamminecobalt (III) cation was also discovered to complex with heparin
interacting through all three of its valencies, which allowed for accurate determination of the
content of anionic groups in sulfoglycosaminoglycans.(104)
Ruthenium complexes have also raised great interest and have been tested against a number of
cancer cell lines.(105-112) Many Ru(III) compounds contain exchangeable ligands and require
activation by the tumor microenvironment.(113) The antitumor properties of the Ru(III)
complexes occur when they are reduced to Ru(II) under biological circumstances of low oxygen
concentration, acidic pH and high levels of glutathione.(114-116) The first approved ruthenium
complex in clinical trials, NAMI-A, [trans-RuCl4(DMSO)(Im)] (Im = imidazole, DMSO =
dimethylsulfoxide), Figure 1.9, has low potency in terms of direct cytotoxicity towards cancer
cells in vitro; however, in vivo, it has significant efficacy in inhibiting tumor metastasis.(117-122)
The mechanism of action of NAMI-A remains to be elucidated, but data suggests that NAMI-A is
capable of binding to DNA and RNA. The fluorescent and photo-activating properties of Rupolypyridyl complexes have been used in analyzing the abundance and degree of sulfation of HS
and evaluating HS-growth factor interactions.(123) Ruthenium red, a polycationic stain, has been
used to visualize acid polysaccharides on the outer surface of cells.(124) While the fluorescent
properties of [Ru(bipy)3]2+ have been used to detect heparin and HS.(125) The application of less
cytotoxic metal complexes can be expected to produce new patterns of metal ion binding with the
HS chain. Further investigation is deserved to elucidate these lower cytotoxic complexes and their
interactions with heparan sulfate.
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Figure 1.11 Heparan sulfate (HS) can play multiple roles during viral infection. On top of cells that express large
amount of HS, HS can capture viral particles and facilitate in cis subsequent interaction with specific entry
receptors. HS from non-permissive cells such as endothelia or epithelia can sequester HIV-1 and then mediate in
trans infection by presenting the virus to permissive cells. HS can contribute to both attachment and transcytosis
of HIV-1 through epithelia. From Ref. 88

Figure 1.12. Chemical structures of cobalt(III) coordination complexes used in early biological studies. From Ref.
100
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Figure 1.13 Comparison of cytotoxicity of Cohex against BHK cells with cisplatin. From Ref. 87

Figure 1.14. The proposed mechanism of action of Co(III)-acacen complexes, including Doxovir. It is
postulated that one of the axial ligands is lost in a dissociative manner, followed by covalent binding to
histidine residues within the active site of key enzymes or signalling proteins. From Ref. 102
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1.3 Glycosaminoglycans

Heparan sulfate proteoglycans (HSPGs) are polysulfated linear polysaccharides that are found on
the cell surface and localized in mast cells.(126) These highly charged polysaccharides are made
up of repeating 1-4 linked polysulfated disaccharide units comprised of glucosamine and
hexuronic acid, with up to three sulfate moieties per unit. Two structurally similar polysaccharides,
heparin and heparan sulfate (HS) are the most complex members of the glycosaminoglycan (GAG)
family, which also consists of chondrotin sulfate, dermatan sulfate, and keratin sulfate.(127)
Heparan sulfate is biosynthesized as a proteoglycan and strategically located on the cell surface
and in the extracellular matrix.(127) The role of HS has been shown to include a variety of
biological processes consisting of cell adhesion, cell growth regulation, blood coagulation, binding
of cell surface proteins, and tumor metastasis.(127)
Heparin chains consist of repeating units of iduronic or glucuronic acids and D-glucosamine which
may be irregularly substituted at the O- or N-sulfate or N-acetyl positions, Figure 1.15.(128) The
sulfate residues act as the primary receptors for protein recognition which is affected by shape,
sulfation pattern, and mobility of the heparin chain.(129) The iduronic acid residue can potentially
adopt either 1C4 chair or 2S0 skew boat conformations with flexibility occurring around the
glycosidic linkage.(130, 131) In heparin the 1C4 to 2S0 confomers ratio is 60:40 while the ratio in
Fondaparinux is 40:60, more importantly when these fragments interact with a receptor the most
favorable conformation is adopted, Figure 1.15.(132-134)
As with other major classes of macromolecules, the biological roles of glycans extend from
negligible to crucial for the development, growth, functioning, or survival of the cell, Figure 1.16.
The biological roles of glycans can be divided into two broad categories: the structural and
modulatory properties of glycans and the specific recognition of glycans by other molecules either
mediating cell-cell interactions or recognizing extracellular molecules. When conjugated with
proteins, the proteoglycans are found in connective tissue with critical functions in cellular
adhesion and migration. When in the extracellular matrix, proteoglycans form large complexes to
14

Figure 1.15. (a) Major repeating disaccharide unit of (i) heparan sulfate; (ii) heparin; and (iii) variable repeating
disaccharide unit of heparin and heparan sulfate. (b) Equilibrium between the two major conformations found
in IdoA(2S) residues of heparin and heparan sulfate. From Refs. 132-134
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other proteoglycans, to hyaluronan, and to fibrous matrix proteins such as collagen, affecting the
activity and stability of proteins and signaling molecules within the matrix . Heparan sulfate is a
sulfated glycosaminoglycan with numerous important biological activities associated with its
interaction with diverse proteins, including growth factors, proteases, lipid-binding proteins, and
adhesion proteins.
Heparan sulfate interacts with a range of proteins, growth factors, and enzymes. Recognition is
affected by the glycosidic linkages, conformation, sulfate position, and associated cations.(135)
Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which
antithrombin inhibits serine proteases in the blood coagulation cascade. Fondaparinux (FPX), a
synthetic glycosaminoglycan, is one example of the structure activity relationship required to
produce an antithrombotic (AT) agent.(136) The variation of number and position of carboxylates
and sulfates on the FPX chain confirmed these essential features for AT binding. The main
example of HS–protein interactions is the binding to fibroblast growth factors (FGFs), a family of
23 structurally related polypeptides involved in developmental and physiological processes
including cell proliferation, differentiation, morphogenesis and angiogenesis.(135, 136) Fibroblast
Growth Factors (FGFs) are involved in differentiation, proliferation, and angiogenesis through
high affinity interactions with their receptors. Heparan sulfate protects FGFs from degradation and
assists their binding to receptors.(137) Again, heparan sulfate chain length, sulfation pattern, and
conformation all play integral roles in their attachment to growth factors.(138) Binding of basic
FGF to cell surface HSPG is necessary for its recruitment of high affinity FGF receptors and for
its activity. In an initial step, these effects are exerted through binding to four highly related
transmembrane tyrosine kinase receptors (FGFR1–FGFR4) resulting in FGF–FGFR dimerization,
Figure 1.17.(139) This results in trans-autophosphorylation of FGFRs at intracellular tyrosine
residues and the activation of the Ras/mitogen-activated protein kinase and/or phosphoinositide 3kinases (PI3K)/Akt signaling networks.(140) Increased stimulation of receptor tyrosine kinases
(RTKs) by growth factors is associated with the metastatic spread of cancerous cells.(141)
Furthermore, heparan sulfate can be cleaved at the glycosidic bonds by both mammalian and
16

Figure 1.16: Involvement of heparin and heparan sulfate in important physiological processes. From Ref. 143

Figure 1: Proposed mechanism of anti-angiogenesis; PPC binding to

Figure 1.17 Free growth factors bind to the HSPGs and are cleaved by heparanse. Heparan Sulfate then
heparan
sulfatebetween
blocksthe
growth
interaction
heparanase
mediates
the dimerization
growthfactor
factor and
its receptorand
for accumulation
intocleavage.
the cancer cell,
resulting in growth. Proposed mechanism of metastatic and angiogenic hindrance from PPC binding.
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bacterial enzymes. In the mammalian case, enzymatic degradation by heparanase releases protumorigenic growth factors.(142)
Due to the highly anionic nature of heparan sulfate, HS may associate with many physiological
relevant cations which affects the conformation of the heparan sulfate chain.(143-145) Manganese
deficiency in animals has significant effects on the production of hyaluronic acid, chondroitin
sulfate, heparin, and other forms of mucopolysaccharides that are important for growth and
maintenance of connective tissue, cartilage, and bone.(146) It was found that Mn2+ had the
strongest afﬁnity toward heparin, in terms of decreasing afﬁnities toward heparin, the relative
relationships were Mn2+ > Cu2+ > Ca2+ > Zn2+ > Co2+ > Na+ > Mg2+ > Fe3+ > Ni2+ > Al3+ >
Sr2+.(147) Furthermore, Mn2+ had the second highest number of heparin-binding sites at 66.(147)
The insulin-like properties of vanadium salts have also attracted much attention in the cases of
insulin resistances or deficiencies.(148-151) Vanadate’s close resemblance to phosphates enables
it to inhibit many of the enzymes that are involved in phosphate metabolism.(152) Recently,
vanadium has been shown to activate the ERK pathway via phosphorylation of the EGF-R.(153,
154) Cu2+ promotes angiogenesis and modulates vascular endothelium growth factor (VEGF)
activity.(155, 156) The application of hard and soft acid and base concepts of these simple metals
can be expected to produce new patterns of metal ion binding with the hard sulfate base on the HS
chain.
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1.4 Inhibitors

The development of heparanase inhibitors for the treatment of highly malignant tumors is therefore
of considerable interest. Heparanase inhibitors are a group of compounds inhibiting/decreasing
heparanase enzymatic activity, which abolish degradation of heparanase on HS of extracellular
matrix (ECM) and thus subsequential cascade. As an analog of the natural substrate of heparanase,
heparin is commonly considered to be a potent inhibitor of heparanase as an alternative enzyme
substrate. This activity is attributed to the high affinity heparin–enzyme interaction and the limited
degradation of heparin. Heparin, as well as other sulfated polysaccharides, inhibits tumor cell
heparanase, however, its use is limited due to its potent anticoagulant activity.(157-159) This
drawback has stimulated research into the potential use of modified, nonanticoagulant species of
heparin.(157-159) There are other examples of heparanase inhibitors as heparan sulfate mimics to
produce an alternative enzyme substrate. Glycol-split N-acetyl heparin shows dramatically
increased heparanase-inhibiting activity with substantial loss of the anticoagulant activity due to
cleavage of C-2–C-3 bonds which are essential for binding to antithrombin, Figure 1.18.( 157-159)
Heparanase enzyme activity can be inhibited by shorter but more extensively sulfated
oligosaccharides, like PI-88, a highly sulfated phosphosulfomannan, Figure 1.18. The success of
PI-88 inspired development of additional oligosaccharide-based heparanase inhibitors, mimicking
GAGs as prototypes, like oligomannurarate sulfate, Figure 1.18. Suramin, Figure 1.18, is a
polysulfonated naphthyl urea that inhibits heparanase with an IC50 of 48 μM.( 157-159) Synthetic,
linear, noncarbohydrate polyanionic polymers have also been studied as heparin mimetics. Besides
heparanase substrate mimetics, development of small-molecular weight compounds directly
inhibiting heparanase activity was also studied.( 157-159) The structure activity relationship study
of this class of compounds led to 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2yl]phenyl]-2,3-dihydro-1,3-dioxo-1 H-isoindole-5-carboxylic acid, benzoxazol-5-yl-acetic acids,
and 1,3-bis-[4-(1 H-benzoimidazol-2-yl)-phenyl]-urea, Figure 1.18, which displayed heparanase
inhibitory activity and antiangiogenic effects.( 157-159) Currently, all heparanase inhibitors raise
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Figure 1.18: Stuctures of Heparanase Inhibitors.
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specificity concerns, which gives rise to new approaches that develop effective and highly
specific heparanase inhibitors.
The development of Growth Factor-Growth Factor Receptor inhibitors for the treatment of
uncontrollable tumor growth is also of considerable interest, Figure 1.19.(160-164) This has led to
the development of targeted agents for cancer treatment to target these pathways, strategies like
monoclonal antibodies (mAbs) and protein kinase inhibitors that are designed to target the GFRs.
mAb therapeutics act by directly blocking the function of GFRs and/or by antibody-dependent
cytotoxicity.(165) Protein kinase inhibitors inhibit the cytoplasmic kinase activity of growth
receptors and subsequently their downstream signaling cascades by rapidly crossing the cell
plasma membranes and competing with phosphate donor adenosine tyrosine phosphate (ATP)
and/or phosphorylation substrates.(166) Similar to heparanase inhibitors, heparin mimetics have
also been used to inhibit growth factors by offering a different substrate than HSPGs. Resistances
have been linked to the compensatory pathways mediated by other GFRs or mutations in
downstream signaling pathways.(167) Targeting multiple GFs/GFRs offers signiﬁcant therapeutic
potential in cancer therapy, since overexpression of GFRs is also responsible for resistance to
different drugs.
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Figure 1.19: Schematic diagrams of membrane bound growth factor receptors and their ligands involve in cancer
progression. Ligands are shown in boxes. (a) Epidermal growth factor receptor (ErbB/Her); (b) insulin-like growth
factor receptor; (c) transforming growth factor-beta receptor; (d) vascular endothelial growth factor receptor; (e)
platelet derived growth factor receptor, and (f) fibroblast growth factor receptor. ErbB2 (HER2) binds no known
epidermal growth factor-like ligands, and ErbB3 shows no tyrosine kinase activity. They relay signals by forming
heterodimer with other ErbB proteins from EGFR family. TGFβRIII does not pose any intracellular tyrosine
kinase domain. From Ref. 161-167

Figure 1.20 Structural analogies between phosphate and sulfate clamps and the arginine fork.
From Ref. 170
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1.5 Metallogylcomics

Heparan sulfate has the highest negative charge density of any known biological macromolecule,
sometimes referred to as “extracellular DNA”, because of its signaling ability, helical nature and
high content of negatively charged sulfate and carboxylate groups with an average of 2.7 sulfate
groups per disaccharide.(168) The highly anionic nature of HS means it associates with
physiologically relevant cations.(169) Therefore, HS may be a ligand receptor for anti-cancer
cationic metal complexes revealing a new mechanism of cellular accumulation with implications
for tumor selectivity.(170, 171) The interaction of PPCs with DNA is through the phosphate clamp,
analogous to the arginine fork, Figure 1.20.(172) The discovery of the phosphate clamp as a
biologically relevant binding motif suggested analogies with the isostructural sulfate. While these
interactions are similar, the sulfate-Pt interactions are weaker due to the negative charge being
more dispersed on a sulfate monoester from delocalization involving three non-ester oxygen atoms
compared to the phosphate diester with only two non-ester oxygen atoms.(173) This sulfate clamp
binding will affect protein recognition in strict analogy to inhibition of protein-DNA interactions
upon formation of Pt-DNA adducts, allowing extension to the consequences of strong PPC-HS
binding on the function of HS. Sulfate cluster binding is delocalized but will result in neutralization
of the sulfate charge and further physically protect the sulfate groups from their receptors.
“Metalloshielding” of HS by metal complexes through the binding of sulfate clusters, Figure 1.17,
could act on the processes of tumor growth and metastasis, expanding into the relevance of metal
complexes with HS.
Cellular internalization of PPCs are critical to their function as DNA binders. Interestingly, cellular
accumulation differs dramatically between the 6+ and 8+ congeners.(32, 170) The cellular
accumulation is higher than for cisplatin and actually increases with charge, further, accumulation
is higher in transformed mast cells in comparison to the parent cells, suggesting possible tumor
selectivity and overcoming acquired resistances of reduced platinum accumulation.(170)
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Discovery of HSPG-mediated cellular accumulation of PPCs has expanded this research to
understanding PPC–HS interactions and the functional consequences of such binding.
Metalloshielding could protect HS from the action of glycan-degrading enzymes and/or protein
recognition, similar to DNA-protein inhibition. Invasiveness of tumor cells involves many events
including adhesion to basement membrane, degradation of the basement membranes through the
action of HPSE, and migration in response to growth factors. Cellular invasion through ECM
requires degradation of the matrix by HPSE, and cell motility in response to growth factors. The
end-point of inhibition of HPSE activity and growth factor binding to HS through modulation of
growth factor signaling is the prevention of cell invasion and angiogenesis.
Understanding the structure activity relationship of metal-heparin binding interactions may extend
as a model for coordination complexes and their interactions to heparan sulfate. The ability to vary
oxidation state, coordination number and geometry, and lability of ligands allows investigation
into the structure and function on heparin. Furthermore, this sulfate-cluster interaction will result
in neutralization of the sulfate charge and protect the sulfate groups from interacting with their
receptors. Metalloshielding may prevent HS function through inhibition of enzyme and protein
recognition to HS. This prevention may occur through two potential approaches either as
heparanase cleavage inhibition or growth factor binding inhibition, Figure 1.21.
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Figure 1.21: Potential chemical approaches to inhibition of HS-associated enzyme and protein recognition and
activation through sulfate masking. From Ref. 103

Figure 1.22: Left: Absorption spectra of MB solutions at different concentration levels. The concentrations (from
bottom to top) were as follows: 0.4, 0.8, 1.2, 1.6, 2.0, 2.4, 2.8, 3.2, 3.6, 4.0, 4.4, 4.8, 5.2, 5.6, 6.0, and 6.4 x 10 -5
mol/L. Right: Absorption spectra of a mixture of MB (2.0 x 10-5 mol/L) and CHS. The concentrations of CHS
(from above to bottom at 664 nm) were as follows: 0.0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 x 10-5 mol/L. From Ref.
180
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1.6 My contributions to the field of metalloglycomics

Pt-DNA interactions have been widely studied with much of our understanding of M-HS binding
arising from these previous studies, for example the phosphate clamp and its isostructural sulfate
clamp.(173) Pt-DNA interactions undergo a “pre-association” or non-covalent interaction before
the covalent interaction is observed, this same “pre-association” may be extended to M-HS
binding.(174) Furthermore, the previous assumption that platinum complexes need to be neutral
to enter cells was contradicted by the higher cellular accumulation of the highly cationic PPCs
over cisplatin.(175) The mechanism of PPCs cellular internalization and reactivity with DNA
prompted studies into PPCs interactions with extracellular heparan sulfate proteoglycans (HSPG)
as the mechanism of internalization and inhibition of function of HS, Figure 1.21. The less
cytotoxic anticancer potential of other metal ammine complexes may be examined to elucidate the
structure-function relationship of interactions with HS.
In these studies, we chose to examine multiple substrates. We examined multiple types of heparin,
one maintained specific chain lengths while the other ranged between 3-18 kDa, however, both
types possessed great heterogeneity of sulfate number and pattern to more closely mimic the
heterogeneity of mammalian HS. Fondaparinux was chosen as a well-defined substrate in order to
more accurately obtain binding parameters and association constants with the metal complexes,
also FPX possesses a single point of cleavage when obtaining heparinase cleavage data.
Since HS interacts mainly through the sulfate regions, we verified that the key binding sites of our
metal complexes were also through these sulfate regions. Previously, the interaction of Methylene
Blue (MB) with heparin has been frequently investigated using spectroscopic techniques.(176179) In water, MB aggregates with heparin through charge neutralization, increasing the frequency
of MB dimer formation through π−π stacking.(180) The MB−heparin aggregation reduces the
absorbance of the sample since there are fewer MB molecules in solution. Higher heparin
concentrations disperse the MB−heparin aggregate due to the electrostatic repulsion between
heparin chains allowing MB to self-aggregate, resulting in an increase in absorbance at 570 nm,
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Figure 1.23: Sulfate loss in the octasaccharide DP8 by binding to polynuclear platinum complexes at varying ESIMS/MS voltages. From Ref. 181

Figure 1.24. 1H NMR chemical shifts for D-Glucosamine-6-O-sulfate plus 1.3 equivalent Zn (OAc). From
Ref. 186
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Figure 1.22.(181) In this work, I developed a competitive assay using MB as a reporter to verify
interactions with the sulfate regions, increasing the concentration of metal complexes protected
more heparin/FPX chains from interacting with MB. This inhibition of MB interaction increased
the amount of free, unbound MB in solution concomitantly increasing the absorbance. This
absorbance increase allowed for the calculation of IC50s of the concentration of metal complexes
required to inhibit MB from interacting with heparin/FPX, furthermore, the apparent dissociation
constants were also calculated.
Confirming the potential for high-affinity binding to the sulfates of heparin, ESI-MS was
previously employed on a model DP8 octasaccharide in the presence of the highly charged 6+
(AH44) and 8+ (TriplatinNC) ions. (182) This non-covalent interaction is the first demonstration
of a platinum compound interaction with a sulfated polysaccharide. The sulfate moieties on
heparin are quite labile and the spectrum of free octasaccharides showed a series of peaks
corresponding to sequential sulfate loss. In contrast, the initial MS of the Pt-heparin adducts shows
little loss compared to the unprotected heparin. ESI-MS/MS of the 1:1 adducts at increasing
energies also shows stabilization toward sulfate loss, Figure 1.23.(181) The stabilization is
dependent on size and charge of the non-covalent platinum compound with the 8+ compound
significantly more effective. Various metal ions have also been shown to induce a conformational
contraction in heparins structure due to the number of metal ion adducts, the ionic radii, and the
ionic valence of metal ions through TOF-MS.(182) This observation suggests a conformational
change of heparin induced by metal ions that may alter the interactions of heparin and heparinbinding proteins. (182) ESMS of heparin fragments as ammonium salts may also provide a
valuable method for their analysis in combination with binding and inhibition assays providing an
opportunity to derive structural requirements, such as size, charge density, and sequence, in
relation to biological activity; while MS/MS analysis may provide complete sequence reporting
for highly sulfated heparin chains if the precursor molecular ion has its acidic groups deprotonated
through Na+/H+ exchange.(183, 184) To confirm sulfate interactions with metal complexes, I
employed ESI-MS in this work to determine stoichiometry and sulfate protection.
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Figure 1.25. Top Left: 59Co NMR spectrum of 10 mM (+/-)-[Co(en)3]Cl3 solution. Left Bottom: 59Co NMR
spectrum of 10 mM (+/-)-[Co(en)3]Cl3 solution combined with 50 mM sodium d-tartrate. Right: Structure of dtartrate. From Ref. 187
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NMR has also been used in order to ascertain which residues in heparin may be responsible for its
metal binding capacities.(185) 1H NMR produced very small shifts of D-Glucosamine-6-O-sulfate
when interacted with zinc acetate, Figure 1.24.(186) The main shifts were observed at the H6 and
the anomericprotons, which corresponds to the sulfate as the key binding site.(4) Since
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Co

possesses a relatively high magnetogyric ratio with a magnetic mixing of its occupied and
excited d orbitals, it experiences substantial paramagnetic deshielding, >15,000 ppm, that will
reveal even minute changes in its chemical environment.(187) The cobalt chemical shift for the
cobalt atom in [Co(en)3]3+ hydrogen–deuterium isotopomers show about a 5 ppm shift for each
hydrogen atom that is replaced by a deuterium atom.(188) Furthermore, with a nuclear spin
number of 7/2 associated with a quadrupole moment that provides a very efficient relaxation
mechanism,
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Co spectra possess broad solution phase resonances. Therefore, the nuclear

quadrupole moment of 59Co requires the cobalt atom to occupy a highly symmetric environment
in order to yield line widths of 100–200 Hz. The cobalt ion in the cobalt complex [Co(en)3]3+
resides in an octahedrally symmetric environment and possesses a relatively narrow line width,
however, when the racemic[Co(en)3]3+ ion pairs with d-tartrate ion, this results in diastereomeric
ion pairs having clearly separated 59Co NMR resonances that differ in chemical shift by about 5–
6 ppm, Figure 1.25.(188) In this work, I followed each proton shift of D-glucosamine-6-O-sulfate
when bound to metal complexes at a 1:1 mixing using 1H NMR. To verify that these cobalt
compounds may interact covalently with the monomer, I also employed 59Co NMR and compared
the obtained shifts with previously published spectra. Since we verified that these metal complexes
interact with heparin/FPX through the sulfate regions, we continued with studies to elucidate the
mechanism of internalization and inhibition of function on HS.
Previously, our lab investigated the internalization of PPCs mediated through HSPGs and
association to the final target of DNA.(189) In this work, we obtained estimations of associations
between metal complexes on heparin/FPX vs DNA using Fluorescence Polarization (FP) and
Ethidium Bromide (EtBr). FP demonstrated similar affinities of metal complexes for heparin as
for DNA. EtBr verified this data through FPX sequestering of the metal complexes from DNA. In
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Figure 1.26. Competition of TAMRA-R9 internalization and Platinum compound in wt CHO cells.
Compounds (10 μM) were added 5 min prior to the addition of TAMRA-R9 (1.0 μM) and analyzed by
fluorescence microscopy. Cells were counterstained with Hoescht 33342. Panels: (A) Control; (B) Cisplatin;
(C) Oxaliplatin; (D) TriplatinNC; (E) AH44; (F) BBR3464. Bar = 10 μm. From Ref. 189
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order to probe the metal-HS interaction nonaarginine was chosen since it binds to cell surface HS.
The interaction of TAMRA-R9 with HS has been investigated using spectroscopic techniques.(189,
190) Cellular uptake of TAMRA-R9 in the presence of platinum drugs was examined, upon drug
incubation, TAMRA-R9 cell entry was prevented in a charge-dependent manner, Figure 1.26.(189)
Furthermore, the affinity of TAMRA–R9 for soluble heparin was also quantitated by direct titration
monitored by fluorescence spectroscopy.(190) To determine the value of the equilibrium
dissociation constant (Kd), binding data were fitted by nonlinear regression analysis to the
equation: Kdn =

[heparin][TAMRA–R9]n/[heparin·nTAMRA–R9].(190)

Because

heparin

(Mr 3000) and TAMRA–R9 (Mr 1836) are essentially homopolymers of similar mass, the value
of n is likely to be near unity, for n = 1, Kd = 109 ± 13 nM.(190) In this work, I developed a
competitive assay using TAMRA-R9 as a reporter to indirectly determine the metalloshielding
ability of these metal complexes on heparin, increasing the concentration of metal complexes
protected more heparin chains from interacting with TAMRA-R9. This inhibition of TAMRA-R9
interaction increased the amount of free, unbound TAMRA-R9 in solution concomitantly
decreasing the fluorescence. This fluorescence decrease allowed for the calculation of IC50s of the
concentration of metal complexes required to inhibit TAMRA-R9 from interacting with heparin.
Direct analysis of metal-heparin/FPX interactions was performed to confirm the strength of
binding using Isothermal Titration Calorimetry (ITC) and Surface Plasmon Resonance (SPR).
Previously, growth factor-homogeneous heparin mimetic interactions were measured using ITC,
Figure 1.27.(191) Binding parameters were obtained with calculated dissociation constants in the
nM range.(191) While growth factor-heterogeneous heparin mimetic interactions were measured
using ITC, Figure 1.28, the binding parameters were obtained with calculated dissociation
constants in the µM range.(192) In this work, I developed and refined the ITC assay to determine
association constants of metal complexes-heparin/FPX that were in the same range as growth
factors-HS. SPR was also used to more closely mimic cell surface bound HSPGs and their
interactions with metal complexes, which were also in the range of previously reported growth
factors-heparin interactions as calculated from SPR in the nM range.(193)
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Figure 1.27: ITC titrations of FGF with heparin mimetics. Left: Sample titration of FGF2 with HM8. Top panel:
raw heating power data; the first peak represents a small pre-injection (5 μl) that is omitted in the integrated
data. Bottom panel: data after peak integration and concentration normalization. Curve fit of the data to a single
site binding model. Right: Isotherms for binding of HM6 (open squares) or HM8 (filled squares) to FGF1, and
for binding of HM6 (open triangles) or HM8 (filled triangles) to FGF2. Dotted vertical lines indicate the
equivalence point of the titrations with HM6and HM8 at a molar ratio (HM:FGF) of 1 and 0.5. The sample cell
contained 5 μM FGF, and HM were titrated from a 65 μM stock solution. From Ref. 191
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Figure 1.28. Analysis of FGF1-heparin hexasaccharide interaction by direct (a) and reverse (b) titrations. In
the direct titration, 100 μM FGF1 was titrated into 7 μM hexasaccharide and in the reverse titration, 100 μM
heparin was titrated into 12.5 μM FGF1. (Upper panel) Calorimetric titration trace with the integrated
isotherms (shown in lower panel). (Solid lines) Best fit to the noncooperative McGhee-von Hippel model. (c)
Thermodynamic dissection of the interaction between FGF1 and heparin hexasaccharide. (Shading) Free
energy of binding (ΔG); (crosshatch) enthalpy of binding (ΔH); (diagonal shading) entropy of binding
(−TΔS). From Ref. 192
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HSs are acted upon by the bacterial enzyme heparinase, used to mimic the cleavage of mammalian
heparanase. Degradation by heparanase releases angiogenic and growth factors leading to tumor
cell migration, growth, and angiogenesis. Heparanase overexpression is associated with tumor
progression and there is significant correlation between metastatic potential and heparanase
activity.(194-197) To examine the efficacy of metalloshielding in blocking heparinase and
heparanase action on HS-containing proteoglycans we used the sulfated pentasaccharide,
Fondaparinux as a model HS-like substrate. FPX is a substrate for both bacterial heparinases and
human heparanase and has been used in assay development for screening the efficiency and
kinetics of potential heparanase inhibitors.(198, 199) FPX is an ideal substrate because it is
homogeneous with a single point of cleavage by either enzyme which leads to the formation of
only two products. 1H NMR and colorimetric assays for enzymatic activity have been
developed.(199) These assays were adapted to examine the inhibitory effect of metal complexes
on the enzymatic (heparinase) degradation of Fondaparinux.(200) 1H NMR follows the proton
shift, mainly the anomeric protons, after cleavage, while the colorimetric assay follows the creation
of a double bond that absorbs at 584 nm. Furthermore, cellular invasion through the extracellular
matrix (ECM) requires degradation of the matrix by HPSE, and cell motility in response to growth
factors. The ability of metal complexes to inhibit cell invasion through matrigel basement
membrane was also accessed using a Boyden-chamber assay.(201) Previously, inhibition of
heparinase cleavage is effective in a charge and concentration-dependent manner for the metal
compounds, Figure 1.29.(200)
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Figure 1.29. Inhibition of heparinase I Fondiparinux
cleavage (3h incubation) by polynuclear platinum
complexes and the arginine-rich R9 protein (1:3
stoichiometry). From Ref. 200
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1.7 Thesis Outline

The study of coordination complexes with HS-GAGs has several applications in the field of
bioinorganic chemistry distinct from the well-studied protein and DNA/RNA interactions.
Extending from simple to polynuclear, metal complexes were chosen to examine the effects on the
structure and function of HS, Figure 1.17. The application of hard and soft acid and base concepts
can be expected to produce new patterns of metal ion binding with the hard sulfate base on the HS
chain. Further, electrostatic and hydrogen-bonding interactions should provide opportunities for
“non-covalent” interactions compared to “covalent” interactions.
Chapter 2 describes work that I collaborated on and that was published in Chemistry: A European
Journal, investigating the interactions of PPCs with the well-defined pentasaccharide
fondaparinux. Chapter 3 describes work that I collaborated on and that was published in Inorganic
Chemistry, investing the interactions of simple metal complexes with heterogeneous heparin.
Chapter 4 describes work that I collaborated on, investigating the interactions of simple covalent
cobalt complexes with fondaparinux. Chapter 5 describes work that I collaborated on, investigating
the interactions of simple non-covalent cobalt complexes with fondaparinux. Chapter 6 describes
work that I collaborated on, investigating the interactions of simple metal complexes with
fondaparinux. Chapter 7 details the synthesis and characterization of Werner’s Complex.
Published work will be included in a format as close as possible to that in which it was published.
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2.1 Abstract:

Cleavage of heparan sulfate proteoglycans (HSPGs) by the enzyme heparanase modulates tumourrelated events including angiogenesis, cell invasion, and metastasis. Metalloshielding of heparan
sulfate (HS) by positively charged polynuclear platinum complexes (PPCs) effectively inhibits
physiologically critical HS functions. Studies using bacterial P. heparinus heparinase II showed
that a library of Pt complexes varying in charge and nuclearity and the presence or absence of a
dangling amine inhibits the cleavage activity of the enzyme on the synthetic pentasaccharide,
Fondaparinux (FPX). Charge-dependent affinity of PPC for FPX was seen in competition assays
with methylene blue and ethidium bromide. The dissociation constant (Kd) of TriplatinNC for
FPX was directly measured by isothermal titration calorimetry (ITC). The trend in DFT calculated
interaction energies with heparin fragments is consistent with the spectroscopic studies.
Competitive inhibition of TAMRA-R9 internalization in human carcinoma (HCT116) cells along
with studies in HCT116, wildtype CHO and mutant CHO-pgsA745 (lacking HS/CS) cells confirm
that HSPG-mediated interactions play an important role in the cellular accumulation of PPCs.

2.2 Introduction:

The heparanase/heparan sulfate proteoglycan (HPSE/HSPG) interaction is central to many
initiating processes of the angiogenesis cascade.(1, 2) Heparanase degrades heparan sulfate (HS)
into shorter fragments at the cell surface and within the extracellular matrix through its β‐
endoglycosidase activity. These considerations, combined with glycan overexpression on many
tumour

surfaces

make

proteoglycans

significant

drug

targets

of

high

biological

relevance.(1, 2) The sulfate residues are the critical recognition features for HS interaction with
protein substrates such as growth factors. We have recently shown that sulfate cluster masking, or
“metalloshielding”, by clinically relevant anticancer polynuclear platinum complexes (PPCs)—
Triplatin (BBR3464) and its substitution‐ inert analogue TriplatinNC—is an effective way to
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Scheme 2.1. Structures of the Polynuclear Platinum Compounds (PPC Library). Counter‐ anions omitted for
clarity. All compounds with the exception of [Pt(NH3)4]Cl2 were synthesised and used as nitrate salts.
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protect HS from the actions of its associated enzymes and proteins.(3-5) By protecting the
substrate, the shielding concept is a complementary and attractive alternative to the time‐
consuming synthesis of small oligosaccharides, which are generally designed to act as competitive
inhibitors toward heparanase.(1, 2) In this sense, the substrate protection is analogous to that of
metal complex–DNA interactions with effects on protein recognition.
To define the detailed structure–activity relationships involved in inhibition of the HPSE/HSPG
interaction through sulfate cluster masking by PPCs, it is necessary to consider the role of HS as
ligand in coordination chemistry. The heterogeneity of heparin and HS, especially with respect to
sulfation patterns, raises challenges for systematic approaches to this understanding.(6, 7) In this
respect, we have previously used Fondaparinux (FPX) for mechanistic studies.(3, 4) FPX is a
well‐ defined, highly sulfated synthetic glycosaminoglycan‐ based fragment that has been used
clinically as an antithrombotic agent since the 1940s.(8) It is a substrate for both bacterial
heparinases and human heparanase and is useful in screening the efficiency and reaction kinetics
of potential heparanase inhibitors.(9-11) Fondaparinux is also an ideal substrate for mechanistic
studies because it is homogeneous, has low molecular weight, and represents a single point of
cleavage for both mammalian and bacterial enzymes.(9, 11) The course of FPX hydrolysis can
conveniently be determined by 1H NMR spectroscopy because the anomeric protons are sensitive
reporters of the cleavage reaction by both heparanase and the bacterial heparinases.(10, 12)
To develop structure–activity relationships, we have synthesised a small focused library of PPCs
(Scheme 2.1) to examine the effects of charge and dangling amine on their interactions with FPX
and the biological consequences thereof. In this paper we describe cleavage inhibition studies in
the presence/absence of the PPC library using bacterial heparinase (P. heparinus heparinase II)
and confirm the generality of the metalloshielding concept for the structurally distinct
enzymes.3, 4 All

complexes

except

the

“control”

mononuclear

Pt‐ tetraammine

[Pt(NH3)4]2+ completely blocked the enzyme activity on FPX. Competition assays with methylene
blue (MB) and ethidium bromide (EtBr) as reporter molecules describe approaches to measure the
affinity of each compound for FPX binding and compare the results with the extensively studied
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Scheme 2.2. Synthesis of MonoplatinNC, DiplatinNC and TetraplatinNC.
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DNA interactions. The combined data is correlated with calculated energies of interaction for
PPC–heparin fragments from DFT. These studies contribute to the systematic development of
metalloglycomics—the study of the effects of metal ions and coordination compounds on
oligosaccharides—expanding the study of bioinorganic chemistry to the third major biomolecule
after the well‐ studied proteins and nucleic acids.(13)

2.3 Results and Discussion:

Synthesis of the PPC library
The library of PPC compounds used in this study is shown in Scheme 2.1. The compounds were
chosen to examine variation in total positive charge, nuclearity (mono/di/tri Pt units) and the
presence or absence of a dangling amine. The modular nature of PPCs lends itself to systematic
synthetic procedures as illustrated for the newly reported compounds MonoplatinNC, DiplatinNC,
and TetraplatinNC in Scheme 2.2.
Inhibition of enzyme activity on FPX by PPCs
Cleavage inhibition studies were performed on the sulfated pentasaccharide Fondaparinux (FPX),
as a model HS‐ like substrate, using the bacterial enzyme (P. heparinus heparinase II). The assay
was performed as reported previously, where the effect of enzyme on FPX cleavage was monitored
by following the anomeric region of the 1H NMR spectrum of FPX.(4, 10) Cleavage of FPX by
the enzyme results in the formation of a trisaccharide unit and a double‐ bond containing
disaccharide unit. Consistent with the formation of a double bond after enzyme treatment, the
signal for HD4 (δ=4.06 ppm in FPX) shifts to δ=5.89 ppm (HD4′) and the signal for HD5 disappears.
Scheme 2.3 shows the enzymatic cleavage products of FPX when treated with P.
heparinus heparinase II and Figure 2.1 shows the cleavage of FPX in the absence of Pt compounds
over 24 h (positive control).
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Scheme 2.3. Structures of Fondaparinux and cleavage products by P.
heparinus heparinase II. In the presence of PPCs, cleavage was completely
inhibited.

Figure 2.1. Cleavage of FPX by P. heparinus heparinase II. FPX was incubated with P. heparinus heparinase II,
and 1H NMR spectra were recorded without enzyme and at different time points after addition of enzyme.
Decrease of 1H NMR peaks of interest are indicated with asterisks. Olefinic proton at 5.89 ppm obtained due
to cleavage of Fondaparinux labelled as D4´ (see scheme 1).
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To evaluate the ability of the PPC library to inhibit the enzymatic cleavage of FPX, the substrate
was pre‐ incubated with each of the Pt complexes in a 1:1 stoichiometric ratio for 10 min prior to
the addition of the enzyme. Figure 2.2 a shows the anomeric region of the 1H NMR spectra of FPX
in the presence of one equivalent of each of the Pt complexes. Upon addition of the enzyme to
each sample, reactions were followed for the next 24 h by 1H NMR spectroscopy (Figure 2.2 b).
All Pt complexes completely inhibited FPX cleavage, with the exception of the mononuclear
[Pt(NH3)4]2+, for which weak signals corresponding to cleavage were observed. MonoplatinNC
differs from the Pt‐ tetraammine by the presence of dangling amine groups, giving an overall
higher charge (see Scheme 2.1). The different behaviour of these two mononuclear complexes in
cleavage inhibition indicates the importance of dangling amines. Following on from our first
demonstration,4 PPCs can now be considered a class of inhibitors of heparanase/heparinase
cleavage. Charge dispersion, either through dangling amines or multiple Pt‐ tetraammine
coordination spheres, is needed for the effective inhibition of enzymatic cleavage of HS substrates.
Di‐ and tetra‐ saccharide fragments inhibit the function of B. eggerthii heparinase II (bacterial
enzyme) on FPX.(10) The tetra‐ saccharide completely inhibited FPX cleavage, whereas the di‐
saccharide inhibited the cleavage for the first 60 min of enzyme exposure after which only minor
levels of cleavage of FPX was observed.(10) Thus, the metalloshielding approach is an attractive
alternative to the time‐ and material‐ costly synthesis of oligosaccharide mimetics.
The nature of the PPC–FPX and PPC–HS interactions
NMR Studies
The NMR chemical shift changes of FPX in the presence of stoichiometric ratios of PPCs were
analysed to delineate the critical features for effective metalloshielding (Table 2.1). Highly
positively charged PPCs induce changes to the chemical shifts of the anomeric protons of
GlcNS(6S), GlcNS(3S)(6S), IdoA(2S) and GlcNS(6S) residues of FPX (Rings A, C, D and E,
respectively, Scheme 2.3), suggesting the importance of delocalized positive charge of PPC for
the favourable interaction with HS fragments. MonoplatinNC produced only slight chemical shift
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Figure 2.2. Anomeric region of the 1H NMR spectra of 1:1 mixtures of FPX and various PPCs a)
after 10 min incubation in 20 mM Tris buffer, pH 7.5; b) 24 h after treatment with P.
heparinus heparinase II enzyme. Peaks indicated with asterisks in (b) represent FPX cleavage
products in the presence of the mononuclear complex, [Pt(NH3)4]2+.

Table 2.1. 1H NMR chemical shift changes [Δδ=δ(FPX : PPC)−δ(FPX)]
after incubation of Pt complexes with FPX for 10 min at 37 °C.
[a] For assignment of the anomeric protons see Scheme 3.
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changes whereas no discernible shifts were seen for [Pt(NH3)4]2+. TriplatinNC and AH44 caused
the largest changes, with AH44 significantly affecting the anomeric protons of the terminal and
central glucosamine units, suggesting a favourable interaction between AH44 and sulfate groups
of Ring A and Ring C, and showing the effect of the third Pt centre, with presumably more
complex–FPX contacts. The HD1 and HD5 protons of IdoA(2S) (Ring D) are also significantly
affected by the trinuclear complexes. DiplatinNC, which carries the same 6+ charge as AH44, but
contains dangling amine groups on both the Pt centres, induces significant shifts only to these two
protons. IdoA(2S) residues of HS are highly conformationally flexible and can adopt both
the 1C4 chair and 2S0 skew boat conformations, whereas GlcNS residues prefer only 4C1 chair
conformation.(14, 15) The ratio of 1C4 and 2S0conformers of the IdoA(2S) residue of FPX in
solution is about 35:65.(14-16) The results suggest that PPCs change the ring conformation and/or
induce conformational changes to the important glycosidic linkages of the IdoA(2S) residue. The
NMR changes observed for the FPX anomeric protons in the 1:1 adducts of FPX–PPC validate the
reasons for effective inhibition of the enzymatic cleavage.
Protection of FPX against sulfate loss
Previous ESI‐MS studies showed that AH44 (6+) and TriplatinNC (8+) protect the sulfate groups
of an octasaccharide (DP8) against dissociation through the formation of sTable 2.1:1 adducts.3 In
the present work we used ESI‐MS to study the protection from sulfate loss of 1:1 PPC–FPX
adducts in the gas phase (Figure 2.3). The most abundant charge state observed in previous MS
studies of FPX was 3−, with three sulfo groups being cleaved and cation/H+ exchange reducing
SO3 loss.(17) Under our conditions, ESI‐MS spectra of free FPX also showed the sequential loss
of three sulfate moieties, whereas under the same conditions and in the presence of PPCs, sulfate
groups of FPX are protected in a manner dependent on charge and number of Pt centres. Consistent
with the high affinity FPX binding of TriplatinNC, no significant sulfate loss occurred. The same
was true for AH44, whereas for 1:1 FPX adducts of DiplatinNC (6+) there was also significant
protection, with only peaks of low intensity observed corresponding to loss of one and two
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SO3 groups. For the lower charged MonoplatinNC (4+), loss of two and three sulfate groups is
observed, but again by far the most dominant peak was the parent ion.
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPXTriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three
sulfates.
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPXTriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three
sulfates.
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPXTriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three
sulfates.
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.
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Figure 2.5. ESI-MS of FPX + AH78 showing multiple charge states with sulfate loss.

Figure 2.6. ESI-MS of FPX + AH44 showing multiple charge states with contamination of AH78
from previous runs.
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Figure 2.7. ESI-MS of FPX + DiPtNC showing multiple charge states.

Figure 2.8. ESI-MS of FPX + MonoPtNC showing multiple charge states with sequential sulfate loss,
and a 1:2 FPX:Pt binding stoichiometry.
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Figure 2.8. ESI-MS of FPX + MonoPtNC showing multiple charge states with sequential sulfate loss,
and a 1:2 FPX:Pt binding stoichiometry.
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DFT modelling of PPC–HS interactions
DFT studies were performed to delineate the effect of structural differences of PPCs in their
binding to various heparin fragments.(4) Interaction energies and comparison with individual
phosphate and sulfate are given in Table 2.2. Based on the previously reported interactions of the
heparin trimer with [Pt(NH3)4]2+, and heparin hexamer with TriplatinNC,(4) we have now
modelled the association of MonoplatinNC and DiplatinNC with a heparin tetramer [IdoA(2S)‐
Glc(NS)(6S)]2, as well as the association of AH44 with the analogous heparin hexamer
[IdoA(2S)‐ Glc(NS)(6S)]3. As previously described,4 the model fragments were derived from the
NMR‐ based structure PDB1HPN of the heparin dodecamer, comprising repeats of the
disaccharide units.(14, 18) The interaction energies as measured by DFT increase in the order Pt‐
tetraammine < MonoplatinNC < DiplatinNC < AH44 < TriplatinNC.
The heparin tetramer–MonoplatinNC model was designed such that the carbon chain of one of the
dangling amine groups stretched over the hydrophobic groove that is formed in the middle by the
hydrocarbon rings of the tetramer. The trans geometry of the Pt coordination sphere in
MonoplatinNC means that the other dangling amine is placed at the edge of the helix, with the free
amine (‐ CH2NH3+) interacting with N‐ sulfate of GlcNS(6S), which is in the middle of two
IdoA(2S) residues. The optimised structure is shown in Figure 2.9 a. The hydrocarbon chain along
the groove is seen to be involved in establishing van der Waals contact with hydrogen atoms from
two of the sugar residues. Moreover, the chain stretches all the way to the other side of the helix,
facilitating interaction of the free amine with N‐ sulfate and O‐ sulfate of terminal GlcNS(6S) and
IdoA(2S) residues, respectively, and also with a carboxylate group of the middle IdoA(2S) residue.
The interaction energy of the complex is −142 kcal mol−1 and is almost three times that of the
previously reported Pt‐ tetraammine‐ trimer interaction (Table 2.2).(4) The higher interaction
energy of MonoplatinNC compared to that of the Pt‐ tetraammine again emphasises the
importance of favourable interactions arising from the dangling amine ligands.
Based on the above structure, the interaction of DiplatinNC with heparin tetramer was designed
by introducing the second Pt centre at the dangling amine that traverses the groove. The optimised
70



Table 2.2. Interaction energies of isolated phosphate and sulfate anions and heparin fragments with Pt
coordination spheres in the PPC library (see Scheme 1). [a] From Ref. 4. [b] [GlcNS(6S)‐ IdoA(2S)‐
GlcNS(6S)]. [c] [IdoA(2S)‐ GlcNS(6S)]2. [d] [IdoA(2S)‐ GlcNS(6S)]3.
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structure of this interaction and the surface maps are shown in Figure 2.9 b. The second Pt centre
forms H‐ bonds with the N‐ sulfate of the terminal GlcNS(6S), the carboxylate of the middle
IdoA(2S) and O‐ sulfate of the terminal IdoA(2S) residues of the tetramer. The calculated
interaction energy is −171 kcal mol−1. The overlay of the optimised structures of the association
complexes formed by the tetramer with MonoplatinNC and DiplatinNC and the free tetramer
reveals the structural change that results following the interactions (Figure 2.10). It is noticeable
that, compared to free tetramer, the outer rings have moved in towards the Pt complex to facilitate
the interactions. MonoplatinNC induces more bending than DiplatinNC because the bulkier second
Pt centre needs to be accommodated among the negatively charged sulfate groups of the terminal
residues of the tetramer.
The structure of AH44 with hexamer reveals that the introduction of a third Pt centre, rather than
the dangling ammine of DiplatinNC, results in strong cluster binding with three sulfate groups
from terminal GlcNS(6S) and the central IdoA(2S) and GlcNS(6S) residues (Figure 2.9 c). The
interaction energy of this model is −202 kcal mol−1, which is greater than the interaction energies
of MonoplatinNC and DiplatinNC models (Table 2.2), indicating the favourable interaction of the
third Pt centre. For AH44, the hydrogen bonding cluster formation results in tighter binding
compared with the cluster formation involving free amine (‐ CH2NH3) groups of DiplatinNC.
As shown in the surface maps (Figure 2.9), electrostatic and hydrophobic interactions facilitate the
tight fit of PPCs with heparin fragments. Although the tetramer and hexamer sequences do not
match exactly that of FPX, the observation of sulfate clusters involving the IdoA(2S) residue is
consistent with the chemical shift changes observed and suggest that the Pt coordination spheres
may reside close to this residue.
Measurement of the FPX–PPC binding interaction
The NMR studies of the FPX–PPC interaction show significant chemical shift changes indicative
of strong binding, which is sufficient to inhibit cleavage of FPX by heparinase. To assess the
strength of the noncovalent FPX–PPC interaction for the different compounds in the PPC library,
two different competitive inhibition assays were developed (Figure 2.11 a). The first was based on
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Figure 2.9. a) Left: Optimised structure of heparin tetramer (stick) interacting with MonoplatinNC (ball
and stick): hydrogen bonding interactions of the free amine of the dangling amine are represented by
green dashed lines. The favourable van der Waals interactions among the hydrogens can be
inferred. Right: Solvent accessibility maps using a probe of 1.4 Å: These shows how well the Pt complex
fits the pockets and grooves in heparin. b) Left: Optimised structure of heparin tetramer (stick) interacting
with DiplatinNC (ball and stick): hydrogen bonding interactions of the second Pt centre are represented
by green dashed lines. Right: Solvent accessibility maps using a probe of 1.4 Å: Top, bottom and side
views show how well the Pt complex fits the pockets and grooves of the heparin unit. c) Left: Optimised
structure of heparin hexamer (stick) interacting with AH44 (ball and stick). Right: Solvent accessibility
maps using a probe of 1.4 Å: These maps show the relationship of AH44 (magenta) to the heparin
hexamer (green).

73

a spectroscopic investigation of the interaction of methylene blue (MB) with heparin and
HS.(6, 19) The second measured the displacement of intercalated ethidium bromide (EtBr) from
DNA, which is a useful assay to gauge the relative strengths of coordination compounds to
oligosaccharides (heparin/HS) versus oligonucleotides (DNA/RNA).(4, 6) To confirm the direct
strength of the FPX–PPC interactions, isothermal titration calorimetry (ITC) assays were also
performed.
Methylene blue reporter assay
The cationic dye methylene blue (MB) has been used to quantify sulfate content on heparin.(1922) The MB absorbance at 664 nm decreases proportionally with increasing heparin concentration,
allowing the calculation of binding constants.(6, 19) The addition of increasing concentrations of
FPX to a solution containing MB also resulted in the gradual decrease of MB absorbance (Figure
2.11 b, left). The association constant between MB and FPX was determined by the Scatchard plot
and the value (4.0±0.1×104 M−1) is two orders of magnitude lower compared with the previously
reported association constant between MB and the chondroitin sulfate (CS) polymer
(1.73×106 M−1).(19) We then studied the effect of metalloshielding on the MB–FPX interaction by
adding aliquots of MB to a solution containing FPX pre‐ incubated with varying concentrations
of PPCs. PPCs are competitive inhibitors of the MB–FPX interaction, as evidenced by the higher
absorbance of MB with increasing platinum complex concentration (Figure 2.11 b and Figure
2.12). The ability of PPCs to metalloshield FPX against MB binding may be reported as an
IC50 value, the concentration required to inhibit 50 % binding of MB to FPX. By using MB as a
reporter, the apparent dissociation constant (Kd(app)) between PPCs and FPX may then be
calculated. The results are shown in Table 2.3 and illustrate the systematic decrease in IC50 with
increase in positive charge. TriplatinNC, having the highest overall charge (8+), required the
lowest concentration to inhibit 50 % of MB binding to FPX, and the lowest apparent dissociation
constant. Slightly higher affinity was again also correlated with the number of Pt centres. Both
AH44 and DiplatinNC have the same 6+ charge, but AH44 with one more Pt centre gave slightly
lower IC50 and Kd(app) values.
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Figure 2.10. Overlay of optimized free heparin tetramer (pink),
heparin tetramer (turquoise) in complex with MonoplatinNC
(purple) and heparin tetramer (green) in complex with DiplatinNC
(violet). The alignment was centred at the middle two rings.

75

Ethidium bromide (EtBr) reporter assay
To compare the PPC–FPX interactions with the well‐ studied PPC–DNA interactions(5, 23, 24)an
ethidium bromide (EtBr) competition assay was developed applying EtBr as the reporter.(4)This
assay exploits the decrease in fluorescent properties when the intercalator is removed from DNA
under the influence of DNA–PPC binding. Upon FPX addition to the EtBr–PPC–DNA system, the
intercalator binds back to DNA as FPX sequesters the PPC (Figure 2.11 a).(4) The comparative
binding of different PPCs for DNA and FPX was estimated based on the FPX concentrations
required to sequester the PPC from DNA, thus allowing EtBr to intercalate, with a concomitant
increase in its fluorescence. Given that the ability to displace EtBr from DNA differs amongst the
complexes themselves, the concentration for any individual PPC required to produce an initial
≥50 % decrease in fluorescence was normalised as the modified EtBr–PPC–DNA fluorescence
([PPCd]) and 100 % fluorescence was control EtBr–DNA. The data are presented in the form of an
EC50 value, which reflects the concentration of FPX, [FPXr], required to restore EtBr fluorescence
to 50 % of the control EtBr–DNA sample in the absence of either PPC or FPX (Figure 2.11 c and
Table 2.3). Note that FPX has no effect on EtBr–DNA fluorescence. This allows a discussion of
the EC50 as a ratio index of [PPCd]/[FPXr] (Table 2.3). The ratio index suggests that above 1, PPCs
have more affinity for FPX than DNA, whereas below 1 PPCs have more affinity for DNA than
FPX. Thus, AH44 has similar affinities for DNA as FPX, with ratio index of 0.97, while
MonoplatinNC, DiplatinNC, and TriplatinNC all had slightly higher affinities for FPX than DNA.
[Pt(NH3)4]2+ has a very high ratio index but this reflects its very weak binding to DNA(25) and
thus was eliminated from the comparison of strongly binding DNA compounds (Figure 2.13).

Isothermal titration calorimetry (ITC)
ITC assays were performed to determine the binding constants between FPX and different PPCs.
Hydrogen bonding and electrostatic interactions contribute to the enthalpy term, whereas changes
in conformational freedom and solvation upon complex formation contribute to the entropy
term.(26, 27) The entropic term reflects the desolvation as a principal contributor.(27) Figure
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Figure 2.11. PPC–HS binding interaction as measured by EtBr and methylene blue (MB) reporter assays. a)
Schematic representation of PPC competitive inhibition of MB binding to FPX and sequestering of DNA bound
PPC by FPX. b) A; absorption spectra of a mixture of MB (18.6 μM) and FPX. The concentrations of FPX
(from top to bottom at 664 nm) were as follows: 0, 1, 2, 3, 5, 10, and 15 μM. B; absorption spectra of a mixture
of MB (18.6 μM), FPX (15 μM), and TriplatinNC. The concentrations of TriplatinNC (from above to bottom at
664 nm) were as follows: 14, 10, 5, and 0.5 μM. c) Curve graph for the EC50 values measured by EtBr reporter
assay showing the preference of PPCs for FPX, samples were normalised to the controls (no FPX as 0 % and
EtBr–DNA as 100 %). TriplatinNC data was taken from Ref. 4.
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2.14 shows the ITC analysis by direct titration for the binding of FPX to TriplatinNC, with similar
plots for other compounds from the PPC library shown in Figure 2.14. The derived dissociation
constants are given in Table 2.4 and the derived thermodynamic binding parameters are given in
Table 2.4. The PPCs follow the same trend seen in the MB assay. The dissociation constants again
show the same charge‐ dependency with the Kd value for TriplatinNC approximately three orders
of magnitude higher than that of [Pt(NH3)4]2+ and AH44 having slightly greater affinity than
DiplatinNC. Few ligand–heparin(HS) data have been reported. ITC has been used in heparin‐
growth factor interaction assays and in defining the thermodynamic parameters obtained from
these interactions. The Kd of a synthetic hexasaccharide with a homogeneous sulfation pattern
interacting with FGF1 and FGF2 gave values of 54 to 855 nM, respectively.(28) On the other hand,
a mixture of heterogeneous heparin chains showed a Kd of 1.1 to 3 μM for interaction with FGF‐
1.(29, 30) Considering the Kd for FPX–TriplatinNC from Table 2.4 as approximately 40 nM (0.4
μM), the strength of this interaction is broadly similar to that seen for FGF–oligosaccharide
interactions.
Summary
Indirect and direct assays give an estimate of the strength of the FPX–PPC interaction. The set of
assays developed give an estimate of strength of binding and relative FPX(HS)/DNA affinities.
Given clear variations in the quantitation of dissociation constants, care should be taken in
extrapolating across the assays discussed due to the inherent differences in the nature of these
assays. Thus, whereas ITC is a “two‐ body” system, the MB and EtBr competition assays become
“three‐ body and four‐ body” systems, respectively, and are consequently more difficult to
interpret. Nevertheless, the trends are consistent within each assay and strongly reflect a charge
dependence. In general, we suggest that use of complementary assays in this manner should be
encouraged to provide an overall picture of the metal complex–heparin(HS) interaction.(13)
Correlation of FPX binding with HSPG‐ mediated cellular accumulation of PPCs
The nature of the PPC–FPX interactions may also be relevant in considering the molecular details
of PPC cellular accumulation mediated by HS proteoglycans. Polyarginine cellular uptake is
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Table 2.3. FPX–PPC dissociation constants as measured by methylene blue (MB), ethidium bromide (EtBr)
reporter assays and isothermal titration calorimetry (ITC).
[a] MB IC50 indicates PPC concentration required to competitively inhibit 50 % of the MB dye from binding to
FPX. Association constants were calculated from the MB assay for PPCs binding to FPX using a two ligand‐ one
binding site Scatchard model. [b] ITC analysis reported in Table S1. [c] TriplatinNC data was taken from Ref. 4.
[d] EC50 is the concentration of FPX required to restore EtBr–DNA fluorescence, and was calculated from the
normalisation of 0 μM FPX as 0 % and DNA–EtBr only as 100 %. [e] Ratio index calculated from the
[PPCd]/[FPXr] where [PPCd] is the concentration required to produce an initial <50 % decrease in fluorescence
and [FPXr] is the concentration required to restore EtBr fluorescence to 50 % of the control EtBr–DNA sample in
absence of either PPC or FPX (see text).
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mediated by cell surface heparan sulfate proteoglycans (HSPGs).(31, 32) The conceptualization
of PPCs as “polyarginine mimics” led to the inhibition of the HSPG‐ mediated cellular
internalisation and nucleolar localization of the fluorescent‐ labelled nona‐ arginine peptide
(TAMRA‐ R9)

and

identification

of

HSPGs

as

receptors

for

PPC

cellular

internalisation.(33, 34) In contrast to the mononuclear clinical platinum agents such as cisplatin
and oxaliplatin, PPCs uniquely utilise this internalisation mechanism, which could provide an
approach for selective uptake into tumours with high levels of HSPGs.(34, 35)
TAMRA‐ R9 entry into human colorectal carcinoma (HCT 116) cells was examined in the
presence of different PPCs, which prevented cell entry of the peptide in a charge‐ dependent
manner (Figure 2.15 a). A complete inhibition of TAMRA‐ R9 fluorescence was observed in the
cells containing TetraplatinNC (10+) and TriplatinNC (8+), whereas the lesser‐ charged analogues
AH44 (6+) and DiplatinNC (6+) reduced the fluorescence somewhat. MonoplatinNC (4+) failed
to reduce any fluorescence. Differential accumulation of PPCs into wild type CHO‐ K1 and mutant
CHO‐ 745 (lacking HS and CS) confirmed the proteoglycan mediation (Figure 2.16).
The relative cellular accumulation of the PPC library in HCT 116 cells suggest the involvement of
dangling amine‐ dependent and size‐ dependent mechanisms (Figure 2.15 b). TriplatinNC′s
higher

cellular

accumulation

results.(34, 36) DiplatinNC,

compared

TriplatinNC,

with
and

AH44

is

TetraplatinNC

consistent

with

previous

showed

similar

cellular

accumulation, even though their overall charges ranged from 6+ to 10+, suggesting an influence
of the dangling amine. There is no strict correlation between TAMRA‐ R9 inhibition and cellular
accumulation—as evidenced in the comparison between DiplatinNC and AH44 (Figure 2.15 a and
b). Likewise, although MonoplatinNC failed to inhibit TAMRA‐ R9internalisation, it showed the
highest cellular accumulation compared with the other PPCs, and showed higher accumulation
into wildtype compared with mutant CHO cells (Figure 2.S7). The smaller size may allow it to use
multiple entry pathways including a size‐ dependent one.(37, 38) Small mononuclear platinum
drugs like cisplatin, carboplatin, and oxaliplatin reportedly use the hCTR1 copper influx
transporter for cell entry.(39) Furthermore, the cellular accumulation and cytotoxicity of the
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Figure 2.12. Absorption spectra of a mixture of MB (18.6 µM), FPX (15 µM), and PPCs. A) The concentrations
of [AH44] (from above to bottom at 664 nm) were as follows: 30, 20, 15, 12, 6, and 1 µM; B) The concentrations
of [DiplatinNC] (from above to bottom at 664 nm) were as follows: 30, 20, 15, and 10 µM; C) The concentrations
of [MonoplatinNC] (from above to bottom at 664 nm) were as follows: 50, 30, 20, 10, and 1 µM; D) The
concentrations of [Pt(NH3)4]2+ (from above to bottom at 664 nm) were as follows: 250, 100, 50, and 20 µM.
Charges omitted for clarity.
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Figure 2.13. Competitive inhibition of PPC-DNA binding by FPX as measured by EtBr reporter assay with 12.5
μM EtBr, 10μM ct-DNA and PPC (12.5μM TriplatinNC, 125μM AH44, 62.5μM DiplatinNC, 125μM
MonoplatinNC and 500μM Pt tetraammine) were incubated for 1h and then increasing concentrations of FPX
from 10-640μM were added and incubated again for an another 1h and read at 530/590 nm.


TriplatinNC data was taken from Peterson et al. 2017. 81
Plot was normalized to 0µM FPX as 0 % and DNA-EtBr
only as 100%.

covalently binding Triplatin (BBR3464) is also affected by copper status.(40 The relative
cytotoxicity of the PPC library in HCT 116 cells was investigated using MTT viability assays
(Figure 2.15 c). The PPC cytotoxicity was unpredictably related to their cellular uptake (Table
2.5).
Summary
This section extrapolated the enzyme inhibition and biophysical studies of the FPX–PPC
interaction to correlate with HSPG‐ mediated PPC cellular accumulation, considering FPX as a
small but well‐ defined HS model.(6, 34) Although there is clear evidence of proteoglycan
mediation for this class of molecules, there is no strict correlation with cellular accumulation. In
general, while HSPGs clearly affect cellular internalisation, the results emphasise that multiple
complementary pathways exist for small molecule internalisation and, for platinum complexes, no
single pathway is “all or nothing”.(36-38) The proteoglycan mediation is unique to the PPC class
and, coupled with the overexpression of glycans on many tumour cell surfaces,(1, 35) the results
do suggest potential avenues for tumour selectivity of PPC agents based on differential uptake.

2.4 Conclusions:

The results presented in this study demonstrate that the library of PPC complexes, with the
exception of the mononuclear [Pt(NH3)4]2+, completely inhibits cleavage of the model HS substrate
(FPX) by the bacterial P. heparinus heparinase II enzyme. Combined with previous results using
both bacterial heparinase I and human heparanase,(3, 4) PPCs are a structurally distinct class of
broad‐ spectrum heparanase cleavage inhibitors acting through metalloshielding. Oligosaccharide
mimetics have been widely studied for their ability to act as inhibitors of the heparanase enzyme,
and a number have entered clinical trials.(41, 42)Metalloshielding is an attractive alternative to
design of heparanase inhibitors and indeed the Phase I and Phase II clinical results of Triplatin
could be reinterpreted in light of these new glycan‐ related findings.(5, 13)
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Figure 2.14. ITC analysis of FPX by direct titration of A) [TriPlatinNC], B) [AH44], C) [DiPlatinNC], D)
[MonoPlatinNC], and E) [Pt(NH3)4]2+. A trace of calorimetric titration (upper panel) and integrated isotherms
(lower panel). The first peak represents a pre-injection that was omitted in the binding calculations.



TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr
only as 100%.
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The focused small library studied here begins to elucidate structure–activity relationships. The
stark contrast between [Pt(NH3)4]2+ and MonoplatinNC in inhibiting the HS cleavage emphasises
the importance of dangling amine moieties as well as increased charge dispersion. The relative
efficacy of the polynuclear set again shows that positive charge dispersion through dangling
amines and Pt coordination spheres play important roles in masking the HS fragments and
protecting them against enzymatic cleavage. The ability to form a “sulfate clamp” from the
interaction of am(m)ines in a Pt coordination unit are a priori likely to be more effective in masking
than the single positive charge of the dangling amine—nevertheless the two structural features do
contribute to the overall effect.
As part of our approach to metalloglycomics, we have developed direct and indirect assays to study
the nature and strength of “noncovalent” interactions on the biomolecule.(6, 13)Consistent trends
emerge—affinity is related to charge and in general these substitution‐ inert complexes show
broadly similar affinity to FPX and DNA. Heparin is often considered as having higher negative
charge density compared with that of polyanionic DNA, with an average negative charge of 2.7
per disaccharide compared to that of two negative charges per base pair for DNA.(7)
In this latter aspect, at least for substitution‐ inert complexes, the approaches to inhibition of HS
or DNA function are formally analogous—both protect the “substrate” from enzyme and/or protein
processing. High‐ affinity DNA binding through the phosphate clamp efficiently inhibits
transcription

factors

such

as

TBP

(TATA

box

binding proteins)

and

restriction

enzymes.(5, 23, 33) The Kd values found for PPC–FPX interactions are broadly similar to those
found for growth factor–oligosaccharide interactions.(28-30) This suggests that metalloshielding
will also be effective in inhibition of oligosaccharide‐ protein function as shown for the effect of
TriplatinNC on FGF‐ heparin interactions.(4) Overall, the results demonstrate the utility of the
metalloglycomics concept in developing new classes of molecules for study of glycan structure
and function. It is clear that oligosaccharides represent a viable alternative cellular target to
oligonucleotides and the results further emphasise the unique dual‐ function nature of the PPC
series compared with the mononuclear clinical agents.
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Table 2.4. ITC analysis showing the obtained binding parameters: dissociation constants (Kd); free energy of
binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS) between PPCs and FPX, best fit to a one
site model. The standard error from 3 measurements is indicated.
[a]
Kd measured in µM
[b]
Kd measured in nM
[c]
Gibbs Free Energy calculated from the enthalpy and entropy of binding



TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr
only as 100%.
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2.5 Experimental Section:

Synthesis and materials
[Pt(NH3)4]Cl2 was prepared by published methods.(43) TriplatinNC and AH44 (as nitrate salts)
were

prepared

as

described

previously.(23, 24) Fondaparinux

(GlcNS(6S)‐ GlcA‐

GlcNS(3S)(6S)‐ IdoA(2S)‐ GlcNS(6S)‐ OMe) was sourced from Sigma–Aldrich.
Synthesis of new compounds
MonoplatinNC: A mixture of trans‐ diamminedichloro‐ platinum (1 mmol) and AgNO3 (1.98
mmol) in anhydrous DMF (18 mL) was stirred overnight with protection from light, and AgCl was
then filtered off. A solution of the mono‐ Boc‐ 1,6‐ hexanediamine (2.2 mmol) in anhydrous
DMF (2 mL) was added to the filtrate. The mixture was stirred for three days at ambient
temperature, protected from light. The solvent was then removed under reduced pressure and the
residue was dissolved in H2O (100 mL) at 50 °C and filtered through a membrane filter to remove
any reduced silver and platinum. The filtrate was evaporated to dryness and the residue was
suspended in 0.5 M HNO3 (25 mL) and stirred for two days at room temperature. The mixture was
filtered through Celite to remove any unreacted starting materials and reduced silver/platinum. The
volume of the filtrate was reduced to almost dryness and acetone was added to force the
precipitation of the product. The formed precipitate (92.3 % yield) was filtered off then washed
with acetone and dried under vacuum. 1H NMR (300 MHz, D2O): δ=3.00 (t, J=6.6 Hz, 4H 4 H),
2.67 (t, J=7.2 Hz 4 H), 1.67 (m, 8 H), 1.39 ppm (m, 8 H); 195Pt NMR (300 MHz D2O): δ=−2658
ppm; elemental analysis calcd (%) for C12H40N10O12Pt: C 20.25, H 5.67, N 19.68; found: C 20.20;
H 5.54; N 19.44.
DiplatinNC‐ Boc: The nitrate salt of [{trans‐ PtCl(NH3)2}2{μ‐ H2N(CH2)6NH2}]2+ (1,1/t,t) was
synthesised from trans‐ diamminedichloroplatinum as previously reported.(44) To 1,1/t,t (1
mmol) dissolved in DMF (50 mL), AgNO3 (1.98 equiv) was added. The reaction was protected
from light and stirred for 16 h, then AgCl was removed by filtering through Celite. Mono‐ Boc‐
1,6‐ hexanediamine (2.2 equiv) was added to the filtrate and the reaction was stirred for two days
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Figure 2.15. An evaluation of PPCs cell uptake, accumulation, and overall cytotoxicity
in colorectal carcinomas cells (HCT 116). a) PPCs (10 μM) competition with
TAMRA‐ R9(1 μM) uptake was compared by the presence of fluorescence dye using
flow cytometry. b) Cellular accumulation of PPCs (10 μM) at 3 and 6 h prior to
collection was analysed using ICP‐ MS for Pt content. Pt readings were normalised
to cell number and number of Pt‐ centres for each compound. c) MTT assays were
employed to determine overall cytotoxicity of PPCs for a 72 h compound incubation.



TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM
FPX as 0 % and DNA-EtBr only as 100%.
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at room temperature. The solution was evaporated to dryness under reduced pressure and the
residue was dissolved in H2O (100 mL) at 60 °C and filtered through Celite to remove any reduced
platinum and silver. The filtrate was evaporated to dryness and acetone was added to precipitate
the product. The precipitate was collected through filtration then washed with acetone and dried
under vacuum to obtain the product (64 % yield). 1H NMR (300 MHz, D2O): δ=3.05 (t, J=9.0 Hz
4 H), 2.65 (m, 8 H), 1.60 (m, 12 H), 1.40 ppm (m, 30 H).
DiplatinNC: DiplatinNC‐ Boc (0.1 mmol) was suspended in 0.1 M HNO3 (25 mL) and stirred for
four days at 50 °C, at which time the suspension had turned into a clear almost colourless solution.
Completion of Boc‐ deprotection was confirmed by 1H NMR spectroscopic analysis. The solution
was filtered through Celite to remove any unreacted starting material. The filtrate was evaporated
to almost dryness and acetone was added to force the precipitation of the product. The residue was
collected through filtration and washed with methanol and acetone. The crude product (yield 93 %)
was recrystallised in water. 1H NMR (600 MHz, D2O): δ=3.00 (t, J=9.9 Hz 4 H), 2.65 (m, 8 H),
1.65 (m, 12 H), 1.37 ppm (m, 12 H); 195Pt NMR (600 MHz, D2O): δ=−2651 ppm; elemental
analysis calcd (%) for C18H62N16O18Pt2: C 18.31, H 5.29, N 18.98; found: C 18.51, H 5.27, N
18.47.
Tetraplatin: A mixture of trans‐ diamminedichloroplatinum (2.2 mmol) and AgNO3 (1.1 mmol)
in anhydrous DMF (18 mL) was stirred overnight at −20° C in the dark to produce, upon warming
to room temperature and filtration, mono‐ activated transplatin. This solution was then added to a
mixture of DiplatinNC (1 mmol) and N,N‐ diisopropylethylamine (DIPEA) (2.2 mmol) in DMF
(20 mL). The reaction mixture was stirred for two days at ambient temperature. The solution was
then evaporated to dryness under reduced pressure. The residue was dissolved in a minimum
amount of H2O and filtered through a syringe filter to remove any unreacted starting materials.
The filtrate was then evaporated to ca. 1 mL under reduced pressure and acetone (25 mL) was
added to precipitate the product. The precipitate (46 % yield) was collected through filtration,
washed with acetone and dried under vacuum. 1H NMR (300 MHz, D2O): δ=2.62 (m, 12 H), 1.61
(m, 12 H), 1.13 ppm (m, 12 H); 195Pt NMR (300 MHz, D2O): δ=−2405, −2663 ppm; elemental
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Figure 2.16. Cellular accumulation of PPCs in wt (CHO K1) and mutant CHO-pgsA-745 cells (lack of both
heparan sulfate and chondrotin sulfate). Platinum complexes were incubated for 1 and 3 hours prior to cell
collection for Pt detection on ICP-MS. Pt readings were normalized to cell number and number of Pt-centers per
compound. See Materials and Methods.



TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr
only as 100%.

Table 2.5. Cytotoxicity of noncovalent PPCs in HCT116 cells (n=2).



TriplatinNC data was taken from Peterson et al. 2017. Plot was
normalized to 0µM FPX as 0 % and DNA-EtBr only as 100%.
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analysis calcd (%) for C18H72Cl2N20O18Pt4: C 12.66; H 4.25; N 16.40; found: C 13.04; H 4.20; N
16.36.
TetraplatinNC: To Tetraplatin (1 mmol) dissolved in DMF (20 mL), AgNO3 (1.98 equiv) was
added. The reaction was protected from light and stirred for 16 h, then AgCl formed during the
reaction was removed by filtering through Celite. Mono‐ Boc‐ 1,6‐ hexanediamine (2.2 equiv)
was added to the filtrate and the mixture was stirred for two days at room temperature. The solution
was evaporated to dryness under reduced pressure and the residue was dissolved in H2O (100 mL)
at 60 °C and filtered through Celite to remove any reduced platinum and silver. The filtrate was
evaporated to dryness. The residue was suspended in 0.1 M HNO3 (25 mL) and stirred for four
days at 50 °C, at which time the suspension had turned into a clear almost colourless solution.
Completion of Boc‐ deprotection was confirmed by 1H NMR spectroscopic analysis. The solution
was filtered through Celite to remove any unreacted starting material. The filtrate was evaporated
to almost dryness and acetone was added to force the precipitation of the product. The residue was
collected through filtration and washed with methanol and acetone. The crude product (yield 84 %)
was recrystallised in water. 1H NMR (300 MHz, D2O): δ=2.95 (t, J=8.4 Hz 4 H), 2.62 (m, 16 H),
1.61 (m, 20 H), 1.35 ppm (m, 20 H); 195Pt NMR (D2O): δ=−2652 ppm; elemental analysis calcd
(%) for C30H106N28O30Pt4: C 17.00; H 5.04; N 18.50; found: C 17.27; H 5.02; N 18.21.
Molecular modelling and DFT calculations
All DFT computations were performed using the Guassian 09 suite of programs, with the
dispersion corrected density functional MO6L, as described in detail elsewhere.(4) The heparin
models were constructed based on the NMR structure, 1HPN.(14, 18) There are two models in the
original PDB file, each corresponding to all the iduronic acid residues in either
a 2S0 or 1C4 conformation. The structure resulting from the IdoA(2S) in a 2S0 form has sulfate
groups well separated compared to the structure from the 1C4 conformation of IdoA(2S). Through
an initial visual assessment of a crude model, the 2S0 form was found to be more suitable for Pt‐
tetraammine

interactions,4 and

the

structure

containing

all

the

IdoA(2S)

in 2S0 confirmation has been used to study the interactions of PPC library with heparin.
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residues

NMR cleavage inhibition assay
1

H NMR spectroscopy was performed in 250 μL Shigemi tubes with an Avance 600 MHz

Ultrashield NMR spectrometer (Bruker) with a 1H/13C/15N gradient cryoprobe system; data were
collected and analysed with the TOPSPIN software (Bruker). The HDO signal was suppressed
using a 2 s rf‐ field during the relaxation delay. The assay was performed according to the previous
reports.(4, 10) FPX (300 μM) was pre‐ incubated for 10 min with each of the Pt compounds (300
μM) in the PPC library (Scheme 2.1) and then was incubated with P. heparinus heparinase II (0.4
U, 4 μL, Sigma–Aldrich) at 37 °C in deuterated Tris buffer (Tris‐ D11 (20 mM), NaCl (100 mM)
and CaCl2⋅2H2O (10 mM)), pH 7.5. 1H NMR spectra were recorded for each sample prior to
addition of enzyme and at different time points thereafter. A control experiment was performed
under the same conditions in the absence of PPC library to confirm the activity of the enzyme on
FPX.
Competitive binding assays
FPX–PPC binding (methylene blue reporter method)
All binding studies were performed in triplicate with an Agilent 8453 diode array
spectrophotometer in a sub‐ micro quartz cuvette with a path length of 10 mm. Aqueous solutions
of methylene blue chloride (at a constant concentration of 18.6 μM) and fondaparinux (1–15 μM)
were prepared for determination of optimal MB‐ FPX binding. A concentration of 15 μM of FPX
was then used for evaluating the inhibition of MB binding by PPCs. Varying concentrations of
PPCs were incubated with constant concentration of FPX (15 μM) for 15 min at 23 °C. To each
sample was added MB to a final concentration of 18.6 μMand the absorbance was measured.
The Scatchard model(19) was applied to calculate the binding constant between MB and FPX by
plotting

versus n, where

, [L]=concentration of free methylene blue, and n is

average number of binding sites [Eq.1]:

(1)

91

where Δϵ is the calculated difference in molar absorptivity between free and bound methylene blue
in water at 664 nm; Cx=concentration of heparin added.
IC50 and Ka(app) values for binding of PPCs to FPX were calculated by converting the MB
absorption values into a normalised value (minimum and maximum absorbance) and
the Ka(app) was determined by using Equation 2

(2)
where KdL is the dissociation constant for the labelled ligand (MB) and binding site (FPX), SL is
the total concentration of the labelled ligand, and (BL)o is the equilibrium of labelled ligand value
when competitor concentration is zero.
FPX competition with PPC–DNA (EtBr reporter method)
All samples were read in a 96 well plate at 530/590 nm using a microplate reader (BioTek
instruments). Ethidium bromide (EtBr) at 5 mM in water was diluted in HEPES buffer (80
mMHEPES, pH 7.2) and incubated with calf thymus (ct) DNA for 5 min at 25 °C to a final control
concentration of 12.5 μM EtBr and 10 μM DNA in a final volume of 100 μL. In separate wells, the
concentration of each individual PPC (dissolved in water and diluted in HEPES buffer) needed
to decrease EtBr fluorescence by at least or greater than 50 % after 1 h incubation was calculated
to be the following: TriplatinNC 12.5 μM, DiplatinNC 62.5 μM, AH44 125 μM, MonoplatinNC
125 μM, and [Pt(NH3)4]2+ 500 μM and denominated as [PPCd]. This concentration was normalised
as the modified (0 %) EtBr–PPC–DNA fluorescence and 100 % fluorescence was the control
EtBr‐ DNA. Next, 10 μL of varying concentrations of FPX (0–640 μM) in HEPES buffer were
added to 90 μL of a combined solution of platinum complex, DNA and EtBr such that the final
concentrations were [PPCd], 12.5 μM (EtBr) and 10 μM (DNA). After 1 h, the fluorescence was
read, allowing the calculation of [FPXr], the concentration of FPX required to restore EtBr
fluorescence to 50 % of the control EtBr‐ DNA sample. Samples were normalised to the controls
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([PPCd] and no FPX as 0 % and EtBr‐ DNA only as 100 %) to calculate EC50 values using Prism
software as per Table 2.3. The ratio index was calculated from the drug concentration divided by
the EC50 value.
Isothermal titration calorimetry
ITC data were collected with a VP‐ ITC Microcalorimeter (MicroCal, LLC). All samples were
degassed for 5 min with a ThermoVac (MicroCal, LLC). For all titrations, injections of Pt
complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at 300 s
intervals from a 300 μL syringe, while stirring at 75 rpm. In all experiments, 100 mMcacodylate
buffer (pH 7.4) was used at 25 °C and the thermal reference cell contained 1.3 mL of 100
mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks was carried out using the
software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one‐ site model
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained by using the Gibbs free energy
equation.
Mass spectrometry
Mass spectra were acquired with a Thermo Electron Corporation Orbitrap Velos mass
spectrometer (Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to
0.7 μL min−1 by using a syringe pump. Electrospray source conditions were kept constant with a
capillary temperature of 230 °C and capillary voltage between 2.3 and 2.5 kV. FPX and Pt
compounds were reconstituted in deionised water to a stock concentration of 40 μM. Samples were
mixed at a 1:1 molar ratio and were incubated at room temperature for 20 min. Samples were
diluted with addition of Milli‐ Q methanol for a final concentration of 1:10 methanol/water.
Biological Evaluation
Cell lines and cell culture
The human colorectal cancer cell line HCT 116 was obtained from the American Type Tissue
Collection. HCT116 cells were cultured in RPMI 1640 media (Invitrogen) with 10 % fetal bovine
serum (FBS) and 1 % penicillin/streptomycin (Gibco) at 37 °C with 5 % CO2.
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MTT cell viability assay
HCT116 cells were seeded in 96‐ well plates (5×103 cells/well) in supplemented media (100 μL).
After incubation overnight, the cells were treated with varying concentrations of the indicated Pt
compound, in sets containing four replicates for each concentration. After drug exposure for 72 h,
1 mM MTT (3‐ (4,5‐ dimethylthiazol‐ 2‐ yl)‐ 2,5‐ diphenyltetrazolim bromide) (Sigma) was
added to each well and incubated for 4 h. The MTT reagent was removed, and 100 μL of DMSO
was added to each well. All incubations were performed at 37 °C with 5 % CO2.
Spectrophotometric readings were determined at 570 nm with a microplate reader (Bio‐ Tek
instruments). Percentage cell survival was determined as treated/untreated controls × 100. Data
are reported as the average of two independent experiments ± SD.
Cellular accumulation
HCT116 cells were seeded in 100 mm dishes (1×106 cells/dish) in supplemented media (20 mL).
After incubation for 24 h, cells were treated with 10 μM of the indicated Pt compounds for 3 and
6 h incubations (37 °C with 5 % CO2). The cells were then washed twice with PBS, harvested with
0.25 % trypsin (Gibco), and washed with 10 mL of PBS. The cell pellets were digested in 1 mL of
nitric acid for 72 h and diluted with H2O (2 mL). The solutions were filtered through a 0.45 GHP
filter. Platinum analysis was performed with a Varian 820 inductively coupled plasma mass
spectrometer (ICP‐ MS). The standards were prepared with K2PtCl4 in concentrations of 10, 50,
100, 150, and 250 ppb. The blank was 7 % nitric acid. Data was normalized to number of platinum
centres per drug.
Cellular internalization
HCT116 cells were seeded in 6‐ well plates (5×105 cells/well) in supplemented media (3 mL).
After incubation for 24 h, cells were treated with 10 μM of the indicated Pt compounds and
incubated for 5 min before the addition of TAMRA‐ R9 (1.0 μM) and further incubation for 1 h at
37 °C with 5 % CO2. Cells were washed three times with PBS, harvested with 0.25 % trypsin
(Gibco), and washed twice with cold PBS. The cells were passed through a cell strainer (40
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μMFlowmi) and then analysed at 488 nm (excitation) and 585±42 nm bandwidth emission with a
Becton Dickinson FACSCanto II Analyzer flow cytometer (BD Biosciences).
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3.1 Abstract:

We present spectroscopic and biophysical approaches to examine the affinity of metal–ammine
coordination complexes for heparin as a model for heparan sulfate (HS). Similar to nucleic acids,
the highly anionic nature of heparin means it is associated in vivo with physiologically relevant
cations, and this work extends their bioinorganic chemistry to substitution-inert metal–ammine
compounds (M). Both indirect and direct assays were developed. M compounds are competitive
inhibitors of methylene blue (MB)–heparin binding, and the change in the absorbance of the dye
in the presence or absence of heparin can be used as an indirect reporter of M–heparin affinity. A
second indirect assay uses the change in fluorescence of TAMRA-R9, a nonaarginine linked to a
fluorescent TAMRA moiety, as a reporter for M–heparin binding. Direct assays are surface
plasmon resonance (SPR) and isothermal titration calorimetry (ITC). The Kd values for
TriplatinNC–heparin varied to some extent depending on the technique from 33.1 ± 2 nM (ITC)
to 66.4 ± 1.3 nM (MB absorbance assay) and 340 ± 30 nM (SPR). The differences are explained
by the nature of the technique and the use of heparin of differing molecular weight. Indirect probes
using the displacement of ethidium bromide from DNA or, separately, fluorescently labeled
oligonucleotide (DNA-Fl) can measure the relative affinities of heparin and DNA for M
compounds. These assays showed essentially equivalent affinity of TriplatinNC for heparin and
DNA. The generality of these methods was confirmed with a series of mononuclear cobalt,
ruthenium, and platinum compounds with significantly lower affinity because of their smaller
overall positive charge but in the order [Co(NH3)6]3+ > [Ru(NH3)6]3+ > [Pt(NH3)4]2+. The results

on heparin can be extrapolated to glycosoaminoglycans such as HS, emphasizing the relevance of
glycan interactions in understanding the biological properties of coordination compounds and the
utility of the metalloglycomics concept for extending bioinorganic chemistry to this class of
important biomolecules.
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Figure 3.1. (a) Proposed structural analogy of the phosphate clamp to DNA (top) and the sulfate
clamp to heparin or a sulfated glycan (bottom) formed by PPCs. (b) Blue circles on the
repeating IdoA(2S)–GlcNS(6S) dimer in heparin (right) and 2′-deoxyguanosine 5′monophosphate (left) in DNA indicating possible electrostatic interaction sites, and a red arrow
showing the favored GuanineN7 site of covalent binding. (c) DNA (PDB: 309D) and heparin
(PDB: 1HPN) having high negative charge densities, and glycans such as HS having different
protein recognition and signaling pathways (blue boxes). Inhibition of these pathways results
in different biological consequences (red boxes).

101

3.2 Introduction:

Glycosaminoglycans (GAGs) such as heparan sulfate (HS) are linear polysaccharides composed
of repeating disaccharide units of alternating uronic acid and hexosamine residues. When
conjugated with proteins, heparan sulfate proteoglycans (HSPGs) are found on the cell surface and
extracellular matrix with critical functions in cellular adhesion and migration.(1,2) HS is
structurally related to heparin, a free GAG chain produced by mast cells that may be deployed as
an immune defense mechanism.(3,4) Heparin usually remains highly sulfated, whereas HS
displays varying degrees of sulfation.(1,2) HS has a multitude of protein partners, mediated
through hydrogen-bonding and electrostatic interactions between sulfated regions of the
polysaccharide and the basic amino acids of the protein.(5−7) Specifically, HSPGs interact with
pro-angiogenic growth factors such as fibroblast growth factor (FGF) to induce dimerization for
subsequent activation of its receptor.(5,8) FGF-2 directly stimulates tumor and endothelial cell
proliferation, migration, and survival.(6) In addition to protein interactions, heparin and HSPGs
are cleaved at glycosidic bonds by bacterial and mammalian enzymes (heparinase and heparanase,
respectively). This HS cleavage leads to degradation of the extracellular matrix and release of
growth factors for tumor angiogenesis.(9) Heparanase has a high abundance in many tumors,
correlating with increased metastatic potential and poor clinical prognosis.(10−12) HSPGs and
their associated proteins and enzymes are thus attractive drug targets because of their promotion
of tumor progression at multiple levels: proliferation, invasion, angiogenesis, and metastasis.(3−7)
The highly anionic nature of heparin and HS means they are associated in vivo with
physiologically relevant cations, similar to nucleic acids.(13−15) Cation association affects the
biomolecule conformation and, in some cases, facilitates heparin–protein interactions such as
Ca2+-dependent heparin–annexin A2 binding.(16) More broadly, Cu2+ promotes angiogenesis,
although the detailed mechanism is not defined.(17,18) Growth factors are also copper-dependent,
with a slightly higher affinity for FGF-1 compared to FGF-2.(19,20) Aquated Ca2+, Mg2+, Fe3+,
and Zn2+ ions, at higher than physiological concentrations, reduce FGF-1 interactions with HS–
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Figure 3.2. Structures of TriplatinNC and metal–ammine compounds used
in this study. Counterions are omitted for clarity.
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heparin.(13) For heparin and HS, there are no strong donor atoms such as the heterocycle nitrogen
atoms of purines and pyrimidines or even sulfur and nitrogen donors of amino acids such as
cysteine and histidine available for binding to metal centers, suggesting that harder acids may
preferentially bind and/or the oligosaccharides can enter into “noncovalent” electrostatic or
hydrogen-bonding interactions (Figure 3.1). In recent papers, we have suggested that
metalloglycomics, defined as the study of metal ion–oligosaccharide interactions, can be expanded
beyond the study of physiologically relevant aquated metal cations to use defined coordination
compounds.(21−24)
Using coordination compounds, alteration of the oxidation state, coordination number, and
geometry and substitution lability of ligands allows for the study of a wide variety of structural
types to examine the structure and function of sulfated oligosaccharides, extending bioinorganic
chemistry to this third major class of biomolecules after DNA/RNA and proteins. Specifically,
HSPGs act as receptors for cellular accumulation of the highly cationic polynuclear platinum
complexes (PPCs).(21) Molecular recognition of a compound such as TriplatinNC (Figure 3.2) is
effected through electrostatic and hydrogen-bonding interactions with the sulfate groups on the
HS chains, analogous to the phosphate clamp formed by the same complex on DNA (Figure
3.1a,b).(22−24) This high-affinity sulfate binding, or metalloshielding, has functional
consequences including stabilization of the sulfate moieties, in a defined sequence octasaccharide,
from dissociation in the gas phase.(23) In biophysical studies, PPC metalloshielding inhibits
oligosaccharide backbone cleavage by both bacterial (heparinase I) and mammalian (heparanase)
enzymes.(22,23) Growth factor binding to HS is inhibited in the presence of TriplatinNC with
consequent effects on downstream kinase signaling.(22) Overall, these interactions lead to the
inhibition of cellular angiogenesis and eventually the inhibition of in vivo metastasis (Figure
3.1c).(25,26)
The molecular-level explanation of these events requires a detailed understanding of PPC–glycan
interactions. The identity and conformation of the sugar and the number and positions of sulfation
make GAGs highly complex systems, with significantly more variability than DNA, also with
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Figure 3.3. MB competition assay for assessment of heparin MW ∼18000 binding. (a)
The absorbance of a constant concentration of free MB ([AbsMB]) at 664 nm decreases
with increasing heparin concentration (from top to bottom with 0–15 μM) with a
concomitant increase in the absorbance of [MB][Hep] at 560 nm. (b) At a constant
concentration of 15 μM heparin in the presence of varying concentrations of
TriplatinNC (from bottom to top with 0–5 μM), MB binding is inhibited, reflected in
the change of [AbsMB]. (c) The percent inhibition of MB (18.6 μM) binding to heparin
(15 μM) by TriplatinNC (5 μM) in the presence of physiologically relevant
concentrations of cations is observed at 664 nm. Charges are omitted for clarity.
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respect to non-bond-forming interactions. As polyelectrolytes, heparin and DNA have strong
electrostatic interactions that, for heparin and other glycans such as HS, are influenced by the
positions and amount of sulfation. Heparin is often used as a model for a highly sulfated HS and
is considered to have the highest negative charge density of any biomolecule at an average of 2.7
sulfate groups per disaccharide.(3) This paper evaluates spectroscopic and biophysical approaches
to examine metal ion–heparin interactions, especially in the case of substitution-inert PPCs such
as

TriplatinNC.

The

fundamental

unit

of

TriplatinNC

is

the

mononuclear

tetraam(m)ineplatinum(II), and charge-related effects may be examined by a comparison of
mononuclear and poly(tri)nuclear species. The generality of these approaches is exemplified by
extension to other mononuclear metal–ammine complexes based on cobalt and ruthenium. The
fluorescent properties of [Ru(bpy)3]2+ and its analogues have been used as analytical probes to
examine the heparin concentration and even content in cells.(27−29) In this paper, we therefore
compared the relative reactivities of the chosen set of compounds toward both biomolecules (DNA
and heparin) and in a novel competition assay showed that heparin is a competitor for metal
complex–DNA binding. The overall results emphasize the relevance of glycan interactions for
understanding the biological properties of coordination compounds and the potential for extending
bioinorganic chemistry to this important class of biomolecules.

3.3 Results and Discussion:

We first examined the binding of TriplatinNC and subsequently extended the studies to the cobalt
and ruthenium systems (Figure 3.2).

The Case of TriplatinNC
Indirect Assays: Methylene Blue (MB) Competition (Absorbance)
The cationic dye MB has been used to quantify heparin content and examine heparin binding
interactions.(30−32) MB interaction with heparin causes a concentration-dependent reduction in
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(a)
The Scatchard model was applied to calculate the association constant of MB to heparin by
𝑛
𝑛
(𝐴𝑚𝑎𝑥 −𝐴)
plotting [𝐿] versus n, using [𝐿] = (A−𝐴
, where [L] was the concentration of free MB, and
)𝐶
𝑚𝑖𝑛

𝑥

where n was the average number of binding sites (𝑛 =

(𝐴𝑚𝑎𝑥 −𝐴)
ΔƐ𝐶𝑥

; ΔƐ was the calculated

difference in molar absorptivity between free and bound methylene blue in water at 664 nm,
and Cx was the concentration of heparin added).1
(b)
To determine the Ka(app) of metal complexes-heparin, the absorbance values were converted to
the percentage of the control (minimum and maximum absorbance) and a competitive model
of

1
𝐾𝑎(𝑎𝑝𝑝)

= 𝐼𝐶50 ×

2𝐾𝑑𝐿 [𝑆𝐿 −(𝐵𝐿 )𝑜 ]
2

, (KdL is the dissociation constant for the labeled

[(𝐵𝐿 )𝑜 +2𝑆𝐿 𝐾𝑑𝐿 −3𝑆𝐿 (𝐵𝐿 )𝑜 ]

ligand (MB) and binding site (heparin), SL is the total concentration of the labeled ligand, and
(BL)o is the labeled ligand equilibrium value when competitor concentration is zero
(BL)o=Bmax).2
(c)
To determine the Kd of TAMRA-R9 to heparin, the fluorescence data was fitted to a sigmoidal
plot using the equation 𝐹 =

𝑎−√𝑎2 −4[𝑅𝑇 ][𝐿𝑇 ]
2[𝐿𝑇 ]

(where 𝑎 = 𝐾𝑑 + [𝑅𝑇 ] + [𝐿𝑇 ], and F is the

measured fluorescence, Kd is the dissociation constant for the fluorescent probe (TAMRA-R9)
and binding site (heparin), RT is the total concentration of the heparin, and LT is the total
concentration of the TAMRA-R9.3
Equation 3.1. The dissociation constants and apparent binding constants were calculated by the Scathcard model 1
for (a) MB-heparin binding, the competitive model2 for (b) metal-ammine compounds-heparin binding using MB
as a reporter, and the nonlinear curve fitting3 for (c) TAMRA-R9 -heparin binding.
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its absorbance. With increasing heparin concentration, the MB absorbance at 664 and 614 nm
decreases while that at 570 nm increases, allowing for calculation of the affinity constants (Figure
3.3a).(30) The Scatchard model (eq 1a) gave a dissociation constant (Kd) value for the MB–heparin
interaction of 351 nM, comparable to a previously reported value of 578 nM (reported originally
as the association constant) measured between MB and chondroitin sulfate (another type of
GAG).(33)
In the presence of heparin bound to varying concentrations of TriplatinNC, the absorbance of
added MB dye (at a constant concentration) varies depending on how much TriplatinNC is released
due to competitive dye binding: [Hep][TriplatinNC] + MB ⇌ [Hep][MB] + TriplatinNC (Figure
3.3b). The disruption of TriplatinNC binding by MB can be reported as IC50, the concentration of
the complex necessary to give 50% of free dye, as monitored by MB absorbance (Table 3.1). By
using MB as a reporter for competitive inhibition in a three-species system, the Kdvalue between
TriplatinNC and heparin was calculated to be 66.4 ± 1.3 nM (Table 3.1 and eq 1b).
We also evaluated the competitive binding interactions between TriplatinNC and MB in the
presence of other physiologically relevant cations. The presence of physiological concentrations
of other cations affects the absorbance of the dye in the MB–heparin interaction.(34) The change
in absorbance varies depending on the degree of cation release due to competitive dye binding,
and this release is based on the concentration, charge, and ionic radius of the cations.(34) High
concentrations of Na+ showed the greatest effect on MB binding, followed by Ca2+ > Mg2+ >
K+(Figure 3.3). With the addition of TriplatinNC (at a constant concentration), MB binding is
further inhibited with no observed difference from the TriplatinNC–heparin binding in the
presence of other cations, although the increase in inhibition is consequently smaller in the case of
the highest concentrations of Na+ at 150 mM. There is a difference between the Na+ effects on
DNA, where concentrations above 600 mM were needed to completely restore condensed DNA
to the relaxed form in the presence of TriplatinNC, which is a very effective DNA condensing
agent.(35,36) We note that the SPR data to be discussed below were obtained in the presence of
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Figure 3.4. Observed absorbance change of binding between MB and heparin with a constant concentration of
18.6 µM MB, 15 µM heparin, 5 µM TriplatinNC, and physiological relevant concentrations of cations; absorbance
changes with added concentrations of cations, while no change between the Pt and heparin binding was observed.
Aqueous solutions of methylene blue chloride (at a constant final concentration of 18.6 µM), heparin MW 18000
(at a constant final concentration of 15 µM), and TriplatinNC (at a constant final concentration of 5 µM) were
used for evaluating the absorbance change of MB-heparin binding by physiological relevant concentrations of
cations (Sodium Chloride: 150 mM, Potassium Chloride: 5 mM, Calcium Chloride: 1.3 mM, and Magnesium
Chloride: 1 mM).

Table 3.1. IC50 and Kd values of TriplatinNC and Metal-ammine compounds in competitive
inhibition assays using MB or TAMRA-R9.
a
The IC50 value was determined as the concentration of complex required for half-maximal
binding of the dye (18.6 μM or 100 nM) to heparin MW ∼18000 (15 or 625 μM) for MB or
TAMRA-R9 binding assays, respectively.
b
Dissociation constants were calculated from the MB assay for TriplatinNC and metal–
ammine compound binding to heparin MW ∼18000 using a competitive inhibitor model.
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150 mM NaCl, confirming that TriplatinNC is capable of binding to heparin at physiologically
relevant concentrations of small cations.
Indirect Assays: TAMRA-R9 Competition (Fluorescence)
TAMRA-R9 is a polycationic, nona-L-arginine peptide linked to a fluorescent TAMRA moiety. In
this case, the fluorescence of TAMRA-R9 at 590 nm (emission) increases with increasing heparin
concentration, and a Kd value of 109 nM for TAMRA-R9–heparin binding has been previously
reported.(37) In our hands, we obtained a Kd value of 405.9 nM, and the difference may be
attributed to the use of a larger heparin (MW 18000) than that previously reported (Figure 3.5a).
There is also slight variability in the Kd values under similar conditions because heparin
preparations can be very heterogeneous.(3,37) We have previously used the fluorescence of
TAMRA-R9 as a reporter to identify HSPGs as receptors for platinum complex cellular
internalization.(21) Analogous to the enhanced fluorescence of an intercalator such as ethidium
bromide (EtBr) upon DNA binding, TAMRA-R9 fluorescence increases when bound to heparin.
Again, in the presence of heparin bound to varying concentrations of TriplatinNC, the addition of
TAMRA-R9 (at a constant concentration) results in the observation of fluorescence proportional
to the amount of TAMRA-R9–heparin binding with TriplatinNC release: [Hep][TriplatinNC] +
TAMRA-R9 ⇌ [Hep][TAMRA-R9] + TriplatinNC (Figure 3.5b). The ability of TriplatinNC to
compete with TAMRA-R9 for heparin binding can be reported as the IC50 required to produce 50%
fluorescence compared to control of heparin dye in the absence of the complex (Table 3.1).
Direct Assays: Surface Plasmon Resonance (SPR)
For direct analysis, SPR was used to estimate the TriplatinNC–heparin affinity. SPR is a labelfree, real-time quantification of the interaction between the immobilized ligand on the sensor chip
and the analyte being injected in a continuous flow over the ligand.(38) When the ligand and
analyte interact, the refractive index changes, and the response is reported as response units (RU).
SPR has been used for determining the heparin concentration, metal–heparin binding, and metal–
heparin binding effects on the growth factor and growth factor receptor recognition.(13,39) A
mixture of metal ions reduced the affinity of FGF-1 binding to heparin from Kd = 22 to 350
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Figure 3.5. TAMRA-R9 competition assay with metal-ammine compounds binding to heparin. (a) Normalized
fluorescence spectra of TAMRA-R9 (100 nM) changes with various concentrations of heparin. TAMRA-R9
binding to heparin is inhibited with increasing concentrations of metal complex. Normalized Fluorescence
spectra of TAMRA-R9 were changed to a percentage of maximum and minimum fluorescence with % inhibition
correlated to a decrease in fluorescence. (b) Concentrations for TriplatinNC were the following: 125, 62.5, 31.3,
15.6, and 7.8 µM. (c) Concentrations for metal-ammines were the following (red) Co(NH3)6]3+; (purple)
[Pt(NH3)4]2+; (blue) [CoCl(NH3)5]2+; and (green) [RuCl(NH3)5]2+: 2500, 1250, 625, 312.5, 156.3, 78.1, 39.1, and
19.5 µM.
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nM.(13)In the study of heparin–protein interactions by SPR, heparin is preferentially immobilized
onto the sensor chip rather than the protein because this more closely mimics natural biological
systems, where HS is found at the cell surface as a proteoglycan and binds to target
proteins.(40,41) A common method for heparin immobilization is to use a biotinylated heparin and
a streptavidin-coated sensor chip.(40) The high charge of TriplatinNC caused significant
nonspecific binding to both the dextran sensor chip surface and streptavidin. Therefore, in
collaboration with Reichert Technologies, a Neutravidin-coated mixed self-assembled monolayer
(mSAM) sensor chip was used to minimize the background noise and resulted in significantly
lower nonspecific binding of TriplatinNC to the sensor surface, although there is still some binding
to the reference, causing some distortion in the binding curves (Figure 3.6). At the lowest 111 nM
concentration, there was a large (repeatable) decrease in the signal, which may be due to random
adsorption of the highly charged molecule in the system. An analysis of the binding curves for the
interaction between heparin and TriplatinNC was generated using the TraceDrawer program.
Although a global fit was not possible, a one-site model and 1:1 TriplatinNC–heparin stoichiometr,
gave a Kd value of 340 ± 30 nM (Figure 3.6). Because the immobilized heparin had MW 15000, it
is plausible that there could be multiple binding sites, which may affect the estimated Kd values.
Direct Assays: Isothermal Titration Calorimetry (ITC)
ITC accurately determines the thermodynamic contributions of both enthalpy (ΔH) and entropy
(−TΔS) changes to the free energies of binding (ΔG). ITC measures the heat released or absorbed
into the system upon the binding of two molecules and is proportional to the overall strength of
binding.(42) ITC has been used in heparin growth factor assays and in defining the thermodynamic
parameters from these interactions.(43,44) A mixture of heterogeneous heparin chains interacting
with FGF-1 gave Kd values of 1.1–3 μM.(45) Using a smaller (MW 3000) heparin, we studied the
heparin–TriplatinNC interaction by ITC. As TriplatinNC was titrated into the reaction cell
containing heparin (Figure 3.7), the produced peaks were integrated to yield the heat released per
titration. Using a one-site model for TriplatinNC–heparin gave a Kd value of 33.1 ± 2 nM (Figure
3.7). The enthalpy term reflects the strong electrostatic and hydrogen-bonding interactions
112

Figure 3.6. Determination of the TriplatinNC–heparin binding affinity by SPR using a
biotinylated heparin (MW ∼15000) immobilized to Neutravidin on a planar mSAM chip. (a)
After injection of 5, 1, 0.333, and 0.111 μM of TriplatinNC, the solution was allowed to flow
over the chip for 5 min to allow binding; a buffer was then injected, and after flowing for 5 min,
dissociation was assessed. (b) The amount of TriplatinNC bound at equilibrium was corrected
for background and plotted versus input TriplatinNC concentration. Analysis by equilibrium
parameters using a 1:1 binding model yielded a Kd value of 340 ± 30 nM.
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occurring between the sulfates and ammines, while the entropic term reflects the possible release
of water molecules as well as the loss of conformational mobility of the iduronic acid
ring.(42) This loss of conformational mobility results in a high entropy value and commonly
reflects the phenomenon of entropy–enthalpy compensation.(46) Overall, the interactions
observed produce a spontaneous and favorable binding between TriplatinNC and heparin (ΔG =
−10.1 ± 0.1 kJ/mol).
Summary
Overall, the results from MB and TAMRA-R9 reporter assays demonstrated strong TriplatinNC–
heparin interactions, which were confirmed by SPR and ITC. MB and TAMRA-R9 dyes had
similar estimated Kd values for binding to heparin itself, 351 and 405.9 nM, respectively. The
TriplatinNC–heparin binding gave similar Kd values of 66.4 ± 1.3 and 33.1 ± 2 nM from the MB
assay and ITC system, respectively, whereas the SPR system displayed a magnitude weaker
affinity (340 ± 30 nM). Because the SPR system measured TriplatinNC interacting with heparin
immobilized to the surface of the sensor chip, this immobilization may reduce the degrees of
freedom of the heparin molecule to interact and thus affect the kinetics and affinity of the
TriplatinNC–heparin interaction.(47) However, the heparin immobilization more closely mimics
natural biological systems where the HS chains are covalently attached to core proteins as HSPGs.
There are few small molecule–heparin binding data for comparison by SPR and ITC because the
majority of studies have been on protein–heparin interactions.
Comparison of the PPC–Heparin and PPC–DNA Affinities
The Kd values with heparin from the indirect reporter assays and the direct SPR and ITC
techniques raise questions about the relative affinity of TriplatinNC for DNA or heparin.
TriplatinNC and substitution-inert complexes in general bind with high affinity to DNA with a
measured Kd(app)value of 17.7 nM (reported as Ka(app)).(48) Given the highly anionic nature of both
biomolecules, what are the relative affinities of a molecule such as TriplatinNC for DNA or
heparin? As mentioned, heparin is considered to have an average of 2.7 sulfate
groups per disaccharide compared to that of two phosphate groups per base pair for DNA. We
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Figure 3.7. Isothermal titration calorimetry measured the heat released by titrations of (a) TriplatinNC, (b)
[Co(NH3)6]3+ , (c) [Ru(NH3)6]3+ , (d) [Pt(NH3)4]2+ , (e) [CoCl(NH3)5]2+ , and (f) [RuCl(NH3)5]2+ into the heparin
solution.
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therefore developed a number of competitive binding assays to answer this question and to
complement the indirect and direct HS–PPC assays. Fluorescence polarization, EtBr, and circular
dichroism (CD) competition assays compared the ability of heparin to compete with DNA for the
binding of charged metal complexes.
DNA Competition Assay
A fluorescence polarization assay measures the tumbling motion of molecules to describe binding
events. Typically, the assay incorporates a small fluorescently labeled molecule, such as a DNA
oligonucleotide, and an interacting molecule of similar or higher molecular weight, such as a
protein. Upon binding, the rotation of the fluorescent molecule decreases, which is measured by
emission fluorescence passing through parallel and perpendicular polarized light paths.(38) For
our purposes, we examined whether changes in the rotation of a small fluorescently labeled DNA
hairpin (DNA-Fl; 23nt; MW 7705) could be detected upon binding of the lower-molecular-weight
metal complex, TriplatinNC (MW 1650).
Reproducible saturation binding curves were established with the concentration of drug required
for half-maximal binding determined to be EC50 = 1.92 μM (Figure 3.8a and Tables 3 and 4).
When the same unlabeled DNA hairpin was subsequently titrated into the reactions, a predicTable
3.shift of the curve occurred as unlabeled DNA competed with labeled DNA for binding of
TriplatinNC with concomitant increases in the apparent EC50 values (Figure 3.8a and Table4). The
fold changes of the apparent EC50 values were 1.1, 1.9, and 11.6 with changing DNA/DNA-Fl
ratios of 0.2:1, 2.11:1, and 21.2:1, respectively (Table 3.4). When heparin MW ∼3000 was used
as the competitor ligand, the EC50 values similarly increased relative to the control DNA-Fl (Figure
3.8b and Table 3.3). In comparison, the fold increases in the EC50 values were 1, 2.1, and 10.3
upon the addition of increasing concentrations (0.2–21.2 μM) of heparin, closely comparable to
the DNA/DNA-Fl ratios used. These results therefore suggest a similar affinity for TriplatinNC
between low-molecular-weight heparin and DNA substrates.
For a second competition assay, we used an adaptation of the well-known EtBr fluorescence assay
to measure the binding affinities of metal complexes.(22,48) The fluorescence from intercalator
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Table 3.2. A comparison of dissociation constants and Gibbs free energy by the
enthalpy and entropy of the calorimetric data fitted to a single site-binding model for
TriplatinNC and metal-ammine complexes.
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binding to DNA is quenched when the intercalator is displaced upon TriplatinNC–DNA binding.
Upon the addition of increasing concentrations of heparin, TriplatinNC is sequestered and the
nucleic acid now becomes available to bind the intercalator, with a resultant increase in
fluorescence (Table 3.5). From Figure 3.8c, we can see that a concentration of 12.5 μM
TriplatinNC reduced EtBr fluorescence to approximately 25% of the control value. A
concentration of 20.5 μM heparin increases fluorescence to approximately 50%, while full
fluorescence is restored in the 35–40 μM range. The experiment allows us to define EC50 as the
sequestration concentration of heparin required to restore 50% EtBr binding (Table 3.5). This
experiment again confirms the similar affinities of the two biomolecules for TriplatinNC.
CD Assay
The competitive binding of heparin and DNA can also be easily envisaged by CD spectroscopy
monitoring of the conformational changes during each event. The CD spectrum of the DNA
structure influenced by its environment and changes such as TriplatinNC binding can be monitored
without the need for labels. The positive CD band of DNA centered at approximately 270 nm is
decreased in the presence of TriplatinNC (Figure 3.9). Upon the addition of heparin to the DNA–
TriplatinNC mixture, the positive band is restored in a heparin concentration-dependent manner
through sequestration of TriplatinNC and restoration of DNA to its original conformation. Neither
heparin nor heparin–TriplatinNC mixtures show any CD absorbance in the 250–280 nm range,
and thus the changes observed are direct visualizations of competitive binding.
Summary
Electrostatic and hydrogen-bonding interactions with noncovalent metal complexes observed on
DNA translate to heparin–HS interactions. To determine the relative affinity of TriplatinNC for
heparin and/or DNA, competition assays were used with reporters for the TriplatinNC–DNA
interaction. Fluorescence polarization and EtBr competition assays showed that TriplatinNC has a
broadly similar affinity for both unlabeled heparin and DNA.
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Figure 3.8. Heparin, a competitive inhibitor of TriplatinNC–
DNA binding. (a) Unlabeled DNA (0–21.2 μM) competed with
fluorescently labeled DNA (23nt and MW 7705) for
TriplatinNC binding. (b) Analogously, the binding of
TriplatinNC to the fluorescently labeled-DNA was reduced upon
the addition of heparin MW ∼3000 (0–21.2 μM). (c) EtBr bound
to ct-DNA was displaced upon the addition of TriplatinNC,
while increasing the concentration of heparin MW ∼18000
sequestered TriplatinNC from DNA, allowing EtBr–DNA
binding to occur. EtBr bound to DNA was normalized to 100%
with EtBr only as 0%.
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Affinity of HS Binding to Metal–Ammine Complexes
Trinuclear complexes are modular in nature, and the strong interactions of TriplatinNC with
heparin

led

us

to

explore

the

individual

contributions

of

the

mononuclear

tetraam(m)ineplatinum(II) units and further compare charge-related effects based on cobalt and
ruthenium analogues (Figure 3.1). While, in principle, the chloropentaammine complexes of
cobalt(III) and ruthenium(III) can enter into covalent interactions through Co–Cl or Ru–Cl
substitution, the nature of the assays developed and the kinetic inertness of substitution on the
cobalt(III) and ruthenium(III) centers suggests that any trends observed across the series of
compounds will be most likely due to simple differences in charge.
MB Assay
In MB assay, [Co(NH3)6]3+ and [Ru(NH3)6]3+ of the mononuclear metal–ammine compounds
exhibited the highest affinity to heparin, although the IC50 values were significantly higher than
that for TriplatinNC (Table 3.1 and Figure 3.10). The efficacy of inhibition is charge-dependent,
and the 2+ compounds [Pt(NH3)4]2+, [RuCl(NH3)5]2+, and [CoCl(NH3)5]2+ required over 10-fold
more compound for inhibition than [Co(NH3)6]3+ with increasing IC50 (Table 3.1). Similar trends
were observed for TAMRA-R9 assay (Table 3.1 and Figure 3.5c).
ITC Assay
The ITC titrations of metal–ammine species to heparin did not give well-defined isotherms,
perhaps because of the inherently lower affinity as measured by the MB reporter assay, and were
not analyzed in detail. Affinity values derived from ITC can also vary depending on the nature of
the heparin as noted above.(45)
DNA Competition Assays
Metal-ion interactions with nucleic acids have been widely studied;(49) more specifically, the
chosen cobalt and ruthenium complexes bind tightly to DNA.(50−54) Thus, we compared the
affinities of metal–ammine compounds for DNA and heparin. Using the fluorescently labeled
DNA-Fl, as was previously done, and heparin MW ∼3000 as the competitor, we examined the
relative binding affinity of metal–ammines for these two substrates. Overall, the metal–ammine
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Table 3.3. Fluorescence Polarization Assays Showing That Heparin Is a Competitor for Metal–Ammine
Compound Binding to DNA
a

EC50 was determined as the concentration of the complex required for half-maximal binding to fluorescently
labeled DNA using heparin MW ∼3000 as a competitor.
b
The fold change EC50 was calculated as (EC50 of the sample with a competitor)/(EC50of the sample without a
competitor).

Table 3.4. TriplatinNC bound to fluorescently labeled DNA
competes with “cold” unlabeled DNA. Upon addition of
unlabeled-DNA, the EC50 of TriplatinNC binding to labeledDNA increases. The EC50 was determined as the concentration
of complex required for half-maximal binding to DNA. The fold
change EC50 is calculated as the (EC50 of sample with
competitor)/ (EC50 of the sample without competitor).
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compounds exhibited at least a 2-fold increase in EC50 for the highest heparin–DNA ratios, with
the largest fold increase of 5.1 observed for [Co(NH3)6]3+ (Table 3.2 and Figure 3.11). Compared
to TriplatinNC, the EC50 values of the metal–ammine compounds binding to DNA were higher
(TriplatinNC8+ < [Co(NH3)6]3+ < [CoCl(NH3)5]2+ < [Pt(NH3)4]2+ ≈ [RuCl(NH3)5]2+), indicating the
expected lower binding affinity to DNA. Upon competition with heparin, the higher fold increase
in EC50 is a measure of the higher heparin affinity, independent of the actual concentrations used
for each compound to achieve half-maximal DNA binding. In this case, the trend suggests a strong
charge effect, with TriplatinNC8+ and [Co(NH3)6]3+ showing the highest relative affinities. The
(smaller) one to 2-fold changes for the lower-charged species may reflect inherently stronger
binding to DNA rather than a diminished heparin affinity, as can be seen in indirect MB and
TAMRA-R9 assays (Table 3.1).
Because previous studies demonstrated [Pt(NH3)4]2+- and [Co(NH3)6]3+-induced DNA
conformational change using CD,(53,54) we employed this method to observe metal–ammine
compound binding to DNA and then the effects of the addition of heparin observed by the return
of the DNA conformation. The potential covalent metal–ammine compounds (up to a
concentration of 500 μM) did not change the DNA conformation at 280 nm, indicating little
interaction, even in comparison to the square-planar [Pt(NH3)4]2+ (data not shown).
For EtBr competition assay, at a concentration identical with that of the intercalator, a much larger
concentration of 500 μM was needed for the mononuclear metal–ammine compounds to displace
the EtBr compared to TriplatinNC (12.5 μM; Table 3.5 and Figure 3.12). Care must be taken in
analyzing these trends across a range of compounds because the inherent affinities of the
compounds themselves for DNA as a starting point differ widely. Further, the different assays
themselves represent different phenomena. The dangers in extrapolating across a series such as the
one studied here is demonstrated for [Pt(NH3)4]2+, which has demonstrably low affinity for
DNA.(55) In principle, charge effects (2+) should be the same as those for the [CoCl(NH3)5]2+ and
[RuCl(NH3)5]2+ compounds, as seen in fluorescence polarization assay (Table 3.3 and Figure 3.8).
An apparently higher affinity for heparin in EtBr assay compared to fluorescence polarization
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Table 3.5. EtBr Competition Assay for Comparison of Metal–Ammine Binding to DNA and
Heparin
a
EC50 is defined as the sequestration concentration of heparin MW ∼18000 required to return 50%
EtBr binding to DNA from the bound metal–ammine compound. EtBr bound to DNA was
normalized to 100%, with EtBr only as 0%.

Figure 3.9. CD spectra of ct-DNA in presence and absence of heparin and metal-ammine compounds (0-82µM
for TriplatinNC, and 0-1000µM for metal-ammines, MW 18000). DNA-compound conformation (measured by
the 280nm absorbance specific for ct-DNA) is restored upon increasing heparin concentrations. HEPES buffer
effects are observed below 230nm for DNA.
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assay may reflect its reduced ability to displace the intercalator, perhaps because of its smaller
square-planar geometry versus the octahedral geometry of the cobalt and ruthenium systems,
giving an apparently (but false) higher heparin affinity. This anomaly emphasizes the need to
employ more than one approach to assess accurately the questions of relative affinity of heparin
and DNA for coordination compounds.
Summary
We observed broadly similar trends for metal–ammine compound interaction with heparin across
the dye reporter techniques and DNA comparison assays. Slight discrepancies can be accounted
for by the nature of the technique. Another caveat is the complexity across the experiments where
the ITC system is a simple two-species system, heparin–dye reporter assays are three-species
system, and DNA comparison assays are four-species systems. Given these caveats, these results
are a testament to the relative accuracy of these methods for determining trends of coordination
compound interaction with heparin.

3.4 Conclusions:

Overall, oligosaccharide interactions with metal-based compounds are understudied in
bioinorganic chemistry. Molecular crowding in the interior of the cell breeds an environment in
which molecules must compete with each other,(56) and small molecules such as cisplatin may
encounter many possible binding partners, affecting biodistribution and metabolism, a reflection
perhaps of the accepted fact that such a small fraction (<5%) of administered drug is considered
to bind to its DNA target.(24) The overall results discussed here suggest comparable affinities for
heparin relative to DNA for charged substitution-inert coordination compounds, regardless of their
intrinsic nucleic acid affinity. This comparison should be capable of extrapolation to
glycosoaminoglycans such as HS. The presence of HS on the cell surface and its relatively similar
affinity to DNA would suggest that glycan binding is thus a competitive cellular event for many
coordination compounds.(21) These results extend our understanding of the importance of the
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Figure 3.10. Metal-ammine compounds inhibit methylene blue from binding to heparin. Concentrations for
metal-ammines were the following from top to bottom at 664 nm with highest and lowest concentrations shown:
(a) [Co(NH3)6]3+ 40, 35, 30, 25, 20, 15, and 1 µM; (b) [Ru(NH 3)6]3+ 70, 60, 50, 40, 30, 20, and 10 µM; (c)
[Pt(NH3)4]2+ 500, 375, 250, 100 and 50 µM; (d) [CoCl(NH 3)5]2+ 1250, 1000, 750, 500, 250, and 100 µM; (e)
[RuCl(NH3)5]2+ 1750, 1500, 1250, 1000, 750, 500, 250, 100, and 25 µM.
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interactions of physiologically relevant aquated metal cations with heparin to defined coordination
compounds. The available coordinating moieties on HS–heparin are the oxygen-donor atoms of
the hard carboxylate and sulfate bases. New patterns of metal-ion binding can be achieved by the
interplay and application of hard–soft acid–base concepts. Further, in considering the concept of
metalloglycomics, a phrase first coined by Codd,(57) coordination compounds can be manipulated
to modify the oxidation state, ligand lability, and coordination number and geometry to produce a
diverse inorganic library.

3.5 Experimental:

Materials
Heparin sodium salts from porcine intestinal mucosa of MW 3000 and 18000,
pentaamminechlorocobalt(III)
hexaamminecobalt(III)

chloride,

chloride

hexaammineruthenium(III)

were

purchased

from

chloride,

Sigma-Aldrich

and
(USA).

Pentaamminechlororuthenium(III) chloride was purchased from Aithace Chemical Corp. (USA).
TAMRA-R9 and methylene blue chloride were purchased from Anaspec (USA) and Fisher
Scientific (USA), respectively. TriplatinNC and tetraammineplatinum(II) chloride were
synthesized according to published methods from refs (58) and (59), respectively. The
concentrations of heparin were calculated using the dimer IdoA(2S)–GlcNS(6S) with a molecular
weight of 609.46 g/mol unless otherwise noted.
MB Binding Assay
All heparin–MB binding studies were performed in triplicate on an Agilent 8453 diode-array
spectrophotometer in a submicrometer quartz cuvette with a path length of 10 mm. Aqueous
solutions of methylene blue chloride (at a constant final concentration of 18.6 μM) and heparin
MW 18000 (1–25 μM) were prepared for determination of the optimal heparin–MB binding. A
final concentration of 15 μM heparin was used for evaluating the inhibition of MB binding by
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Figure 3.11. Heparin, a competitor for DNA binding
to metal–ammine compounds. The binding of metal–
ammine compounds to fluorescently labeled DNA is
reduced upon the addition of MW ∼3000 heparin (0–
21.2 μM).
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TriplatinNC (1–5 μM), whereas the metal–ammine compounds were studied at the higher 1 μM to
1.75 mM range. The heparin and metal complexes were incubated at room temperature for 15 min
before the addition of methylene blue chloride. Aqueous solutions of methylene blue chloride (at
a constant final concentration of 18.6 μM), heparin (MW 18000; at a constant final concentration
of 15 μM), and TriplatinNC (at a constant final concentration of 5 μM) were used to evaluate the
inhibition of TriplatinNC–heparin binding by physiological relevant concentrations of cations
(sodium chloride, 50, 100, and 150 mM; potassium chloride, 5 mM; calcium chloride, 1.3 mM;
magnesium chloride, 1 mM).
TAMRA-R9 Binding Assay
All heparin–TAMRA-R9 binding studies were carried out in triplicate. Solutions of TAMRAR9 (100 nM) and heparin 18000 MW (3 μM to 10 mM) in cacodylate buffer (200 mM, pH 7.4)
were prepared to determine the heparin concentration for optimal fluorescence. Heparin (625 μM)
and metal–ammine compounds (in the range 7.8 μM to 2.5 mM) were incubated for 15 min at
room temperature for compound–heparin binding before the addition of TAMRA-R9 (100 nM)
and measurement of the fluorescence.
SPR
Binding experiments were carried out at 25 °C on a Reichert Technologies (Depew, NY)
SR7500DC two-channel system equipped with a Neutravidin-coated mSAM sensor chip (Reichert
Technologies, part 13306065) using 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 150 mM NaCl, and 0.005% Tween-20 (HBST) as the running buffer. Prior to heparin
capture, the Neutravidin-coated mSAM sensor chip was preconditioned with three consecutive
injections of 50 mM NaOH for 1 min, respectively. Biotinylated heparin (MW ∼15000, Sigma) at
a concentration of 100 μg/mL was subsequently injected onto the avidin surface on the left channel
and captured to a level of 110 μRIU (∼110 RU), whereas the right channel was left as the bare
avidin surface to serve as a reference for nonspecific binding of TriplatinNC. Under a flow rate of
25 μL/min, TriplatinNC was injected over both channels at concentrations of 5, 1, 0.33, and 0.11
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Figure 3.12. Ethidium bromide competition assay for comparison of
metal-ammine compounds binding to ct-DNA and heparin (MW ~18000).
EtBr displaced by metal-ammine compound-DNA binding rebinds to
DNA upon the concentration-dependent sequestration of the metalammine compound (500 µM) by heparin. EtBr bound to DNA was
normalized to 100% with EtBr only as 0%.
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mM, respectively, for 2 min followed by a 5 min dissociation in a HBST running buffer. The
kinetic data were analyzed using TraceDrawer (Ridgeview Instruments) with a 1:1 model, while
the equilibrium data were fit using Scrubber (Biologic Software) to a 1:1 binding model.
ITC
Calorimetric data were collected using a VP-ITC microcalorimeter (MicroCal, LLC). All samples
were degassed for 5 min using a ThermoVac (MicroCal, LLC). For all titrations, injections of
TriplatinNC and metal–ammine compounds (0.546 and 4 mM, respectively) were pipetted
automatically into the reaction cell containing 1.3 mL of heparin MW 3000 (0.1 and 0.4 mM) at
300 s intervals from a 300 μL syringe with stirring at 75 rpm. In all experiments, a 100 mM
cacodylate buffer (pH 7.4) was used at 25 °C, and the thermal reference cell contained 1.3 mL of
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks was carried out using
the software supplied with the calorimeter (Origin 7.0). The heat released was fitted using Origin
7.0 to determine Ka, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation.
Fluorescence Polarization
50 μL binding reactions were carried out at room temperature in 96-well, low-binding, black plates
(Greiner) using 100 nM to 25 μM of each compound in 1.25 mM NaCl, 0.125 mM HEPES (pH
7.2), and 1 μM 3′ fluorescein-labeled hairpin DNA (GGGGCGACTGGTGAGTACGCCCC; MW
= 7705; Sigma). Readings were recorded immediately after mixing (for no competitor readings).
Subsequently, 1 μL of 10 μM heparin (MW = approximately 3000; Sigma) was titrated into each
reaction. Readings were recorded immediately. This was followed by titrations of 1 μL of 100 μM
heparin and then 1 μL of 1 mM heparin, with immediate readings after each addition. The
EC50calculation was based on the average of three separate experiments.
Ethidium Bromide (EtBr) Displacement Assay with Heparin
Calf-thymus DNA (ct-DNA) was dissolved and dialyzed in HEPES buffer (80 mM HEPES, pH
7.2). Buffer exchanges occurred three times every 12 h. The DNA concentration was determined
by UV–vis with absorbance at 260 nm and the average molecular weight of a nucleotide (333
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g/mol). EtBr at 5 mM in water was diluted in HEPES buffer and incubated with ct-DNA in HEPES
buffer for 5 min at room temperature. An aliquot of 1 mM TriplatinNC (4 mM for other
compounds) in water was diluted in HEPES buffer and incubated for 1 h to reduce fluorescence to
approximately 30% (20–25% for other compounds). Finally, increasing concentrations of heparin
MW 18000 in buffer from 20.5 to 82 μM final (100–1000 μM final for other compounds) were
incubated for an additional 1 h. Final concentrations were the following: EtBr, 12.5 μM; ct-DNA,
10 μM; TriplatinNC, 12.5 μM (500 μM for other compounds). All samples were read (after a total
of 2 h 5 min) in a 96-well plate at 530/590 nm using a microplate reader (Bio-Tek instruments).
Samples were normalized to the controls (EtBr only as 0% and EtBr–DNA as 100%). All
incubations were done at 37 °C.
CD Studies
TriplatinNC (ri = 0.075 compound/DNA ratio) or metal–ammine compounds (ri = 5) were
incubated with 100 μM ct-DNA for 1 h at 37 °C in HEPES buffer (80 mM HEPES, pH 7.2). Then
heparin MW ∼18000 was added with 10.25–230 μM final concentrations (only 10.25–82 μM are
shown) and incubated for an additional 1 h at 37 °C. Final concentrations after heparin addition
were the following: 100 μM ct-DNA and 7.5 μM TriplatinNC (ri = 0.075) or 500 μM (ri = 5). After
the incubations, samples were placed in a 10 mm submicro cuvette to record the CD spectra at
room temperature using a Jasco J600 spectropolarimeter.
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4.1 Abstract

Spectroscopic and biophysical approaches were developed to examine the affinity and
stoichiometry of simple cobalt complexes for Fondaparinux (FPX) as a model for Heparan Sulfate
(HS). HSs play vital roles in both cancer cell proliferation, angiogenesis, metastasis, and
differentiation; and viral particle attachment. Cobalt containing complexes, like CTC-96, were
shown to inhibit Herpes Simplex Virus 1 replication through HS binding, and this work extends
FPX binding to these simple cobalt complexes. Cobalt complexes are competitive inhibitors of
methylene blue (MB)–FPX binding, and the change in absorbance of the dye in the presence or
absence of sulfated FPX was used as an indirect reporter of cobalt-FPX affinity. The dissociation
constant (Kd) was also directly measured using Isothermal Titration Calorimetry (ITC).
Stoichiometry and sulfate protection was determined using electrospray ionization mass
spectrometry (ESI-MS). Cleavage of HS by the enzyme heparanase also modulates tumor
angiogenesis, cell invasion, and metastasis. Metalloshielding of HS cleavage by these cobalt
complexes will effectively inhibit tumor-related events. Studies using P. heparinus heparanase I
showed that these cobalt complexes inhibit the cleavage activity of the enzyme. These results will
further the understanding of the metalloglycomics concept into the third important class of
biomolecules from the well-studied protein and DNA/RNA and their interactions.

4.2 Introduction

Proteoglycans containing Heparan Sulfate (HS), a sulfated glycosaminoglycan, play a major role
in the cell signaling process, adhesion and migration.(1,2) Heparan sulfate proteoglycans (HSPGs)
are HSs conjugated with proteins and can be found on the cell surface or in the extracellular
matrix.(1,2) HSPGs are over-expressed on the surface of many cancer cells.(3,4) The sulfate
residues on HS are the recognition site for many different protein substrates including proangiogenic growth factors, similar to the phosphate clamp-arginine fork motif.(5-10) Fibroblast
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Figure 4.1. Structures of cobalt complexes used. Counterions are omitted for clarity.

Figure 4.2. Structures of D-Glucosamine-6-O-sulfate, Fondaparinux, and cleavage products
by P. heparinum heparinase I. In the presence of cobalt complexes, cleavage was inhibited.
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growth factors (FGF) directly stimulates the cancer cell’s growth, metastasis and survival.(6)
Enzymatic cleavage of HSPG at the glycosidic linkages by heparanase (HPSE) causes release of
angiogenic growth factors initiating the angiogenic cascade.(11-13) HPSE is also over-expressed
in tumors with significant correlation between metastatic potential and heparanase activity.(14)
Furthermore, HS plays a vital role in the attachment of viral envelope glycoproteins to the cell
surface.(15) Viral particles attach to HS by their glycoproteins causing subsequent interactions
with specific cell entry receptors leading to viral cell replication.(15) Cobalt containing complexes
binding HS has been shown to disrupt synthesis of viral structural proteins.(15) HS is thus an
attractive drug target to inhibit tumor cell progression and viral replication. We have shown that
“metalloshielding” or sulfate cluster masking of HS by metal complexes protect HS from
enzymatic cleavage by the mammalian heparanase, prevents growth factors from binding to HS
and/or prevents release of bound growth factors.(6, 7) We hypothesize that such binding by cobalt
complexes may also act at the point of viral entry; preventing viral particle attachment and thus
inhibiting the replication of the viral cells.
In order to determine the importance of structure-activity relationship on the “metalloshielding”
potential of the metal complex library, affinity and cleavage inhibition studies were performed on
Fondaparinux, as a model HS-like substrate. Fondaparinux is a well-defined, octasulfated
pentasaccharide with a single point of cleavage for both bacterial and human HPSE.(11,13) We
have previously presented spectroscopic and biophysical approaches to examine the affinity of
metal−ammine coordination complexes for heparin.(16) Metal−ammine compounds are
competitive binders to heparin. Results have shown that simple cobalt compounds bind with
relatively high affinity, even greater than that of the simple platinum compound,
tetraammineplatinum(II).(16) To further explore the less cytotoxic cobalt, as compared to
platinum, and its interactions with HS, the differences between covalent and non-covalent
interactions will be examined. New patterns of cobalt-heparin binding can be achieved by the
application of hard–soft acid–base concepts.
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A

B

Figure 4.3. A) Fondaparinux cleavage by heparinase I. B) Pentamminechlorocobalt (III)
inhibits heparinase I cleavage of fondaparinux more effectively than tdichlorobis(ethylenediamine)cobalt (III) or tris(ethylenediamine)cobalt (III).

Figure 4.4. Pentamminechlorocobalt (III) inhibits the heparinase I induced invasion of
matrigel by MDA-MB231 cells more than t-dichlorobis(ethylenediamine)cobalt(III) or
tris(ethylenediamine)cobalt (III).
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To develop the structure-activity relationships, we have chosen a small library of cobalt complexes
to examine the effects of covalent and non-covalent interactions on their interactions with FPX.
In this paper, we describe cleavage inhibition studies in the presence/absence of the cobalt library
using bacterial HPSE.(17) A competition assay using methylene blue (MB) as a reporter describes
an approach to measure the affinity of each compound for FPX and compare that to a direct
titration of each cobalt complex into FPX using isothermal titration calorimetry (ITC). Binding
stoichiometry and type of binding to compare covalent and non-covalent interactions were
examined using mass spectrometry (MS) and nuclear magnetic resonance (NMR). The overall
results emphasize the importance of understanding the properties of glycan interactions with
coordination complexes.

4.3 Results and Discussion

The library of simple cobalt compounds is shown in Figure 4.1. The compounds were chosen to
study the covalent interactions between hard base oxygens on the glycan chain with the hard acid
cobalt metal. These covalent interactions will also be compared to a non-covalent compound to
determine strength of binding and overall stoichiometry.
The cleavage patterns for bacterial heparinase I (often used as a model for the mammalian enzyme)
are shown in Figure 4.2. Colorimetric assays for enzymatic activity and inhibitor screening have
been developed.(18) We therefore adapted the assay to examine the inhibitory effect of cobalt
complexes on the enzymatic (heparinase) degradation of Fondaparinux. The pentasaccharide
substrate was incubated with cobalt complex prior to enzyme exposure and cleavage measured
versus control in absence of added complex. Inhibition of heparinase cleavage is effective for the
non-covalent

compound,

pentaamminechlorocobalt(III),

followed

by

the

covalent

t-

dichlorobis(ethylenediamine)cobalt(III), Figure 4.3.
Cellular invasion through the extracellular matrix (ECM) requires degradation of the matrix by
HPSE, and cell motility in response to growth factors. The ability of cobalt complexes to inhibit
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B

A

C

Figure 4.5. A) 1H NMR spectra of 1:1 mixtures of D-glucosamine-6-O-sulfate and
various cobalt complexes from top to bottom: tris(ethylenediamine)cobalt(III), tdichlorobis(ethylenediamine)cobalt(III), pentaamminechlorocobalt(III), and Dglucosamine-6-O-sulfate. B) 59Co NMR spectrum of tris(ethylenediamine)cobalt(III)
(bottom)
and
1:1
mixture
of
D-glucosamine-6-O-sulfate
and
59
tris(ethylenediamine)cobalt(III) (top). C) Co NMR spectrum of 1:1 mixture of Dglucosamine-6-O-sulfate and t-dichlorobis(ethylenediamine)cobalt(III) (top) and 1:1
mixture of D-glucosamine-6-O-sulfate and pentaamminechlorocobalt(III) (bottom).

Table 4.1. 1H and 59Co chemical shift changes (Δδ = δ(monomer : Co) –
δ(monomer/Co)) after incubation of Co complexes with D-glucosamine-6-O-sulfate.
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cell invasion through matrigel basement membrane was accessed using a Boyden-chamber
assay.(19) Serum-starved cells were seeded into the top chamber onto a matrigel membrane with
heparinase I or without (migration control). Complex was added to the top chamber in serum-free
media. The bottom chamber was filled with media containing 10% serum (no drug). In Figure 4.4,
pentaamminechlorocobalt(III) shows minimal cell migration at the 50 μM. The results of the two
heparinase cleavage assays clearly distinguishes that the pentaamminechlorocobalt(III) exhibits
the

greatest

inhibition

of

dichlorobis(ethylenediamine)cobalt(III)

heparinase
with

cleavage
minimal

followed
inhibition

by
by

tthe

tris(ethylenediamine)cobalt(III).
The NMR chemical shift changes of D-glucosamine-6-O-sulfate (monomer) in the presence of
cobalt complexes were investigated to delineate the binding interactions. Addition of cobalt
complexes shifted the protons of the monomer, Figure 4.5 A. Upon measurements performed from
the freshly prepared 1:1 Co:Monomer complexed mixture, distinct shifts were observed due to fast
interactions. It is readily apparent that only small downfield shifts (.000 to .018 Δppm) are
observed disregarding t-dichlorobis(ethylenediamine)cobalt(III), Table 4.1. These weaker shifts
are due to the non-covalent interactions produced by these cobalt complexes. However, tdichlorobis(ethylenediamine)cobalt(III) produced shifts (-.034 to -.049 Δppm) that were at least 4
fold greater than any other cobalt complex shift. The covalent interactions produced larger shifts
by coordination of the cobalt to the sulfate or any other oxygen on the monomer. Due to the lack
of solubility pentaamminechlorocobalt(III) peaks did not shift considerably.
59Co

NMR

spectra

of

cobalt

complexes

with

monomer

were

also

obtained.

Tris(ethylenediamine)cobalt(III) peak was observed similar to previously published data, Table
4.2, at 7144 ppm (literature - 7145 ppm).(20) Upon measurements performed from the freshly
prepared 1:1 Co:Monomer complexed mixture, distinct shifts were observed due to fast
interactions, Table 4.1. It is readily apparent that only a small upfield shift of -61 ppm, Figure 4.5
B.

However,

pentaamminechlorocobalt(III)

and

t-dichlorobis(ethylenediamine)cobalt(III)

produced shifts of -1983 and -4164 ppm respectively, that were considerably greater than the non143

Table 4.2. Species detected using 59Co NMR. *charges were omitted for clarity.
Published chemical shifts were obtained from ref. 20.

A

B

C

Figure
4.6.
ESI-MS
of
1:1
adducts
of
FPX
and
A)
tdichlorobis(ethylenediamine)cobalt(III) in the 2- charge state, both covalent and noncovalent
interactions
are
observed
with
loss
of
sulfates,
B)
pentaamminechlorocobalt(III) in the 3- charge state, both covalent and non-covalent
interactions are observed with loss of sulfate with the parent peak of FPX also
observed, and C) tris(ethylenediamine)cobalt(III) in the 3- and 4- charge states. Parent
peak of FPX with loss of sulfates was also observed at the 4- charge state.
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covalent cobalt complex shifts, Figure 4.5 C. The covalent interactions of the cobalt coordinating
to the sulfate or any other oxygen on the monomer produced larger shifts. The
pentaamminechlorocobalt(III) peak was observed at 8885 ppm (8887 ppm),

while the

pentaammineaquacobalt(III) was shifted downfield to 9155 ppm (9147 ppm).(20) After addition
of monomer to the solution, the peak representing two monomers, one bound covalently and one
bound non-covalently to the cobalt complex, is upfield shifted to 6909 ppm, while the peak
representing a coordinated water with a two non-covalent monomers was observed at 7231 ppm.
This 1:2 Co:monomer stoichiometry follows the trend observed in the monomer mass
spectrometry data. Since the t-dichlorobis(ethylenediamine)cobalt(III) rapidly isomerizes in
aqueous solutions with a greater abundance of cis being formed, we only observed the cis chloride
isomer at 8961 ppm (8974 ppm). Due to the complexity of the spectra, we used
tris(ethylenediamine)cobalt(III) as a standard, which agreed to the previous spectra. After addition
of monomer, we again observed a similar shift of tris(ethylenediamine)cobalt(III). High symmetry
complexes have narrower lines while low symmetry complexes have broader lines, cis is broader
than trans, therefore all peaks are attributed to a cis geometry due to the broad nature observed.(20)
Again, following the mass spectrometry data, there will be a 1:2 binding stoichiometry of
Co:monomer.

An

upfield

shift

was

observed

at

5400

ppm

attributed

to

c-

diaquabis(ethylenediamine)cobalt(III) with 2 non-covalently bound monomers. Further upfield at
5200 ppm, a peak was observed of covalently bound water and monomer with another noncovalent bound monomer. A very broad peak was observed at 4797 ppm, which is likely due to
both a bidentate bound monomer with a non-covalent bound monomer and bismonomer covalently
bound.
The analysis of the NMR spectra are based largely on the chemical shifts of the peaks and the
quadrupole splitting. The former measures electron density around the 1H nucleus when the
chloride ligand is replaced by sulfate from the monomer. Furthermore, Co(III) chemical shifts are
heavily influenced by the nephelauxetic effect in the 59Co NMR spectra.(21) This refers to a
decrease in the Racah interelectronic repulsion parameter when the cobalt forms a covalent
145

FPX+[Co(en3)]
FPX+[Co(en3)]-SO3
FPX+[Co(en3)]+Na
FPX+[Co(en3)]

C37H70CoN9O49S8
C37H70CoN9O46S7
C37H69CoN9NaO49S8
C37H71CoN9O49S8

434.77 (4-)
414.78 (4-)
440.26 (4-)
580.03 (3-)

MW
Observed Calculated
1739.08
1739.04
1659.12
1659.08
1761.04
1761.02
1740.09
1740.04

FPX+[Co(NH3)5]
FPX+[Co(NH3)5]+H2O
FPX+[Co(NH3)5]
FPX+[Co(NH3)5]-SO3
FPX+[Co(NH3)5]+H2O
FPX+[Co(NH3)5]
FPX+[Co(NH3)5]+H2O

C31H61CoN8O49S8
C31H63CoN8O50S8
C31H62Co N8O49S8
C31H62CoN8O46S7
C31H64CoN8O50S8
C31H63Co N8O49S8
C31H65CoN8O50S8

410.99 (4-)
415.50 (4-)
548.34 (3-)
521.68 (3-)
554.34 (3-)
823.01 (2-)
832.01 (2-)

1643.96
1662.00
1645.02
1565.04
1663.02
1646.02
1664.02

1643.96
1661.97
1644.97
1565.01
1662.98
1645.98
1663.99

FPX+[Co(en2)]
FPX+[Co(en2)]-SO3
FPX+[Co(en2)]+H2O
FPX+[Co(en2)]+2H2O
FPX+[Co(en2)]
FPX+[Co(en2)]-SO3
FPX+[Co(en2)]-2SO3
FPX+[Co(en2)]-3SO3
FPX+[Co(en2)]-4SO3
FPX+[Co(en2)]-5SO3
FPX+[Co(en2)]-6SO3
FPX+[Co(en2)]+H2O
FPX+[Co(en2)]+H2O-SO3
FPX+[Co(en2)]+2H2O
FPX+[Co(en2)]+2H2O-SO3
FPX+2[Co(en2)]

C35H63CoN7O49S8
C35H63CoN7O46S7
C35H65CoN7O50S8
C35H67CoN7O51S8
C35H64CoN7O49S8
C35H64CoN7O46S7
C35H64CoN7O43S6
C35H64CoN7O40S5
C35H64CoN7O37S4
C35H64CoN7O34S3
C35H64CoN7O31S2
C35H66CoN7O50S8
C35H66CoN7O47S7
C35H68CoN7O51S8
C35H68CoN7O48S7
C39H76Co2N11O49S8

560.00 (3-)
533.35 (3-)
566.01 (3-)
571.99 (3-)
840.51 (2-)
800.53 (2-)
760.55 (2-)
720.57 (2-)
680.59 (2-)
640.61 (2-)
600.51 (2-)
849.51 (2-)
809.84 (2-)
858.52 (2-)
818.52 (2-)
928.25 (2-)

1680.00
1600.05
1698.03
1715.97
1681.02
1601.06
1521.10
1441.14
1361.18
1281.22
1201.02
1699.02
1619.68
1717.04
1637.04
1856.50

1679.98
1600.02
1697.99
1715.99
1680.98
1601.03
1521.07
1441.11
1361.16
1281.20
1201.24
1698.99
1619.04
1717.00
1637.05
1856.02

2Monomer+[Co(en3)]
2Monomer+[Co(en2)]
Monomer+[Co(en2)Cl2]

C18H48CoN8O16S2
C16H40CoN6O16S2
C10H28Cl2CoN5O8S

755.19 (1+)
695.12 (1+)
507.26 (1-)

755.19
695.12
507.26

755.19
695.13
507.04

Composition*

Formula

m/z (charge)

Table 4.3. Species detected on the ESI-MS spectra. *protons and charges were omitted for
clarity. FPX represent the parent Fondaparinux species and Monomer represents Dglucosamine-6-O-sulfate.
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interaction with the monomer, producing less repulsion between two electrons in a doubly
occupied d-orbital.(19) This repulsion parameter likely arises from one or two causes, the effective
positive charge on the metal has decreased from a negative bound ligand and/or an increase in
orbital size from a covalent interaction. The latter is sensitive to the symmetry of the structural
environment

around

the

transition

metal,

specifically

the

symmetrical

tris(ethylenediamine)cobalt(III) when bound to multiple monomers loses symmetry and multiple
peaks are observed. The racemic [Co(en)3]3+ ion pairs with D-glucosamine-6-O-sulfate, resulting
in the diastereomeric ion pairs having clearly distinct chemical shifts.(22) Comparison of NMR to
MS gives a clear picture of binding stoichiometry between these cobalt complexes and monomer.
Negative mode electrospray ionization (ESI) is commonly used for identification and analysis of
heparin. We have previously shown through ESI-MS studies that FPX undergoes sulfate loss in
the gas phase.(9) Analysis regarding the retention of labile sulfate groups on the heparin backbone
has shown metal cations stabilize sulfate groups.(23) In the present work we examine the
stoichiometry of cobalt complexes bound to FPX and their ability to protect against sulfate loss.
We again compare the difference in covalent and non-covalent interactions, Table 4.3.
Peaks corresponding to a hydrogen bonding interaction between tris(ethylenediamine)cobalt(III)
and FPX were observed at 434.77 m/z (4-) and 580.03 m/z (3-), Figure 4.6. Peaks were also
observed corresponding to a retained sodium ion at 440.26 m/z (4-) and loss of one sulfate at
414.78 m/z (4-). The cobalt compounds may coordinate to water resulting in a noncovalent
interaction, or may coordinate to the sulfates resulting in a covalent interaction since the chloride
would

be

dissociated

from

the

compound.

Pentaamminechlorocobalt(III)

and

t-

dichlorobis(ethylenediamine)cobalt(III) have the ability to interact both covalently and noncovalently, Figure 4.6. Covalent and non-covalent interactions were both observed for
pentaamminechlorocobalt(III) at the 2-, 3-, and 4- charge states. The cobalt compounds may
coordinate to water resulting in a noncovalent interaction, or may coordinate to the sulfates
resulting in a covalent interaction since the chloride would be dissociated from the compound. A
1:1 binding interaction was observed covalently at 823.01 m/z (2-), 548.34 m/z (3-) along with
147

Figure 4.7. A trace of calorimetric titration (upper panel) and integrated isotherms (lower panel).
The first peak represents a pre-injection that was omitted in the binding calculations. A) ITC
analysis of FPX by direct titration of tris(ethylenediamine)cobalt(III). B) ITC analysis of FPX
by direct titration of pentaamminechlorocobalt(III).

[Co(en)3]3+
[Co(NH3)5Cl]2+

Kd (µM)
18.6 ± 3.0
87.7 ± 17.7

ΔG (kJ/mol)
-6.5 ± 0.1
-5.5 ± 0.3

ΔH (J/mol)
-374.8 ± 7.5
-345.7 ± 20.2

-TΔS (kJ/mol*K)
-6.1
-5.2

Table 4.4. ITC analysis showing the obtained binding parameters: dissociation constants (Kd);
free energy of binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS)
between cobalt compounds and FPX. The standard error from 3 measurements is indicated.
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loss of one sulfate at 521.68 m/z (3-), and 410.99 m/z (4-). The non-covalent interaction uses
hydrogen bonding either between the ammines or coordinated water of the cobalt and the sulfates
of the FPX. The non-covalent interaction was also observed with a coordinated water at 832.01
m/z (2-), 554.34 m/z (3-), and 415.50 m/z (4-). Covalent and non-covalent interactions were both
observed for t-dichlorobis(ethylenediamine)cobalt(III) at the 2- and 3- charge states. The cobalt
compounds may coordinate to the sulfates producing a covalent interaction since the chlorides are
dissociated from the compound. Water may also coordinate to one of the free ligand sites, still
allowing a covalent interaction between cobalt and FPX. The non-covalent interaction uses
hydrogen bonding either between the ammines or bound water of the cobalt and the sulfates of the
FPX since water is coordinated to both of the free ligand sites of the cobalt compound. A 1:1
binding interaction was observed covalently at 560.00 m/z (3-) and with one coordinated water at
566.01 m/z (3-), and non-covalently with 2 coordinated waters at 571.99 m/z (3-). Loss of one
sulfate was also observed at 533.35 m/z (3-) with no coordinated water. A 1:1 binding interaction
was observed covalently at 840.51 m/z (2-) and with one coordinated water at 849.51 m/z (2-), and
non-covalently with 2 coordinated waters at 858.52 m/z (2-). Loss of one to six sulfates was also
observed at 800.53, 760.55, 720.57, 680.59, 640.61, and 600.51 m/z (2-) respectively with no
coordinated water, while at loss of one sulfate was observed both covalently with one coordinated
water at 809.84 m/z (2-) and non-covalently with two coordinated waters at 818.52 m/z (2-). A 2:1
binding stoichiometry of Co:FPX was observed at 928.25 m/z (2-) with no coordinated waters.
We also observed more sulfate loss with covalent interactions, since hydrogen bonding interactions
allow for sulfate cluster interactions more sulfates are protected. While the covalent interactions
would only protect one sulfate from loss. Non-covalent interactions protect more sulfates as
compared to covalent interactions likely due to the non-covalent interaction’s ability to
“metalloshield” a larger group of sulfate clusters, while the covalent interaction may only protect
one sulfate through bidentate binding.
To compare the binding stoichiometry observed in the monomer NMR, monomer binding with
cobalt complexes was also studied. Peaks were observed for an interaction between
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Figure 4.8. MB competition assay for assessment FPX binding. At a constant concentration
of FPX (15 μM) in the presence of varying concentrations of A)
tris(ethylenediamine)cobalt(III) (from bottom to top with 30, 40, 50, 80, 90, 100, 250, 500
μM), B) t-dichlorobis(ethylenediamine)cobalt(III) (from bottom to top with 40, 50, 60, 70,
80, 90, 200, 300, 400, 500 μM), and C) pentaamminechlorocobalt(III) (from bottom to top
with 40, 50, 60, 70, 80, 90, 100, 200 μM); MB binding is inhibited, reflected in the change of
[AbsMB] at 664 nm.

[Co(en)3]3+
[Co(en)2Cl2]1+
[Co(NH3)5Cl]2+

IC50 (µM)a
71.0 ± 2.9
116.1 ± 1.6
75.6 ± 1.2

Kd(app) (µM)b
33.3 ± 1.4
54.4 ± 0.8
35.4 ± 0.5

Table 4.5. IC50 and Kd values of cobalt complexes in competitive inhibition assays using MB.
a
The IC50 value was determined as the concentration of complex required for half-maximal
binding of the dye (18.6 μM) to FPX (15 μM).
b
Dissociation constants were calculated from the MB assay for cobalt complexes binding to
FPX using a competitive inhibitor model.
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tris(ethylenediamine)cobalt(III) and monomer at a 1:2 Co:monomer stoichiometry at 755.19 m/z
(1+).

A

1:2

covalent

binding

interaction

was

observed

between

t-

dichlorobis(ethylenediamine)cobalt(III) and monomer at 695.12 m/z (1+), while a 1:1 noncovalent binding interaction was observed at 507.26 m/z (1-) with no dissociated chlorides.
ITC measures the amount of heat energy released or absorbed into the system upon the interaction
of two molecules. ITC determines the thermodynamic influences of both the change in enthalpy
(ΔH) and entropy (ΔS) changes to calculate the free energy of binding (ΔG). ITC assays were
performed to determine the binding constants between FPX and the cobalt compound library.
Covalent and non-covalent interactions contribute to the enthalpy term, while conformational
freedom changes and solvation upon complexation contribute to the entropy term.(24,25)
While the major contribution for the derived thermodynamic binding parameters arose from the
entropy term, binding interactions can still be evaluated from the enthalpy binding term, Table 4.4.
Tris(ethylenediamine)cobalt(III) produced a Kd (18.6 µM) and greatest Gibbs Free energy (-6.5
kJ/mol), this is likely due to the hydrogen bonding ability and larger overall size compared to other
ligands, Figure 4.7. Pentaamminechlorocobalt(III) produced a Kd of 87.8 µM and the weakest
Gibbs Free energy (-5.5 kJ/mol), Figure 4.7. The calculated binding parameters of
pentaamminechlorocobalt(III) are likely weaker due to its ability to only interact with one sulfate
covalently. The ITC titrations of t-dichlorobis(ethylenediamine)cobalt(III) to FPX did not give a
well-defined

isothermal

trace,

perhaps

due

to

the

rapid

isomerization

of

t-

dichlorobis(ethylenediamine)cobalt(III) in aqueous solutions. The major contribution arose from
the entropy term, produced by the release of solvent molecules from FPX upon binding. While the
enthalpy terms are similar between the two cobalt complexes showing similar strength of hydrogen
bonding, the difference in the entropy term produces a discrepancy in the dissociation constant.
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine
heparin binding interactions.(26-29) The MB absorbance at 664 nm and 614 nm decreases
proportionally with increasing sulfate concentration from addition of FPX to the solution. We have
previously shown that with addition of FPX to a solution containing a constant concentration of
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MB, the absorbance decreases as free MB is bound to increasing concentrations of FPX.(17) The
association constant between FPX and MB was previously calculated using a Scatchard plot (4.1
x 104 M-1).(16, 17)
We again used the MB assay to study the ability of the cobalt library to inhibit MB binding through
metalloshielding of FPX. With increasing concentrations of cobalt compounds in solution, FPX is
metalloshielded from MB interacting with the FPX allowing more free-MB to be in solution
resulting in an increase of absorbance. The ability for these cobalt compounds to “metalloshield”
was calculated as an IC50 value, the concentration of cobalt compound required to inhibit 50% of
the MB to bind to the FPX. Pentaamminechlorocobalt(III) and tris(ethylenediamine)cobalt(III)
both have the ability to ‘metalloshield’ multiple sulfate clusters from binding to MB resulting in
similar concentrations required (75.6 and 71.0 µM respectively), Table 4.5 and Figure 4.8. Again,
we observed a higher concentration required for the covalent

interaction of

t-

dichlorobis(ethylenediamine)cobalt(III) (116.1 µM) which may be due to the one sulfate covalent
protection over hydrogen bonding cluster interactions or to the rapid isomerization artificially
increasing the concentration needed, Figure 4.8. By using MB as a reporter, we are able to calculate
the apparent dissociation constant (Kd(app)) between the cobalt complexes and FPX.

4.4 Conclusions

The focused small library studied here begins to elucidate structure–activity relationships. The
stark

contrast

between

pentaamminechlorocobalt(III)

t-dichlorobis(ethylenediamine)cobalt(III)

and

in inhibiting the HS cleavage emphasizes the importance of

hydrogen bonding in sulfate cluster protection. The overall results discussed here suggest
comparable affinities for cobalt complexes binding to FPX as previously discussed.(16, 17) ITC
shows that cobalt complexes interacting with FPX, Kds of 18.6 to 90.1 µM, are comparable to a
mixture of heterogeneous heparin chains complexing with FGF-1, Kds of 1.1 to 3 µM.(30,31) MB
and MS assays suggest that covalent interactions of these cobalt compounds may only interact
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with a single sulfate, while non-covalent hydrogen bonding may interact with a cluster of sulfates.
This was observed using MB as a reporter, requiring a higher concentration of covalently
interacted cobalt complexes over the non-covalent complexes. This was also observed in the MS
with

a

greater

number

of

sulfates

lost

through

the

covalent

interaction

of

t-

dichlorobis(ethylenediamine)cobalt(III) with up to six sulfates lost from FPX in the 2- charge state,
while the non-covalent interaction showed lower abundance of lost sulfates. Therefore
“metalloshielding” of FPX through sulfate clusters would be greater in the non-covalent
compounds over the covalent interactions. However, the NMR results show that covalent
interactions, using application of hard–soft acid–base concepts, occur much stronger than the noncovalent interactions. These assays give an estimate of the strength of the FPX–cobalt binding and
provide a relative calculation of affinities. However, given clear disparities in the quantitation of
dissociation constants, care should be taken in extrapolating across the assays discussed due to the
inherent differences in the nature of these assays. Thus, whereas ITC is a “two-body” system, the
MB competition assay becomes a “three-body” system, and is consequently more difficult to
interpret. Overall, the results validate the importance of the metalloglycomics concept in
developing new classes of molecules for study of glycan structure and function, further
emphasizing the need to explore the dual‐ function therapeutic nature of the less cytotoxic cobalt
complexes.

4.5 Experimental Section

Synthesis and Materials
D-glucosamine-6-O-sulfate was purchased from Carbosynth Ltd.(USA). Fondaparinux and
pentaamminechlorocobalt(III) chloride were purchased from Sigma-Aldrich (USA). Methylene
blue chloride was purchased from Fisher Scientiﬁc (USA). Tris(ethylenediamine)cobalt(III)
chloride,

t-dichlorobis(ethylenediamine)cobalt(III)

153

chloride,

and

potassium

hexacyanocobaltate(III) were synthesized according to published methods from refs 32, 33, and
34, respectively.
Heparinase Studies
Colorimetric HPSE activity assay
The indicated concentration of each compound was incubated for 15 min. at room temperature
with 50 µM fondaparinux in buffer containing 40mM NaOAc, pH 5. After addition of 0.25U
heparinase I for 1h at 37°C, the reactions were stopped by adding 100 µl 1.69mM WST-1
(Dojindo). After heating the plate to 60°C for 30 min., absorbance readings at 584 nm were
collected using a spectrophotometer (Biotek). The points on the graph represent the mean of two
independent experiments containing two replicates for each concentration.
Matrigel Invasion HPSE assay
Drug + Heparinase Incubation
Growth factor reduced matrigel chambers (Corning) were treated with either PBS (-HPSE and
+HPSE) or 50 µM of cobalt compound for 1 hour. Following treatment, chambers were then
treated with additional PBS (-HPSE) or 0.3 units of heparinase I (+HPSE and Drug + HPSE).
Matrigel chambers were then placed in 37°C incubator for 16 hours to allow heparinase digestion
of matrigel to take place. Following this digestion, matrigel inserts were washed 10x times with
PBS in order to remove remaining enzyme or drug. Inserts were then filled with DMEM:F12 media
(Gibco) containing low percentage of FBS (0.2%). Inserts were then placed into new wells
containing chemoattractant (10%FBS).
Cell Invasion
Next, 8x104 serum starved MDA-MB231 cells were seeded into each chamber. Cells were then
placed into the incubator for 12 hours to allow for invasion to occur. Following this, cells which
had invaded were fixed and stained using methanol/crystal violet, imaged, and counted manually.
Percent invasion was determined by normalizing cells invaded through matrigel to cells which
migrated through control insert.
Direct Binding Assays:
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Isothermal Titration Calorimetry
Calorimetric data was collected using a VP-ITC Microcalorimeter (MicroCal, LLC). All samples
were degassed for 5 minutes using a ThermoVac (MicroCal, LLC). For all titrations, injections of
cobalt complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at
300 second intervals from a 300 µL syringe while stirring at 75 rpm. In all experiments, 100 mM
cacodylate buffer (pH 7.4) was used at 25oC and the thermal reference cell contained 1.3 mL of
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks were carried out using
the software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one site model
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation.
NMR Studies
1

H NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data

being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was preincubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 4.1)
in deuterated water.
59

Co NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data

being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was preincubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 4.1)
in deuterated water. Chemical shifts are reported relative to Co(CN)63-.
Mass Spectrometry
Mass spectra were acquired on a Thermo Electron Corporation Orbitrap Velos mass spectrometer
(Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to 0.7 µL/min
using a syringe pump. Electrospray source condition were kept constant with a capillary
temperature of 230oC and capillary voltage between 2.3 and 2.5 kV. FPX and cobalt complexes
were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed at a 1:1
molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted with
addition of Milli-Q methanol for a final concentration of 1:10 methanol:water.
Competitive Binding Assays:
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Methylene Blue Reporter Method
A change in absorbance of MB at 664 nm accompanies it binding to the sulfates on FPX. This
change was used to quantitate the affinity of MB (at a constant final concentration of 21.98 µM)
for FPX in water. Varying concentrations of cobalt complexes were incubated with constant
concentration of FPX (at a constant final concentration of 15 µM) for 15 mins at room temp. To
each sample was added constant concentration of MB. All binding studies were performed in
triplicate on an Agilent 8453 diode array spectrophotometer in a sub-micro quartz cuvette with a
path length of 10 mm.
IC50 and Ka(app) values for binding of cobalt complexes to FPX were calculated by converting the
MB absorption values to a normalized value (minimum and maximum absorbance) and the Ka(app)
was determined using the following equation:
1
𝐾𝑎(𝑎𝑝𝑝)

= 𝐼𝐶50 𝑥

2𝐾𝑑𝐿 [𝑆𝐿 −(𝐵𝐿 )𝑜 ]
2

[(𝐵𝐿 )𝑜 +2𝑆𝐿 𝐾𝑑𝐿 −3𝑆𝐿 (𝐵𝐿 )𝑜 ]

,

where KdL is the dissociation constant for the labeled ligand (MB) and binding site (FPX), SL is the
total concentration of the labeled ligand, and (BL)o is the equilibrium of labeled ligand value when
competitor concentration is zero.
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Chapter 5: Interactions of Non-covalent Metal Complexes with Fondaparinux

5.1 Results and Discussion

Negative mode electrospray ionization (ESI) is commonly used for characterization of heparin due
to its highly acidic nature. We have previously shown through ESI-MS studies that FPX undergoes
sulfate loss in the gas phase. (1) Analysis regarding the retention of labile sulfate groups on the
heparin backbone has shown metal cations stabilize sulfate groups. (2) In this work we examine
the stoichiometry of metal complexes bound to FPX and the ability of these metal complexes to
protect against sulfate loss, Table 5.1.
Peaks corresponding to a hydrogen bonding interaction between hexaamminecobalt(III) and FPX
were observed at 415.25 m/z (4-), 554.01 m/z (3-), and 831.52 m/z (2-), Figure 5.1. Peaks were also
observed corresponding to a retained sodium ion at 561.33 m/z (3-) and one to three retained
sodium ions at 842.51, 853.50, and 864.49 m/z (2-) respectively. A 2:1 binding stoichiometry of
Co:FPX was also observed at 910.55 m/z (2-). Continuing with Werner’s complex, one peak
corresponding to a hydrogen bonding interaction between Werner’s Complex and FPX with a 2:2
binding stoichiometry was observed at 816.59 m/z (5-), Figure 5.1. Switching to an electrostatic
compound rather than a hydrogen bonding compound, peaks corresponding to tris(2,2’bipyridine)cobalt(III) and FPX were observed at a 1:2 Co:FPX stoichiometry at 620.99 m/z (6-),
745.39 m/z (5-), 931.98 m/z (4-), and 1242.98 m/z (3-), Figure 5.1. A 1:1 binding stoichiometry
was also observed 1110.99 m/z (2-). Continuing with tris(2,2’-bipyridine)ruthenium(II), peaks
corresponding to an electrostatic bonding interaction between tris(2,2’-bipyridine)ruthenium(II)
and FPX were observed with a 2:1 Ru:FPX stoichiometry at 660.55 m/z (4-), 881.08 m/z (3-), and
1321.62 m/z (2-), Figure 5.1. A peak was also observed corresponding to a retained sodium ion at
892.74 m/z (3-). An 1:1 binding stoichiometry was also observed at 517.76 m/z (4-), 690.68 m/z
(3-), and 1036.52 m/z (2-). Peaks were also observed corresponding to a retained sodium ion at
698.67 (3-) and to one and two retained sodium ions at 1047.51 and 1058.51 m/z (2-) respectively.
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Figure 5.1. ESI-MS of 1:1 adducts of FPX and A) hexaamminecobalt(III) in the 2-, 3-, and 4charge states with the parent peak of FPX also observed at the 4- charge state with a 2:1
Co:FPX stoichiometry at the 2- charge state, B) Werner’s complex in the 5- charge state with
an observed 2:2 Co:FPX stoichiometry, C) tris(2,2’-bipyridine)cobalt(III) in the 2- through 6charge states with observed 1:1 and 1:2 Co:FPX stoichiometry and loss of 1 sulfate, and D)
tris(2,2’-bipyridine)ruthenium(II) in the 2- through 4- charge states with observed 1:1 and 2:1
Co:FPX stoichiometry.
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A peak was also observed with one retained sodium ion and loss of sulfate at 1007.48 (2-). We
also observed more sulfate loss with electrostatic interactions, since hydrogen bonding interactions
allow for sulfate cluster interactions, more sulfates are protected. Cobalt complexes with the ability
to interact through hydrogen bonding were able to protect the FPX from sulfate loss through sulfate
cluster interaction with an ability to “metalloshield” a larger group of sulfate clusters where one
ammine can interact with multiple oxygens. Conversely, sulfate loss was observed after
interactions with the electrostatic complexes. The compounds using only electrostatic interactions
will have more of dispersed charge with larger ligands that produces a weaker interaction between
the metal complexes and FPX.
ITC measures the amount of heat energy released or absorbed into the system upon the interaction
of two molecules. ITC determines the thermodynamic influences of both the change in enthalpy
(ΔH) and entropy (ΔS) changes to calculate the free energy of binding (ΔG). ITC assays were
performed to determine the binding constants between FPX and the metal compound library.
Electrostatic and hydrogen bonding interactions contribute to the enthalpy term, while
conformational freedom changes and solvation changes that occur upon complexation contribute
to the entropy term. (3, 4)
While the major contribution for the derived thermodynamic binding parameters arose from the
entropy term, binding interactions can still be evaluated from the enthalpy binding term, Table 5.2.
Hexaamminecobalt(III) has an intermediate Kd (59.5 µM) and Gibbs Free energy (-5.8 kJ/mol)
which is likely due to the hydrogen bonding ability and smaller size of the coordinated ligands,
Figure 5.2. WC had the greatest Kd and Gibbs Free energy (296 nM and -8.78 kJ/mol, respectively).
This is due to the overall 6+ charge and largest size, which displaces the most solvent molecules
and forces a FPX conformational change. Tris(2,2’-bipyridine)cobalt(III) has the lowest Kd (90.1
µM) and the weakest Gibbs Free energy (-5.5 kJ/mol), Figure 5.2. The less favorable binding
parameters of tris(2,2’-bipyridine)cobalt(III) likely arise from the lack of hydrogen bonding
interactions. ITC titrations of tris(2,2’-bipyridine)ruthenium(II) into FPX did not give a welldefined isothermal trace, perhaps due to weak binding arising from a lack of hydrogen bonding
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415.25 (4-)
554.01 (3-)
561.33 (3-)
831.52 (2-)
842.51 (2-)
853.50 (2-)
864.49 (2-)
910.55 (2-)

MW
Observed
1661.00
1662.03
1683.99
1663.04
1685.02
1707.00
1728.98
1821.10

Calculated
1660.99
1662.00
1683.98
1663.00
1684.99
1706.97
1728.95
1821.07

C62H173Co8N30O110S16

816.19 (5-)

4080.95

4080.91

FPX+[Co(bipy)3]
2FPX+[Co(bipy)3]
2FPX+[Co(bipy)3]
2FPX+[Co(bipy)3]
2FPX+[Co(bipy)3]

C61H73CoN9O61S8
C92H123CoN12O110S16
C92H124CoN12O110S16
C92H125CoN12O110S16
C92H126CoN12O110S16

1110.99 (2-)
620.99 (6-)
745.39 (5-)
931.98 (4-)
1242.98 (3-)

2221.98
3725.94
3726.95
3727.92
3728.94

2221.99
3725.93
3726.93
3727.94
3728.95

FPX+[Ru(bipy)3]
FPX+[Ru(bipy)3]
FPX+[Ru(bipy)3]+Na
FPX+[Ru(bipy)3]
FPX+[Ru(bipy)3]+Na
FPX+[Ru(bipy)3]+Na-SO3
FPX+[Ru(bipy)3]+2Na
FPX+2[Ru(bipy)3]
FPX+2[Ru(bipy)3]
FPX+2[Ru(bipy)3]+Na
FPX+2[Ru(bipy)3]

C61H71N9O49RuS8
C61H72N9O49RuS8
C61H71N9NaO49RuS8
C61H73N9O49RuS8
C61H72N9NaO49RuS8
C61H72N9NaO46RuS7
C61H71N9Na2O49RuS8
C91H96N15O49Ru2S8
C91H97N15O49Ru2S8
C91H109N15O49Ru2S8
C91H97N15O49Ru2S8

517.76 (4-)
690.68 (3-)
698.67 (3-)
1036.52 (2-)
1047.51 (2-)
1007.48 (2-)
1058.51 (2-)
660.55 (4-)
881.08 (3-)
892.74 (3-)
1321.62 (2-)

2071.04
2072.04
2096.01
2073.04
2095.02
2014.96
2117.02
2642.20
2643.24
2678.22
2643.24

2071.01
2072.02
2096.02
2073.03
2095.01
2015.05
2116.99
2642.13
2643.14
2678.22
2643.14

Composition*

Formula

m/z (charge)

FPX+[Co(NH3)6]
FPX+[Co(NH3)6]
FPX+[Co(NH3)6]+Na
FPX+[Co(NH3)6]
FPX+[Co(NH3)6]+Na
FPX+[Co(NH3)6]+2Na
FPX+[Co(NH3)6]+3Na
FPX+2[Co(NH3)6]

C31H64CoN9O49S8
C31H65CoN9O49S8
C31H64CoN9NaO49S8
C31H66CoN9O49S8
C31H65CoN9NaO49S8
C31H64CoN9Na2O49S8
C31H63CoN9Na3O49S8
C31H81Co2N15O49S8

2FPX+2WC

Table 5.1. Species detected on the ESI-MS spectra. *protons and charges were omitted for
clarity. FPX represent the parent Fondaparinux species.
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interactions, consistent with what was observed in the following MB assay. The major contribution
arose from the entropy term in the case of the simple cobalt complexes. This was produced by the
release of solvent molecules from FPX upon binding. The “U”-shaped traces that were observed
are indicative of a strong conformational change produced by WC interacting with FPX and a
weaker conformational change produced by hexaamminecobalt(III) with FPX.
The NMR chemical shift changes of D-glucosamine-6-O-sulfate (monomer) in the presence of
cobalt complexes were investigated to delineate the binding interactions. Addition of cobalt
complexes shifted the proton signals of the monomer, Figure 5.3. Upon measurements performed
from the freshly prepared 1:1 Co:Monomer mixture, distinct shifts were observed due to fast
interactions. Only small downfield shifts (.000 to .007 ppm) are observed for the non-covalent
interactions disregarding Werner’s Complex, Table 5.3. Werner’s Complex produced shifts (up to
.017 ppm) that were at least 2 fold greater than any other non-covalent cobalt complex shift.
Werner’s Complex produced larger shifts due to the stronger binding of the complex to the
monomer. Since no considerable shifts were observed in the case of tris(2,2’-bipyridine)cobalt(III)
due to electrostatic interactions with no hydrogen bonding, tris(2,2’-bipyridine)ruthenium(II) was
not investigated. The major shifts were observed through the sulfate interaction between Werner’s
Complex and FPX, while a non-discriminate binding to both sulfate and hydroxy groups were
observed for hexaamminecobalt(III).
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine
heparin binding interactions.(5-8) The MB absorbance at 664 nm and 614 nm decreases
proportionally with increasing sulfate concentration from addition of FPX to the solution. We have
previously shown that with addition of FPX to a solution containing a constant concentration of
MB, the absorbance decreases as free MB is bound to increasing concentrations of FPX. (9) The
association constant between FPX and MB was previously calculated using a Scatchard plot (4.1
x 104 M-1). (9, 10)
We again used the MB assay to study the ability of the metal library to inhibit MB binding through
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Figure 5.2. ITC analysis of FPX by direct titration with A) hexaamminecobalt(III) B) Werner’s
complex and C) tris(2,2’-bipyridine)cobalt(III). A trace of calorimetric titration (upper panel)
and integrated isotherms (lower panel). The first peak represents a pre-injection that was
omitted in the binding calculations.

[Co(NH3)6]3+
WC6+
[Co(bipy)3]3+

Kd
59.5 ± 7.8[a]
296 ± 34[b]
90.1 ± 20.3[a]

ΔG (kJ/mol)
-5.8 ± 0.2
-8.78 ± 0.1
-5.5 ± 0.5

ΔH (J/mol)
-557.1 ± 15.7
-1336 ± 8
-526.9 ± 51.1

-TΔS (kJ/mol*K)
-5.2
-7.4
-4.9

Table 5.2. ITC analysis showing the obtained binding parameters: dissociation constants (Kd);
free energy of binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS) between
cobalt compounds and FPX. The standard error from 3 measurements is indicated.
[a] Kd measured in µM.
[b] Kd measured in nM.
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metalloshielding of FPX. With increasing concentrations of metal compounds, FPX is
metalloshielded from MB, allowing more free-MB to be in solution, resulting in an increase of
absorbance at 664 nm. The ability of these metal compounds to “metalloshield” was calculated as
an IC50 value, the concentration of metal compound required to inhibit 50% of the MB to bind to
the FPX. Werner’s Complex and tris(2,2’-bipyridine)cobalt(III) required the lowest concentrations
to inhibit MB binding (41.4 and 36.4 µM respectively), Figure 5.4 and Table 5.4. The similarity
in concentrations is attributed to the overall larger size of the ligands and their ability to spatially
inhibit MB binding to the sulfates. A higher concentration was required for the smaller
hexaamminecobalt(III) compound (64.5 µM). Similarly to the ITC assay, a greater concentration
of tris(2,2’-bipyridine)ruthenium(II) (676.2 µM) was required to inhibit MB binding to FPX.
These weak interactions by tris(2,2’-bipyridine)ruthenium(II) arise from the lower charge and lack
of hydrogen bonding. By using MB as a reporter, we are able to calculate the apparent dissociation
constant (Kd(app)) between the cobalt complexes and FPX.

5.2 Experimental

Mass Spectrometry
Mass spectra were acquired on a Thermo Electron Corporation Orbitrap Velos mass spectrometer
(Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to 0.7 µL/min
using a syringe pump. Electrospray source condition were kept constant with a capillary
temperature of 230oC and capillary voltage between 2.3 and 2.5 kV. FPX and cobalt complexes
were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed at a 1:1
molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted with
addition of Milli-Q methanol for a final concentration of 1:10 methanol:water.
Isothermal Titration Calorimetry
Calorimetric data was collected using a VP-ITC Microcalorimeter (MicroCal, LLC). All samples
were degassed for 5 minutes using a ThermoVac (MicroCal, LLC). For all titrations, injections of
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Figure 5.3. 1H NMR spectra of 1:1 mixtures of D-glucosamine-6-O-sulfate and various metal
complexes from top to bottom: hexaamminecobalt(III), Werner’s complex, tris(2,2’bipyridine)cobalt(III), and D-glucosamine-6-O-sulfate.

Δδ = δ(monomer : Co) – δ(monomer) (ppm)
αH1 αH2 αH4/βH6’ αH6’ αH5/βH6 αH6
0.006 0.006
0.006
[Co(NH3)6]3+ 0.007 0.006 0.001
0.012 0.000
0.017
WC6+
0.009 0.005 0.005
0.002
0.000
0.001
0.000
0.002
[Co(bipy)3]3+ 0.001

Table 5.3. 1H chemical shift changes (Δδ =
δ(monomer : Co) – δ(monomer)) after incubation
of metal complexes with D-glucosamine-6-Osulfate.
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cobalt complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at
300 second intervals from a 300 µL syringe while stirring at 75 rpm. In all experiments, 100 mM
cacodylate buffer (pH 7.4) was used at 25oC and the thermal reference cell contained 1.3 mL of
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks were carried out using
the software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one site model
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation.
NMR Studies
1

H NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data

being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was preincubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 5.5)
in deuterated water.
Methylene Blue Reporter Method
A change in absorbance of MB at 664 nm accompanies it binding to the sulfates on FPX. This
change was used to quantitate the affinity of MB (at a constant final concentration of 21.98 µM)
for FPX in water. Varying concentrations of cobalt complexes were incubated with constant
concentration of FPX (at a constant final concentration of 15 µM) for 15 mins at room temp. To
each sample was added constant concentration of MB. All binding studies were performed in
triplicate on an Agilent 8453 diode array spectrophotometer in a sub-micro quartz cuvette with a
path length of 10 mm.
IC50 and Ka(app) values for binding of cobalt complexes to FPX were calculated by converting the
MB absorption values to a normalized value (minimum and maximum absorbance) and the Ka(app)
was determined using the following equation:
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Figure 5.4. MB competition assay for assessment FPX binding. At a constant concentration of
15 μM FPX in the presence of varying concentrations of A) hexaamminecobalt(III) (from
bottom to top with 30, 40, 50, 60, 70, 80, 90, 100 μM), B) Wener’s complex (from bottom to
top with 10, 20, 30, 40, 50 μM), C) tris(2,2’-bipyridine)cobalt(III) (from bottom to top with
10, 20, 30, 40, 50, 60, 70, 80, 90, 100 μM) D) tris(2,2’-bipyridine)ruthenium(II) (from bottom
to top with Ruthenium only (1 mM), 10, 20, 40, 60, 80, 100, 500, 1000 μM); MB binding is
inhibited, reflected in the change of [AbsMB] at 664 nm.

[Co(NH3)6]3+
WC6+
[Co(bipy)3]3+
[Ru(bipy)3]2+

IC50 (µM)a
64.5 ± 1.1
41.4 ± 0.1
36.4 ± 0.9
676.2 ± 17.3

Kd(app) (µM)b
30.2 ± 0.5
20.1 ± 0.2
17.7 ± 0.4
316.8 ± 8.1

Table 5.4. IC50 and Kd(app) Values of metal compounds in the competitive inhibition assay using
MB as a reporter.
a) The IC50 value was determined as the concentration of complex required for half-maximal
binding of the dye (21.98 μM) to FPX (15 μM) for the MB binding assay.
b) Dissociation constants were calculated from the MB assay for metal compounds binding to
FPX using a competitive inhibitor model.
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Werner’s hexol

Hexamminecobalt(III)

Tris(2,2'-bipyridine)cobalt(III)

Tris(2,2'-bipyridine)ruthenium(II)

Figure 5.5. Library of cobalt complexes used. Counterions omitted for clarity.
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where KdL is the dissociation constant for the labeled ligand (MB) and binding site (FPX), SL is the
total concentration of the labeled ligand, and (BL)o is the equilibrium of labeled ligand value when
competitor concentration is zero.
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6.1 Abstract

The interaction between simple metal cations and fondaparinux leads to sulfate cluster binding,
thus providing a simple platform to investigate “metalloshielding” of sulfates using a reporter dye,
stabilization of sulfates using ESI-MS, and cleavage inhibition of glycosidic linkages using
bacterial heparinase.

6.2 Introduction

Heparan sulfate proteoglycans (HSPGs) are found in the extracellular matrix or on the cell surface
once proteins associate with heparan sulfate (HS), a sulfated glycosaminoglycan. HSPGs play a
major role in the cell recognition process, adhesion, and migration.(1,2) Cancer cells over-express
HSPGs on their cell surface. HS sulfate residues are the recognition site for many different protein
substrates including pro-angiogenic growth factors, interacting similar to the phosphate clamparginine fork motif. Fibroblast growth factors (FGFs) directly stimulate the growth, metastasis and
survival of cancer cells.(3) HSPG enzymatic cleavage at glycosidic linkages by heparanase
(HPSE) causes release of angiogenic growth factors initiating the angiogenic cascade. HPSE is
also over-expressed in tumors with significant correlation between metastatic potential and
heparanase activity.(4-7) HS is, thus, an attractive drug target to inhibit tumor cell progression
through “metalloshielding” or sulfate cluster masking of HS by metal complexes protecting HS
from enzymatic cleavage by the mammalian heparanase, and preventing growth factors from
binding to HS and/or preventing release of bound growth factors.
The highly anionic nature of HSs means they are associated with physiologically relevant
cations.(8-10) Cation association aﬀ ects the biomolecule conformation and can facilitate
heparin−protein interactions such as Ca2+-dependent heparin−annexin A2 binding.(11) Growth
factors are also copper-dependent, with a slightly higher aﬃnity of HS for FGF-1 compared to
FGF-2.(12-15) Aquated Ca2+, Mg2+, Fe3+, and Zn2+ ions, at higher than physiological
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Figure 6.1. MB competition assay for assessment FPX binding. At a constant concentration of 15 μM
FPX and 21.98 μM MB in the presence of varying concentrations of A) Manganese(II) chloride (from
bottom to top with 10, 20, 30, 50, 60, 70, 80, 200, 300, 400, and 500 μM), B) Vanadium(III) chloride
(from bottom to top with 10, 20, 30, 70, 80, 90, 200, 300, 400, and 500 μM), C) Vanadyl(III) sulfate
(from bottom to top with 50, 60, 70, 80, 90, 100, 250, 300, and 400 μM) and D) absorption spectrum
of MB and Vanadyl(III) sulfate (from bottom to top with 100, 250, and 500 μM); MB binding is
inhibited, reflected in the change of [AbsMB] at 664 nm.
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concentrations, reduce FGF-1 interactions with HS.(8) In order to determine the importance of
hard-soft acid-base concepts on the “metalloshielding” potential of the metal complex library,
binding and cleavage inhibition studies were performed using Fondaparinux as a model HS-like
substrate. Fondaparinux (FPX) is a well-defined octasulfated pentasaccharide with a single point
of cleavage for bacterial HPSE. New patterns of metal-heparin binding can be achieved by the
application of hard–soft acid–base concepts.
To develop the HSAB concepts, we have chosen a small library of metal complexes to examine
their effects with FPX. This communication describes cleavage inhibition studies in the presence
and absence of Manganese(II) chloride using bacterial HPSE. A competition assay was
implemented using methylene blue (MB) as a reporter to measure the “metalloshielding” of MB
for each compound. Sulfate stability was examined using mass spectrometry (MS). The overall
results emphasize the importance of understanding the properties of glycan interactions with metal
complexes, to expand bioinorganic chemistry into this important class of biomolecules.

6.3 Results and Discussion
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine
heparin binding interactions.(16-18) With increasing sulfate concentration from addition of FPX
to the solution, the MB absorbance at 664 nm and 614 nm decreases proportionally. It has been
previously shown that upon addition of FPX to a solution of MB, the absorbance decreases as more
MB is bound to FPX.(19) The association constant between FPX and MB was previously
calculated using a Scatchard plot (4.1 x 104 M-1).(19)
The MB assay was used to study the ability of the metal library to inhibit MB binding through
“metalloshielding” of FPX. Varying concentrations of metal complexes were incubated with
constant concentration of FPX (15 µM) for 15 mins at room temperature. MB was added to each
(to a constant final concentration of 21.98 µM). With increasing concentrations of metal
compounds in solution, FPX is “metalloshielded” from MB, preventing interaction with FPX. The
additional free-MB in solution resulting in an absorbance increase, Figure 6.1. The ability of these
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IC50 (µM)a

IC50 (µM)b

MnCl2

333 ± 1

354 ± 78

VCl3

264 ± 1

NA

VOSO4

535 ± 1

NA

Table 6.1. IC50 values of metal compounds in the competitive inhibition assay using MB as a reporter.
a) The IC50 value was determined as the concentration of complex required for half-maximal
binding of the dye (21.98 μM) to FPX (15 μM) for the MB binding assay.
b) The IC50 value was determined as the concentration of complex required to inhibit 50% of
HPSE cleavage on FPX.

FPX+Mn+Na
FPX+Mn
FPX+Mn-SO3

C31H47MnN3NaO49S8
C31H49MnN3O49S8
C31H49MnN3O46S7

526.28 (3-)
778.94 (2-)
738.98 (2-)

MW
Observed Calculated
1578.87
1578.83
1557.88
1557.86
1477.96
1477.90

FPX+V
FPX+V+Na
FPX+V
FPX+V-SO3

C31H46N3O49S8V
C31H47N3NaO49S8V
C31H48N3O49S8V
C31H48N3O46S7V

387.72 (4-)
787.43 (2-)
776.44 (2-)
736.46 (2-)

1550.88
1574.86
1552.88
1472.92

1550.84
1574.84
1552.86
1472.90

FPX+VO+Na
FPX+VO+Na-SO3
FPX+VO
FPX+VO-SO3
FPX+VO-2SO3
FPX+VO-3SO3
FPX+VO+Na
FPX+VO+Na-SO3
FPX+VO+Na-2SO3
FPX+VO+Na-3SO3
FPX+VO
FPX+VO-SO3
FPX+VO-2SO3
FPX+VO-3SO3

C31H48N3NaO50S8V
C31H48N3NaO47S7V
C31H49N3O50S8V
C31H49N3O47S7V
C31H49N3O44S6V
C31H49N3O41S5V
C31H49N3NaO50S8V
C31H49N3NaO47S7V
C31H49N3NaO44S6V
C31H49N3NaO41S5V
C31H50N3O50S8V
C31H50N3O47S7V
C31H50N3O44S6V
C31H50N3O41S5V

530.63 (3-)
503.97 (3-)
523.30 (3-)
496.65 (3-)
496.99 (3-)
443.34 (3-)
796.45 (2-)
756.47 (2-)
716.49 (2-)
676.51 (2-)
785.46 (2-)
745.48 (2-)
705.50 (2-)
665.52 (2-)

1591.89
1511.91
1569.90
1489.95
1490.97
1330.02
1592.90
1512.94
1432.98
1353.02
1570.92
1490.96
1411.00
1331.04

1591.84
1511.88
1569.86
1489.90
1409.95
1329.99
1592.85
1512.89
1432.94
1352.98
1570.87
1490.91
1410.95
1331.00

Composition*

Formula

m/z (charge)

Table 6.2. Species detected on the ESI-MS spectra. *protons and charges were omitted for clarity. FPX
represent the parent Fondaparinux species.
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metal compounds to “metalloshield” was calculated as an IC50 value, the concentration of metal
compound required to inhibit 50% of MB binding, Table 6.1. The higher charged Vanadium(III)
requires the lowest concentration, 264 µM, while Vanadyl(III) requires the highest concentration,
535 µM, due to the decrease in overall charge of the complex due to the presence of negatively
charged oxygen. Manganese(II) requires an intermediate concentration, 333 µM. While the V(III)
and Mn(II) complexes interact covalently with protection proportional to the charge of each metal;
the VO, while still covalent, requires a higher concentration due to the oxygen being retained, both
lowering the overall charge of the complex and limiting the number of available interaction sites
on the Vanadium. Due to MB’s ability to interact with sulfates, we also measured the absorbance
change of MB in the presence of Vanadyl(III) sulfate. An analogous change in absorbance was
observed using similar concentrations of Vanadyl(III) sulfate to those used in the inhibitory MB
assay. This would artificially decrease the absorbance requiring a higher concentration of metal
required to inhibit MBs binding to FPX.
Negative mode electrospray ionization (ESI) is commonly used for identification and analysis of
heparin. We have previously shown through ESI-MS studies that FPX undergoes sulfate loss in
the gas phase.(19) Analysis regarding the retention of labile sulfate groups on the heparin backbone
has shown metal cations stabilize sulfate groups.(20) In the present work, the stoichiometry of
metal complexes bound to FPX and their ability to protect against sulfate loss. FPX and metal
complexes were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed
at a 1:1 molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted
with addition of Milli-Q methanol for a final concentration of 1:9 methanol:water. Peaks
corresponding to a covalent interaction between Manganese(II) and FPX were observed at
778.9447 m/z (2-) with loss of one sulfate at 738.9751 m/z (2-), Table 6.2. A Peak was also
observed corresponding to the previous interaction with a retained sodium ion at 526.2888 m/z (3). Peaks corresponding to a covalent interaction between Vanadium(III) and FPX were observed
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Figure 6.2. Structure of Fondaparinux, and cleavage products by P. heparinus heparinase I. In the
presence of Manganese(II) chloride, cleavage was inhibited.
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[MnCl2] (mM)

Figure 6.3. Inhibition of heparinase I through
interaction of Manganese(II) chloride with FPX. Data
are expressed as percentages relative to controls
containing no Manganese(II) chloride.
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at 387.7184 m/z (4-) and 776.4411 m/z (2-) with loss of one sulfate at 736.4632 m/z (2-), Table 6.2.
A Peak was also observed corresponding to a retained sodium ion at 787.4316 m/z (2-). Peaks
corresponding to a covalent interaction between Vanadyl and FPX with a retained sodium were
observed at 398.22067 m/z (4-) with loss of one sulfate at 378.2310 m/z (4-), Table 6.2. Peaks of
the previous interaction were also observed at 523.6379 m/z (3-) and loss of sulfate at 496.9847
m/z (3-), along with peaks corresponding to a retained sodium ion at 531.2971 m/z (3-) and loss of
one sulfate at 504.6441 m/z (3-). Peaks were also observed corresponding to Vanadyl and FPX
covalent interaction at 785.9596 m/z (2-) with loss of one, two, and three sulfates at 745.9811,
706.0016, and 666.0220 m/z (2-), respectively. Again, retained sodium was observed at 797.4489
m/z (2-) with loss of one to three sulfates at 757.4705, 717.4907, and 677.5122 m/z (2-),
respectively.
The interaction peaks observed were relatively weak compared to the parent FPX peaks. Greater
sulfate loss was observed in the case of Vanadyl, since the negative oxygen was retained. The
oxygen was retained due to the strong interaction between Vanadium and oxygen using HSAB
chemistry. The positive charge of the Vanadium complex would be lowered concomitantly
inhibiting the Vanadium from interacting with a greater number of sulfates.
The cleavage patterns for the interactions between FPX and mammalian heparanase or bacterial
heparinase I (often used as a model for the mammalian enzyme) are shown in Figure 6.2.(21) A
colorimetric assay was adapted to examine the inhibitory effect of metal complexes on the
enzymatic heparinase degradation of FPX. Manganese(II) chloride was incubated for 15 min at
room temperature with 50 µM FPX in 40mM NaOAc buffer, pH 5. After addition of 0.25 U
heparinase I for 1 hour at 37 °C. The reactions were stopped by adding 100 µL 1.69 mM WST-1
(Dojindo), and absorbance readings were recorded at 584 nm. The pentasaccharide substrate was
incubated

with

metal

complex

prior

to

enzyme

exposure

and

cleavage

was

measured versus control in absence of added complex. Inhibition of heparinase cleavage is
effective in a concentration-dependent manner for Manganese(II) chloride, Figure 6.3 and Table
6.1. Time course studies show that Manganese(II) chloride instantly inhibited activity with little
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or no variation with time, while the Vanadium(III) complexes interacted with the assay and did
not produce reportable results.

Overall, these results emphasize that the study of simple cations with oligosaccharides has
substantial potential in the new area of metalloglycomics. Simple metal cations such as Zn2+ and
Ca2+ affect the activity and conformation of heparin mimetics. Our results highlight the potential
“metalloshielding” effect by metal complexes of heparin mimetics through modification of metal
oxidation state and substitution lability of ligands, and use of HSAB concepts. Vanadium, a hard
acid, reacts with oxygen, a hard base, forming a stronger bond than Manganese, an intermediate
acid, with oxygen. Vanadium also produces a stronger interaction than Manganese due to a higher
overall charge of the complex and due to its ability to interact with more sulfate groups. Vanadyl,
containing oxygen, lowered the overall charge of the metal complex and limited the amount of
“metalloshielding”. The study of simple metal cations extends the application of bioinorganic
chemistry from protein and DNA-RNA interactions into the new era of metalloglycomics.
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Chapter 7: Synthesis and Characterization of Werner’s Complex

7.1 Synthesis

Ammonium carbonate (7.0 g, 0.0728 mol) was dissolved in 20.0 mL of water, 20.0 mL of
concentrated aqueous ammonia was then added. In a second container, cobalt (II) nitrate
hexahydrate (5.0 g, 0.017 mol) was dissolved in 10.0 mL of water. The two solutions were
combined with stirring. Slowly, 3.0 mL of the 30% hydrogen peroxide solution was added. Once
the hydrogen peroxide has been added, the solution was evaporated to a volume of 30 mL. During
the evaporation time, ammonium carbonate (1.7 g, 0.0173 mol) was added to the solution. When
the solution volume was about 30 mL, the solution was filtered and the filtrate was cooled on ice.
Red/purple crystals of product formed. These crystals were collected and washed with a few
milliliters of ice-cold water and then ethanol, and dried. 2.0 g of the product was dissolved in 55
mL of 0.6 M nitric acid. The solution was then treated with 25 mL of ethanol, slowly. The resulting
precipitate was filtered off. 2.0 g of the product was dissolved in 25 mL of 0.2 M aqueous
ammonia. After 24 hours purple/black crystals began to form. After 3 days the crystals were
collected. 2.0 g, 40.8% recovered.

Figure 7.1. Werner’s Complex
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7.2 Characterization

1H NMR:
Theoretical:
2.49ppm DMSO
2.95 and 4.29 ppm (3:3) axial and equatorial NH3
3.34 ppm (1.2) waters of crystallization
-1.69 ppm (1) OH
Experimental:
2.49ppm DMSO
2.9 and 4.3 ppm (3.02:3) axial and equatorial NH3
3.3 ppm (6.56) waters of crystallization
-1.7 ppm (.98) OH

Figure 7.2. 1H NMR of Werner’s Complex in DMSO.
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UV:
Theoretical:
311(4.95x10^3), 504(212), 627(126) wavelength (mol-1 cm-1)
Experimental:
311(4.79x10^3), 504(204), 627(127) wavelength (mol-1 cm-1)

Figure 7.3. UV spectra of Werner’s Complex in water.
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IR:
Present:
OH stretch 3600-3300
NH4 stretch 2375 and 3169, 1626, 817
NO3 stretch 1329
Co-N stretch 462
Co-O stretch 543
Not present:
SO4 stretch 1115
CO3 stretch 1715, 1240

Figure 7.4. IR spectra of Werner’s Complex.

Elemental Analysis:
Theoretical for Co4H42N18O24: C 0.00, H 5.19, N 25.24. Experimental: C <0.10, H 4.78, N 25.24
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Chapter 8: Conclusions

The results on heparin and Fondaparinux interactions with metal complexes can be extrapolated
to glycosoaminoglycans such as HS. This emphasizes the relevance of glycan interactions in
understanding the biological properties of coordination compounds and the utility of the
metalloglycomics concept for extending bioinorganic chemistry to this class of important
biomolecules.
The focused small library of PPCs studied here begins to elucidate structure–activity relationships.
The stark contrast between [Pt(NH3)4]2+ and MonoplatinNC in inhibiting the HS cleavage
emphasizes the importance of dangling amine moieties as well as increased charge dispersion. The
relative efficacy of the polynuclear set again shows that positive charge dispersion through
dangling amines and Pt coordination spheres play important roles in masking the HS fragments
and protecting them against enzymatic cleavage. The ability to form a “sulfate clamp” from the
interaction of am(m)ines in a Pt coordination unit are likely to be more effective in masking than
the single positive charge of the dangling amine—nevertheless the two structural features do
contribute to the overall effect. Trends were assessed, affinity is related to charge and in general
these substitution‐ inert complexes show broadly similar affinity to FPX and DNA. The
approaches to inhibition of HS or DNA function are formally analogous since both protect the
“substrate” from enzyme and/or protein processing. High‐ affinity DNA binding through the
phosphate clamp efficiently inhibits transcription factors such as TBP (TATA box binding
proteins) and restriction enzymes. While, the Kd values found for PPC–FPX interactions are
broadly similar to those found for growth factor–oligosaccharide interactions in the nM range. This
suggests that metalloshielding will also be effective in inhibition of oligosaccharide‐ protein
function as shown for the effect of TriplatinNC on FGF‐ heparin interactions.
The small library of simple metal ammine complexes, along with the lead compound TriPtNC,
confirmed the generality of metal complexes and their affinity for HS. The Kd values found for
metal ammine–FPX interactions are broadly similar to those found for growth factor–
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oligosaccharide interactions in the µM range. Again, the overall results suggest comparable
affinities for heparin relative to DNA for charged metal compounds, regardless of their intrinsic
nucleic acid affinity. The presence of HS on the cell surface and its relatively similar affinity to
DNA would suggest that glycan binding is thus a competitive cellular event for many coordination
compounds. These results extend our understanding of the importance of the interactions of
physiologically relevant aquated metal cations with heparin to defined coordination compounds.
The available coordinating moieties on HS–heparin are the oxygen-donor atoms of the hard
carboxylate and sulfate bases. Therefore, new patterns of metal-ion binding can be achieved by
the interplay and application of hard–soft acid–base concepts. Further, in considering the concept
of metalloglycomics, coordination compounds can be manipulated to modify the oxidation state,
ligand lability, and coordination number and geometry to produce a diverse inorganic library.
These studies also confirm the affinity of simple coordination complexes with heparin, using a
series of mononuclear cobalt, ruthenium, and platinum compounds with affinity for heparin
ordered Co > Ru > Pt. This suggests that cobalt complexes may be more effective at
metalloshielding oligosaccharide‐protein function.
Simple cobalt compounds bind with relatively high affinity to heparin, even greater than that of
the simple platinum compound, tetraammineplatinum(II), extending this work into a library of
cobalt

complexes.

The

contrast

between

t-dichlorobis(ethylenediamine)cobalt(III)

and

pentaamminechlorocobalt(III) in inhibiting HS cleavage of FPX and matrix emphasizes the
importance of hydrogen bonding in sulfate cluster protection. The overall results discussed here
suggest comparable affinities for cobalt complexes binding to FPX as previously discussed. ITC
shows that cobalt complexes interacting with FPX, Kds of 18.6 to 90.1 µM, are comparable to a
mixture of heterogeneous heparin chains complexing with FGF-1, Kds of 1.1 to 3 µM. MB and
MS assays suggest that covalent interactions of these cobalt compounds may only interact with a
single sulfate, while non-covalent hydrogen bonding may interact with a cluster of sulfates. This
was observed using MB as a reporter, requiring a higher concentration of covalently interacted
cobalt complexes over the non-covalent complexes. This was also observed in the MS with a
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greater

number

of

sulfates

lost

through

the

covalent

interaction

of

t-

dichlorobis(ethylenediamine)cobalt(III) with up to six sulfates lost from FPX in the 2- charge state,
while the non-covalent interaction showed lower abundance of lost sulfates. Therefore
“metalloshielding” of FPX through sulfate clusters would be greater in the non-covalent
compounds over the covalent interactions. However, the NMR results show that covalent
interactions, using application of hard–soft acid–base concepts, occur much stronger than the noncovalent interactions. These assays give an estimate of the strength of the FPX–cobalt binding and
provide a relative calculation of affinities. This suggests that cobalt complexes with hydrogen
bonding ability will be more effective at metalloshielding oligosaccharide‐protein function.
Interactions between non-covalent cobalt complexes and FPX were also studied. More sulfate loss
was observed with electrostatic interactions, while cobalt complexes with the ability to interact
through hydrogen bonding were able to protect the FPX from sulfate loss through sulfate cluster
interaction with an ability to “metalloshield” a larger group of sulfate clusters where one ammine
can interact with multiple oxygens. The compounds using only electrostatic interactions will have
more of dispersed charge with larger ligands that produces a weaker interaction between the metal
complexes and FPX. Further, electrostatic interactions between cobalt and FPX were stronger as
compared to electrostatic interactions between ruthenium complexes and FPX. ITC titrations of
tris(2,2’-bipyridine)ruthenium(II) into FPX did not give a well-defined isothermal trace, perhaps
due to weak binding arising from a lack of hydrogen bonding interactions, consistent with what
was observed in the MB assay. The multinuclear Werner’s Complex exhibited similar association
as the PPCs for FPX. Again, this suggests that multinuclear cobalt complexes with hydrogen

bonding ability will be more effective at metalloshielding oligosaccharide‐protein function.
In addition, simple metal complexes interact with Fondaparinux and may be considered in the
development of future antimetastatic drugs in application of hard-soft acid-base concepts.
Vanadium, a hard acid, reacts with oxygen, a hard base, forming a stronger bond than Manganese,
an intermediate acid, with oxygen. Vanadium also produces a stronger interaction than Manganese
due to a higher overall charge of the complex and due to its ability to interact with more sulfate
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groups. Vanadyl, containing oxygen, lowered the overall charge of the metal complex and limited
the amount of “metalloshielding”. New patterns of metal-ion binding can be achieved by the
interplay and application of hard–soft acid–base concepts.
Further studies should be performed using the less cytotoxic cobalt complexes to confirm their
strength of interactions to HS. Assays using ITC would show the competitive binding of cobalt
complexes vs growth factors binding to FPX. Linear, multinuclear cobalt complexes should also
be studied, mimicking the lead compounds TriplatinNC or BBR3464. These linear cobalt
complexes should interact relatively similarly as the PPCs with the anionic HS while maintaining
the low cytotoxic profile. A BBR3464 mimic would allow strong covalent interactions between
the hard acid of cobalt and the hard base of oxygen, while the non-covalent hydrogen bonding
would allow sulfate cluster interactions for strong metalloshielding. Furthermore, the poor
pharmacokinetic results that plagued BBR3464 should be overcome by limiting the inactivation
of sulfur containing biomolecules and producing a target that is overexpressed on cancer cells.
Overall, these results demonstrate the utility of the metalloglycomics concept in developing new
classes of molecules for study of glycan structure and function. It is clear that oligosaccharides
represent a viable alternative cellular target to oligonucleotides and these results further emphasize
the unique dual-function nature of metal complexes.
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Appendix

Synthesis and Characterization

trisethylenediaminecobalt(III) chloride
Cobalt(II) chloride hexahydrate (6.0 g, 25.0 mmol) was dissolved in 17.5 mL of water. Another
solution was prepared by dissolving 4.51 mL of anhydrous ethylenediamine (2.7 eq, 67.5 mmol)
in 12.5 mL of water and cooled to 0 °C on ice and neutralized partially with 4.35 mL of 6 M HCl
(25.5 mmol). Both solutions were mixed together and 5 mL of 30% hydrogen peroxide was added
with stirring. The solution was then boiled to a volume of approximately 30.0 mL. 30 mL of 12
M HCl was added, followed by addition of 60 mL of ethanol and allowed to cool to room
temperature for 30 mins. The solution was cooled to 0 °C and the precipitate was collected and
washed with ice-cold ethanol and ether (10 mL each). The final product was dried in air. Yellow
crystals collected 4.3 g 61.7%.
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1H NMR:
Theoretical:
4.80 ppm D2O
5.2 and 4.8 ppm (6:6) NH2
2.8 ppm (12) CH2
Actual:
5.2 ppm (6) NH2 and 4.8 ppm (under D2O)
2.8 ppm (12) CH2

Figure A.1. 1H NMR of Co(en)3Cl3 in water.
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trans-dichlorobis(ethylenediamine)cobalt(III) chloride
300 mL of water was heated in a 600 mL beaker and maintained at a moderate boil. In an
evaporating dish, 4.0g of Cobalt (II) Chloride Hexahydrate (16.6 mmol) was combined with 10
mL of water. To this was added 15 mL of 10% ethylenediamine (en) (0.23 mmol). The evaporating
dish was placed on top of the beaker of boiling water. The mixture was stirred over this steam bath
for 40 minutes; the volume of the solution was maintained at about 5 mL by occasionally adding
small portions of water. During this process, the Co2+ was oxidized to Co3+ by the oxygen in the
air. Good agitation was necessary to promote solvation of the oxygen. To the solution, 12 mL of
Concentrated 12 M HCl was added. Heating and stirring was continued without addition of water
until a thin slurry of crystals was formed. The slurry was cooled to Room Temperature by setting
the evaporating dish on the lab bench and stirred occasionally for 15 minutes. The mixture was
collected using a Buchner funnel with Side-Arm Flask attached to an aspirator. The precipitate
was washed with a minimal amount of 6 M HCl (2 mL) and air dried. 1.19 g collected green
precipitate (20.8%).
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1H NMR:
Theoretical:
4.80 ppm D2O
5.2 (1) NH2
2.8 ppm (1) CH2
Actual:
5.2 ppm (1) NH2
2.8 ppm (1) CH2

Figure A.2. 1H NMR of Co(en)2Cl2Cl in water.
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UV-VIS λmaz:
Theoretical
cis: 390, 530 nm
trans: 450, 625 nm
Actual
cis: 380, 520 nm
trans: 450, 625 nm
1
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Figure A.3. UV-VIS spectra of isomerization of Co(en)2Cl2Cl in water.
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800

Isothermal Titration Calorimetry

Figure A.4. ITC of isomerization of Co(en)2Cl2Cl in water.
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